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A B S T R A C T
Background
The coronavirus disease 2019 (COVID-19) pandemic has resulted in substantial mortality. Some specialists proposed chloroquine (CQ) and
hydroxychloroquine (HCQ) for treating or preventing the disease. The eJicacy and safety of these drugs have been assessed in randomized
controlled trials.
Objectives
To evaluate the eJects of chloroquine (CQ) or hydroxychloroquine (HCQ) for
1) treating people with COVID-19 on death and time to clearance of the virus;
2) preventing infection in people at risk of SARS-CoV-2 exposure;
3) preventing infection in people exposed to SARS-CoV-2.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Current Controlled Trials (www.controlled-
trials.com), and the COVID-19-specific resources www.covid-nma.com and covid-19.cochrane.org, for studies of any publication status and
in any language. We performed all searches up to 15 September 2020. We contacted researchers to identify unpublished and ongoing
studies.
Selection criteria
We included randomized controlled trials (RCTs) testing chloroquine or hydroxychloroquine in people with COVID-19, people at risk of
COVID-19 exposure, and people exposed to COVID-19.
Adverse events (any, serious, and QT-interval prolongation on electrocardiogram) were also extracted.
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Data collection and analysis
Two review authors independently assessed eligibility of search results, extracted data from the included studies, and assessed risk of bias
using the Cochrane ‘Risk of bias’ tool. We contacted study authors for clarification and additional data for some studies. We used risk ratios
(RR) for dichotomous outcomes and mean diJerences (MD) for continuous outcomes, with 95% confidence intervals (CIs). We performed
meta-analysis using a random-eJects model for outcomes where pooling of eJect estimates was appropriate.
Main results
1. Treatment of COVID-19 disease
We included 12 trials involving 8569 participants, all of whom were adults. Studies were from China (4); Brazil, Egypt, Iran, Spain, Taiwan, the
UK, and North America (each 1 study); and a global study in 30 countries (1 study). Nine were in hospitalized patients, and three from
ambulatory care. Disease severity, prevalence of comorbidities, and use of co-interventions varied substantially between trials. We found
potential risks of bias across all domains for several trials.
Nine trials compared HCQ with standard care (7779 participants), and one compared HCQ with placebo (491 participants); dosing schedules
varied. HCQ makes little or no diJerence to death due to any cause (RR 1.09, 95% CI 0.99 to 1.19; 8208 participants; 9 trials; high-certainty
evidence). A sensitivity analysis using modified intention-to-treat results from three trials did not influence the pooled eJect estimate.
HCQ may make little or no diJerence to the proportion of people having negative PCR for SARS-CoV-2 on respiratory samples at day 14 from
enrolment (RR 1.00, 95% CI 0.91 to 1.10; 213 participants; 3 trials; low-certainty evidence). HCQ probably results in little to no diJerence in
progression to mechanical ventilation (RR 1.11, 95% CI 0.91 to 1.37; 4521 participants; 3 trials; moderate-certainty evidence). HCQ probably
results in an almost three-fold increased risk of adverse events (RR 2.90, 95% CI 1.49 to 5.64; 1394 participants; 6 trials; moderate-certainty
evidence), but may make little or no diJerence to the risk of serious adverse events (RR 0.82, 95% CI 0.37 to 1.79; 1004 participants; 6
trials; low-certainty evidence). We are very uncertain about the eJect of HCQ on time to clinical improvement or risk of prolongation of QT-
interval on electrocardiogram (very low-certainty evidence).
One trial (22 participants) randomized patients to CQ versus lopinavir/ritonavir, a drug with unknown eJicacy against SARS-CoV-2, and did
not report any diJerence for clinical recovery or adverse events.
One trial compared HCQ combined with azithromycin against standard care (444 participants). This trial did not detect a diJerence in
death, requirement for mechanical ventilation, length of hospital admission, or serious adverse events. A higher risk of adverse events was
reported in the HCQ-and-azithromycin arm; this included QT-interval prolongation, when measured.
One trial compared HCQ with febuxostat, another  drug with unknown eJicacy against SARS-CoV-2  (60 participants). There was no
diJerence detected in risk of hospitalization or change in computed tomography (CT) scan appearance of the lungs; no deaths were
reported.
2. Preventing COVID-19 disease in people at risk of exposure to SARS-CoV-2
Ongoing trials are yet to report results for this objective.
3. Preventing COVID-19 disease in people who have been exposed to SARS-CoV-2
One trial (821 participants) compared HCQ with placebo as a prophylactic agent in the USA (around 90% of participants) and Canada.
Asymptomatic adults (66% healthcare workers; mean age 40 years; 73% without comorbidity) with a history of exposure to people with
confirmed COVID-19 were recruited. We are very uncertain about the eJect of HCQ on  the primary  outcomes, for which few events
were reported: 20/821 (2.4%)  developed confirmed COVID-19 at 14 days from enrolment, and 2/821 (0.2%) were hospitalized  due to
COVID-19 (very low-certainty evidence). HCQ probably increases the risk of adverse events compared with placebo (RR 2.39, 95% CI 1.83 to
3.11; 700 participants; 1 trial; moderate-certainty evidence). HCQ may result in little or no diJerence in serious adverse events (no RR: no
participants experienced serious adverse events; low-certainty evidence).
One cluster-randomized trial (2525 participants) compared HCQ with standard care for the prevention of COVID-19 in people with a history
of exposure to SARS-CoV-2 in Spain. Most participants were working or residing in nursing homes; mean age was 49 years. There was no
diJerence in the risk of symptomatic confirmed COVID-19 or production of antibodies to SARS-CoV-2 between the two study arms.
Authors' conclusions
HCQ for people infected with COVID-19 has little or no eJect on the risk of death and probably no eJect on progression to mechanical
ventilation. Adverse events are tripled compared to placebo, but very few  serious adverse events were found. No further trials of
hydroxychloroquine or chloroquine for treatment should be carried out.
These results make it less likely that the drug is eJective in protecting people from infection, although this is not excluded entirely. It is
probably sensible to complete trials examining prevention of infection, and ensure these are carried out to a high standard to provide
unambiguous results.
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)
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P L A I N   L A N G U A G E   S U M M A R Y
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been
exposed to the virus?
What is the aim of this review?
COVID-19 is an infectious respiratory disease caused by a coronavirus called SARS-CoV-2. If the infection becomes severe, people may need
intensive care and support in hospital, including mechanical ventilation.
Drugs used for other diseases were tried out in COVID-19, and this included chloroquine, used for malaria; and hydroxychloroquine used
for rheumatic diseases, such as rheumatoid arthritis or systemic lupus erythematosus. We sought evidence of the eJects of these drugs
in treating people ill with the disease; in preventing the disease in people at risk of getting the disease,  such as health workers; and
people exposed to the virus developing the disease.
Key messages
Hydroxychloroquine does not reduce deaths from COVID-19, and probably does not reduce the number of people needing mechanical
ventilation.
Hydroxychloroquine caused more unwanted eJects than a placebo treatment, though it did not appear to increase the number of serious
unwanted eJects.
We do not think new studies of hydroxychloroquine should be started for treatment of COVID-19.
What was studied in the review?
We searched for studies that looked at giving chloroquine and hydroxychloroquine to people with COVID-19; people at risk of being exposed
to the virus; and people who have been exposed to the virus.
We found 14 relevant studies: 12 studies of chloroquine or hydroxychloroquine used to treat COVID-19 in 8569 adults; two studies of
hydroxychloroquine to stop COVID-19 in 3346 adults who had been exposed to the virus but had no symptoms of infection. We did not find
any completed studies of these medicines to stop COVID-19 in people who were at risk of exposure to the virus; studies are still under way.
The studies took place in China, Brazil, Egypt, Iran, Taiwan, North America, and Europe; one study was worldwide. Some studies were partly
funded by pharmaceutical companies that manufacture hydroxychloroquine.
What are the main results of our review?
Treating COVID-19
Compared with usual care or placebo, hydroxychloroquine:
· clearly did not aJect how many people died (of any cause; 9 studies in 8208 people);
· probably did not aJect how many people needed mechanical ventilation (3 studies; 4521 people);
· may not aJect how many people still tested positive for the virus aQer 14 days (3 studies; 213 people).
We are uncertain whether hydroxychloroquine aJected the number of people whose symptoms improved aQer 28 days.
Compared with other antiviral treatment (lopinavir plus ritonavir), chloroquine made little or no diJerence to the time taken for symptoms
to improve (1 study; 22 people).
Compared with usual care in one study in 444 people, hydroxychloroquine given with azithromycin (an antibiotic) made no diJerence to:
· how many people died;
· how many needed mechanical ventilation; or
· time spent in hospital.
Compared with febuxostat (a medicine to treat gout), hydroxychloroquine made no diJerence to how many people were admitted to
hospital or to changes seen on scans of people's lungs; no deaths were reported (1 study; 60 people).
Preventing COVID-19 in people exposed to it
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We are uncertain whether hydroxychloroquine aJected how many people developed COVID-19, or how many people were admitted to
hospital with COVID-19, compared with those receiving a placebo treatment (1 study; 821 people).
Compared with usual care, hydroxychloroquine made no diJerence to the risk of developing COVID-19, or antibodies to the virus, in people
exposed to it (1 study; 2525 people).
Unwanted e$ects
When used for treating COVID-19, compared with usual care or placebo, hydroxychloroquine:
· probably increases the risk of mild unwanted eJects (6 studies; 1394 people);
· may not increase the risk of serious harmful eJects (6 studies; 1004 people).
When given along with azithromycin, hydroxychloroquine increased the risk of any unwanted eJects, but made no diJerence to the risk
of serious unwanted eJects (1 study; 444 people).
Compared with lopinavir plus ritonavir, chloroquine made little or no diJerence to the risk of unwanted eJects (1 study; 22 people).
When used for preventing COVID-19, hydroxychloroquine probably causes more unwanted eJects than placebo, but may not increase the
risk of serious, harmful unwanted eJects (1 study; 700 people).
How confident are we in our results?
We are confident about our results for how many people died and moderately confident about how many needed mechanical ventilation.
We are moderately confident about the unwanted eJects of hydroxychloroquine treatment, but less confident about our results for serious
unwanted eJects; these results might change with further evidence.
How up-to-date is this review?
We included evidence published up to 15 September 2020.
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)



























































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Hydroxychloroquine (HCQ) compared to standard care or placebo for the treatment of people with COVID-19
Patients or population: adults with mild to severe COVID-19 
Settings: hospital inpatients and ambulatory care in the community
Intervention: HCQ

































HCQ results in little or no difference to death due to any cause.
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having negative PCR for SARS-CoV-2 on respiratory samples at
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We are uncertain whether HCQ increases or decreases the pro-
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The evidence is very uncertain about the effect of HCQ on pro-
longation of QT-interval on ECG.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; ECG: electrocardiogram; HCQ: hydroxychloroquine; HR: hazard ratio; PCR: polymerase chain reaction RCT: randomized controlled trial; RR: risk ra-
tio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
a Abd-Elsalam 2020; Cavalcanti 2020; Chen 2020a; Chen 2020c; Horby 2020; Mitjà 2020a; Pan 2020; Skipper 2020; Tang 2020. Of these, no participants died in Chen 2020a; Chen
2020c; Mitjà 2020a; Tang 2020.
bNot downgraded for risk of bias, as most of the evidence comes from Horby 2020 and Pan 2020, which have low risk of bias for this outcome.
cNot downgraded for indirectness, but it is noted that the population in the largest trial, Horby 2020, was mostly severely/critically unwell.
dThis was selected as the most relevant of three related outcomes reported by trials in this review. Analyses for the other outcomes (time to negative PCR for SARS-CoV-2 on
respiratory samples; negative PCR for SARS-CoV-2 at day 7 from enrolment) did not demonstrate an important benefit/harm.
e Chen 2020a; Chen 2020c; Tang 2020.
fDowngraded by one level for serious indirectness: almost all people had mild or moderate COVID-19; all were hospitalized; and all were from one region.
gNot downgraded for imprecision: narrow confidence interval, not including appreciable benefit nor harm. The sample size has approximately 80% power to detect an absolute
diJerence of 13%, or 90% power to detect an absolute diJerence of 15%, in this outcome for the group receiving HCQ versus those receiving standard care.
h Cavalcanti 2020; Horby 2020; Tang 2020.
iNot downgraded for indirectness: the three trials all recruited participants admitted to hospital.
jDowngraded by one level for serious imprecision: lower confidence interval bound represents no benefit nor harm from HCQ, whereas the upper bound suggests appreciable
harm.
k Tang 2020.
lDowngraded by one level for serious risk of bias: unclear risk of attrition and reporting bias, and high risk of other bias.
mDowngraded by one level for serious imprecision: lower confidence interval bound represents appreciable harm from HCQ, whereas the upper bound suggests no appreciable
benefit.
n Cavalcanti 2020; Chen 2020a; Chen 2020b; Mitjà 2020a; Skipper 2020; Tang 2020.
oDowngraded by one level for serious risk of bias: all trials except Skipper 2020 were open-label. Chen 2020a had a high risk of selection and reporting bias; Chen 2020b a high risk
of performance, detection, and reporting bias and unclear risk of selection bias; Mitjà 2020a a high risk of performance, detection, attrition, and reporting bias for this outcome,
and unclear risk of selection bias; Skipper 2020 a high risk of reporting bias and unclear risk of attrition bias; and Tang 2020 an unclear risk of attrition and reporting bias. We
deemed Skipper 2020, Mitjà 2020a, and Tang 2020 as at high risk of other bias.
pNot downgraded for inconsistency: despite high statistical heterogeneity (I2 = 87%), all of the eJect estimates were above a risk ratio of 1, with only one trial having a confidence
interval that crossed 1.




















































































































































































rDowngraded by two levels for very serious imprecision: low number of events, and lower confidence interval bound represents appreciable harm from HCQ, whereas the upper
bound includes appreciable benefit.
s Cavalcanti 2020.
tDowngraded by one level for risk of bias: Cavalcanti 2020 was unblinded, which could have led to detection bias, meaning more participants with QT prolongation were identified
in the HCQ group.
uDowngraded by one level for indirectness: Cavalcanti 2020 included only hospitalized patients, and excluded participants with severe disease, in whom problems with drug
interactions and cardiac arrhythmia are more likely.
vDowngraded by one level for imprecision: Cavalcanti 2020 had a low event rate for this outcome, and a small sample size leading to a very broad confidence interval.
 
 
Summary of findings 2.   Hydroxychloroquine (HCQ) compared to placebo for the prevention of COVID-19 in people who have been exposed to SARS-
CoV-2
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The evidence is very uncertain about the effect of HCQ on de-
velopment of confirmed COVID-19 at 14 days from enrolment.
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The evidence is very uncertain about the effect of HCQ on risk
of being hospitalized due to COVID-19.
Participants with any ad-
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; HCQ: hydroxychloroquine; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one level for serious indirectness: one trial, limited to North America; few older and comorbid participants, possibly due to social media-based recruitment and
internet-based data collection (Boulware 2020).
bDowngraded by two levels for very serious imprecision: confidence interval around eJect estimate includes appreciable benefit and appreciable harm.
cThis outcome, as reported by Boulware 2020, was closest to our predefined outcome of 'disease severity of participants who develop COVID-19, as defined by study authors'.
dDowngraded by one level for imprecision: no events in either group, therefore risk ratio is not estimable. The optimal information size to be confident that this is a true reflection
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B A C K G R O U N D
Description of the condition
Coronavirus disease 2019 (COVID-19) is a viral infection transmitted
by respiratory  droplet spread. It is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19
commonly presents as a mild respiratory tract illness, with fever
and cough the most commonly reported symptoms; however, in
some people this progresses to cause a life-threatening respiratory
syndrome (Guan 2020).
SARS-CoV-2 is a novel coronavirus that has caused a pandemic
since December 2019. Over 27 million people have been diagnosed
with COVID-19, and as of 7 September 2020 over 890,000 people
have died (JHU 2020). The World Health Organization (WHO)
declared COVID-19 a public health emergency of international
concern on 30 January 2020, and a pandemic on 11 March 2020
(WHO 2020a).
National data from China and Italy describe severe disease in
14% to 20% of people with COVID-19, and a further 2% to 5%
are reported to have critical illness (ISS 2020; Wu 2020). Early
mortality estimates ranged from around 2% to 12%, though this
has varied considerably between countries and as the pandemic
has progressed (ISS 2020; Wu 2020). Severe disease is characterized
by hypoxia, and progressive acute respiratory distress syndrome
appears to be the driver for mortality, although patients can
experience a syndrome with clinical and laboratory features of
severe systemic inflammation, termed a “cytokine storm” (Guan
2020; Mehta 2020).
At the other end of the spectrum, asymptomatic infection is not
uncommon; national Italian data describe this in approximately
10% of all people with a confirmed COVID-19 diagnosis (ISS
2020). More recently, wide-ranging longer-term morbidity has been
described in the absence of a severe initial illness (Greenhalgh
2020).
Transmission is by direct contact with people with the
infection,  indirectly via  contact with respiratory secretions on
objects and surfaces, or from droplets generated by sneezing and
coughing (WHO 2020b). Concerns have been raised about airborne
transmission: viability of SARS-CoV-2 has been demonstrated for at
least three hours when suspended in an aerosol (van Doremalen
2020). The amount of virus found in the respiratory tract appears to
be higher in people with severe versus those with mild disease, with
shedding of virus in the nasopharynx occurring for up to 25 days
in people with severe disease (Liu 2020a). The virus has also been
found in stools, with one study reporting live virus in non-diarrhoeal
stool, thus raising concerns about faecal-oral transmission (Wang
2020a).
Multiple episodes of transmission by pre-symptomatic or
asymptomatic people have been described (Bai 2020; Rothe 2020).
The main method for diagnosis of COVID-19 is by polymerase
chain reaction (PCR) of respiratory tract samples, mostly from
the nasopharynx or oropharynx. However, some guidelines advise
nasal swabs (CDC 2020), and some evidence suggests lower
respiratory samples, such as sputum, may have higher sensitivity
(Wang 2020a). Serological tests  are being used for detecting
antibodies to SARS-CoV-2 for confirmation of past infection,
although there are concerns regarding the evidence for  their
accuracy and value  in certain populations and clinical situations
(Deeks 2020).
Transmission is common in, though not limited to, households
(Pung 2020). Self-isolation, quarantine, and travel restrictions can
limit community transmission (Kraemer 2020), but prevention
measures within households can be more challenging. Healthcare
workers are at high risk of being infected. Data from Italy show that
20% of frontline healthcare workers responding to the pandemic
have developed COVID-19 (Lancet 2020). There were widespread
shortages of personal protective equipment (Lewis 2020). With
established community transmission in many countries, healthcare
workers are also at risk outside of health facilities. Despite
vaccine roll-out having commenced in some countries, achieving
target coverage will take several months, and will not eliminate
symptomatic infections in the near future. Consequently, there is
great interest in using existing drugs as treatment for or prevention
of COVID-19.
Several potential antivirals have been suggested for use in
treating people with COVID-19.  Remdesivir, a drug trialled for
Ebola virus disease and Middle East respiratory syndrome
(MERS),  showed  promising results in vitro (Wang 2020b).
An early  trial showed no benefit on time to clinical
improvement,  mortality, or clearance of the virus from the
respiratory tract  (Wang 2020c). Subsequently, two randomized
trials have reported a beneficial eJect of remdesivir on measures
of clinical improvement in patients hospitalized  with COVID-19,
but no significant eJect on mortality (Beigel 2020; Spinner 2020).
Other experimental antivirals being studied include the influenza
treatments umifenovir (Arbidol),  Deng 2020, and favipiravir,
Cai 2020, and the antiretroviral protease inhibitor combination
lopinavir/ritonavir (Cao 2020). Of the many other options being
investigated, corticosteroids are now recommended by WHO for
patients with COVID-19 requiring oxygen or higher respiratory
support therapy (WHO 2020d), having been reported to reduce
mortality in this population in a systematic review (REACT 2020).
Other options that have yet to show benefit in randomized trials
are tocilizumab (Stone 2020), convalescent plasma (Agarwal 2020),
and camostat  mesylate (HoJman 2020). Several studies have
used  novel methods to assess whether existing drugs can be
repurposed for COVID-19 treatment (Chandel 2020; Zhou 2020).
Description of the intervention
Chloroquine (CQ) and hydroxychloroquine (HCQ) are 4-
aminoquinoline compounds, derivatives of quinine, and have been
used as antimalarial drugs since the 1940s (Ben-Zvi 2012). HCQ
is an analogue of CQ in which one of the N-ethyl substituents of
CQ is β-hydroxylated. HCQ and CQ have similar pharmacokinetic
properties, with high oral bioavailability and tissue penetrance,
partial hepatic metabolism, and high volumes of distribution as
they diJuse into adipose tissue (Ben-Zvi 2012).
Both drugs have been used widely and for many years for the
treatment and prevention of malaria (although they are now largely
ineJective against falciparum malaria)  and in the treatment of
rheumatological conditions, such as systemic lupus erythematosus
and rheumatoid arthritis (Fiehn 2020; Steinhardt 2011).
The mechanism of action in malaria is thought to result from
inhibition of the biocrystallization of hemozoin, causing cytotoxic
accumulation of heme (Schrezenmeier 2020). For rheumatological
conditions, the mechanism of action is not fully delineated, but
appears to arise from multiple eJects. As weak bases, both CQ
and HCQ accumulate in the acidic environment within lysosomes,
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)










Cochrane Database of Systematic Reviews
and thus interfere with lysosomal activity and autophagy, which
in turn may inhibit major histocompatibility complex (MHC)
class II expression and antigen presentation, inhibiting immune
activation (Schrezenmeier 2020). CQ and HCQ also interfere with
Toll-like receptor (TLR)  signalling, again via changes to local
pH but also through direct binding to nucleic acids. TLR signal
pathways stimulate cytokine production, and CQ and HCQ have
been demonstrated to inhibit production of various cytokines
including interleukin (IL)-1, IL-6, tumour necrosis factor (TNF), and
interferon gamma (IFNγ) by mononuclear cells (van den Borne
1997).
CQ and HCQ have well-described adverse eJect  profiles.
Common adverse eJects include gastrointestinal upset and
headache (Ben-Zvi 2012). Several adverse eJects  are associated
with chronic therapy, such as QT-interval prolongation on
electrocardiogram,  other cardiac arrhythmia, and retinopathy
(Fiehn 2020). CQ is generally less tolerable than HCQ, and can cause
acute poisoning at a lower dose, as has been seen in reports from
the USA and Nigeria of members of the public taking CQ without a
prescription (CNN 2020; Owens 2020).
There are two types of CQ salts: CQ phosphate and CQ sulphate.
Most dosing recommendations for CQ refer to the salt rather than
the base compound. Usual doses for CQ are 250 mg to 500 mg CQ
phosphate (155 mg to 310 mg CQ base) per dose, or CQ sulphate 200
mg (150 mg CQ base), with weekly dosing for malaria prophylaxis,
and daily dosing for treatment  of malaria and rheumatological
conditions. HCQ is given at a dose of 400 mg weekly for malaria
prophylaxis, and 200 mg to 400 mg daily for rheumatological
disease (Ben-Zvi 2012).
How the intervention might work
Some researchers have suggested that both CQ and HCQ could be
clinically eJective against COVID-19. Studies have reported in vitro
activity against SARS-CoV-2 (Liu 2020b; Wang 2020b; Yao 2020), and
pharmacokinetic modelling suggests eJicacy of a few postulated
dosing regimens for treatment (Yao 2020).
Liu 2020b reported that CQ and HCQ appear to inhibit transport
of SARS-CoV-2 virions from early endosomes to endolysosomes in
Vero E6 cells, which may be a requirement for release of the viral
genome and subsequent viral replication. Wang 2020b performed
a "time-to-addition" assay using Vero E6 cells and found that CQ
appeared to both inhibit entry of SARS-CoV-2 into cells and inhibit
viral replication aQer cell entry. The authors of both studies also
speculate that CQ and HCQ could impact on disease severity in
COVID-19 through modulating the excess cytokine release that
appears to contribute to life-threatening forms of the disease (Liu
2020b; Wang 2020b).
Why it is important to do this review
Given the pace of the pandemic, and the extraordinary impact on
public health and society in many countries, there is high demand
for eJective prevention and treatment interventions for COVID-19.
CQ and HCQ are inexpensive drugs that are registered in most
countries, and are included on the WHO essential medicines list
(WHO 2019). They can be delivered orally, and both drugs have well-
described safety profiles in adults and children. Given the uncertain
eJects of  antiviral drugs for  treatment  of COVID-19, or the
eJectiveness of the newly developed vaccines, identifying existing
medicines that may be of benefit is of high importance. Despite
the small number of published studies, some governments have
recommended using HCQ as prophylaxis for healthcare workers,
and some prominent political figures have asserted that CQ or HCQ
should be used as a first-line treatment for COVID-19. Sadly, there
have already been instances of significant harm where individuals
have misinterpreted news stories about the use of CQ and suJered
toxicity as a result (CNN 2020).
CQ and HCQ for treatment of COVID-19
Earlier national guidelines, mostly in  February to April
2020,  recommended  CQ or HCQ for the treatment of individuals
with COVID-19. Belgian guidelines recommended HCQ for severe
disease, and advised that it be considered for mild-moderate
disease (WIV-ISP 2020). Chinese guidelines advised consideration
of CQ in all hospitalized patients, although later iterations have
expressed caution regarding dosing and special patient groups
(Wong 2020). Italian guidelines recommended early use of CQ
or HCQ, or lopinavir/ritonavir (Brescia-COVID Group 2020). More
recently, concerns about adverse eJects have led to removal
of recommendations to use  CQ and HCQ from several national
guidelines, alongside which the US Food and Drug Administration
revoked their initial emergency use authorization provided for use
of CQ and HCQ in the treatment of COVID-19 (FDA 2020), and the
UK Medicines and Healthcare products Regulatory Agency enforced
suspension of recruitment to trial arms using CQ or HCQ as an
intervention (Robinson 2020).
Initial observational studies reported eJicacy  of CQ and HCQ.  A
widely publicized small, non-randomized study from  Marseille,
France,  reported that HCQ was associated with earlier negative
PCR for SARS-CoV-2 among 20 patients given HCQ compared
to those  who had refused to take HCQ or who had presented
to other hospitals (Gautret 2020a). Subgroup analyses reported
quicker  clearance of the virus for six participants who had
azithromycin in combination with HCQ versus those who received
neither drug  (Gautret 2020a). There has been widespread
criticism of the methods, reporting, and conclusions of this study
 (Machiels 2020). The same group then published two observational
single-arm cohorts of patients treated with HCQ plus azithromycin,
reporting benefit of the combination (Gautret 2020b; Million 2020).
Soon aQer this, another research group from France reported much
poorer clinical and virological outcomes in 11 hospitalized patients
treated with both drugs (Molina 2020).  A quasi-experimental
study of patients admitted with moderate COVID-19 in four French
hospitals reported no diJerence in eJicacy outcomes, but reported
early discontinuation  of HCQ in 9 of 84 participants due to
abnormalities on electrocardiography (Mahévas 2020).
More recently, a number of larger non-randomized studies have
reported beneficial eJects of HCQ. A retrospective cohort study
in  Michigan, USA compared  four groups of a total of 2541
patients hospitalized with confirmed COVID-19 according to
physician-directed treatment assignment: 1202 received HCQ; 147
azithromycin alone; 783 HCQ with azithromycin; and 409 received
neither drug (Arshad 2020). A significant reduction in mortality
was reported when HCQ was received  (hazard ratio (HR) 0.49,
95% confidence interval (CI) 0.29 to 0.83). DiJerences in baseline
characteristics suggested underlying confounding, although an
underpowered propensity-matching analysis reported persistence
of the reported mortality benefit  (Arshad 2020). The quantity
of missing data and early patient  exclusions  were  not reported
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(Arshad 2020). Another study retrospectively comparing 4542
patients in Belgian hospitals reported lower risk of death in the
group  who received HCQ as per national guidance (804/4542,
17.7%) versus 3533 patients who did not receive HCQ (957/3533,
27.1%) (Catteau 2020). AQer adjusting for multiple covariates,
this diJerence was found to be statistically significant  (adjusted
HR 0.68, 95% CI 0.62 to 0.76) (Catteau 2020). Of note, nearly 50%
of patients screened for eligibility were excluded, though some of
these patients were found to have similar baseline characteristics
to those included in the analysis (Catteau 2020).
At the time of writing the  protocol for this review, China had
reported two small randomized trials of HCQ, with mixed results
(Chen 2020a; Chen 2020b). Several trials have since been reported
and are included in this review.
CQ and HCQ for preventing COVID-19
Despite no human data on prophylaxis early in the pandemic, the
Indian Council of Medical Research (ICMR) recommended HCQ as
pre-exposure prophylaxis for frontline healthcare workers having
“high-risk” contact with patients with suspected or confirmed
COVID-19, and postexposure prophylaxis for household and
healthcare worker contacts of patients with confirmed COVID-19
(ICMR 2020). The background section of this recommendation
referred to  in vivo evidence for eJicacy of HCQ for the treatment
of COVID-19, and inferred prophylactic eJicacy from therapeutic
eJicacy (ICMR 2020). Concerns have been raised by multiple groups
regarding this approach (Rathi 2020).
Since then, two comparative studies have reported the eJect of use
of CQ or HCQ for prophylaxis of COVID-19, one of which is a
randomized trial (Boulware 2020), and the other a case-control
study conducted by the ICMR  (Chatterjee 2020).  The former is
included in this review. The case-control study involved a telephone
survey of healthcare workers tested for SARS-CoV-2  when
suspected of having symptomatic COVID-19: the 378 cases (172
of whom took HCQ) had a positive PCR test for SARS-CoV-2,
whilst 373 controls (193 of whom used HCQ) had a negative test
(Chatterjee 2020).  Whilst use of HCQ versus no use of HCQ was
not found to be significantly associated with confirmed COVID-19,
a dose-response eJect was reported, with lower odds of positive
PCR the higher the number of weekly doses reported to have
been taken:  for four or five maintenance doses of HCQ aQer an
initial loading dose, the adjusted odds ratio using  multivariate
regression analysis was 0.44 (95% CI 0.22 to 0.88) (Chatterjee 2020).
Reported side eJects were uncommon.  Methods were reported
incompletely, such as the sampling approach for cases and controls
from the database of 21,402 healthcare workers, of whom 1073 has
a positive PCR test (Chatterjee 2020). The target sample size was
not met, though this was calculated for HCQ prophylaxis as a binary
exposure variable, rather than the duration-based groups used in
the eventual analysis (Chatterjee 2020).  Several trials exploring
the use of CQ or HCQ for prophylaxis of COVID-19 are ongoing
(Cortegiani 2020).
Adverse events have been a particular concern with CQ and HCQ.
Studies using data from pharmacovigilance databases prior to the
use of these drugs, and azithromycin, have suggested caution
regarding even short-term use due to their association with cardiac
adverse eJects (Nguyen 2020; Singh 2020).  A randomized trial
comparing higher-dose CQ (41 participants) versus lower-dose CQ
(40 participants)  in  patients hospitalized with severe COVID-19
in northern Brazil was stopped early by the independent safety
monitoring board due to higher death and cardiac serious adverse
events, including QT-interval prolongation on electrocardiogram,
in the group receiving higher-dose CQ (Borba 2020).  An  article
published in The Lancet  reporting higher incidence of death and
serious adverse events in patients receiving CQ or HCQ with or
without a macrolide drug (azithromycin or clarithromycin),  as
documented in a large international surgical registry. The Lancet
later retracted this when the data and analysis were questioned,
though regulatory authorities and trial steering groups had already
decided to stop trials or trial arms investigating CQ and HCQ (Mehra
2020).
At the time of development of the protocol for this review, other
systematic reviews had already been produced. Due to the intense
interest in finding a therapeutic that is safe and eJective for
COVID-19, many review papers have been published over the
last six months.  Reviews published early in the outbreak relied
on pre-clinical data, expert commentary, and small, mostly non-
randomized studies. A systematic review of CQ for the treatment of
COVID-19, which searched PubMed and Embase up to 1 March 2020,
identified no published studies other than the aforementioned
letter (Gao 2020), though 23 clinical trials of CQ or HCQ  were
found on registries (Cortegiani 2020).  Another systematic review
of CQ and HCQ for treating COVID-19, published as a preprint on
30 March 2020, concluded: “There is theoretical, experimental,
preclinical and clinical evidence of the eJectiveness of chloroquine
in patients aJected with COVID-19” (Kapoor 2020). A further review
included one non-randomized study and one randomized trial,
and concluded: "Without further evidence, HCQ is not appropriate
for patients with COVID-19 in primary care" (McCormack 2020). A
systematic review of antimalarials (CQ and HCQ) for the treatment
of COVID-19 was produced by the Epistemonikos Working Group,
which synthesized the results of two small randomized trials and
found low- to very low-certainty evidence regarding eJicacy and
harms (Epistemonikos 2020).
We propose that, in this context, a systematic review of randomized
controlled trials using standard Cochrane methods that provides
summary estimates of eJects for both treatment and prophylactic
use of CQ and HCQ, with an appraisal of the certainty of the
evidence using the GRADE approach, is important for the general
public, clinicians, and policymakers. We plan to update this review
in an expedited fashion as new data become  available from the
trials that are currently in progress on prevention.
O B J E C T I V E S
To evaluate the eJects of chloroquine (CQ) or hydroxychloroquine
(HCQ) as:
1. an antiviral treatment on death and time to clearance of the virus
from clinical samples in people with COVID-19;
2. a prophylactic treatment on prevention of COVID-19 in people at
risk of SARS-CoV-2 exposure;
3. a prophylactic treatment on prevention of COVID-19 in people
who have been exposed to SARS-CoV-2.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Objective 1. People who have COVID-19, as defined by study
authors.
Objective 2. People who are at risk of SARS-CoV-2 exposure, as
defined by study authors.
Objective 3. People who have been exposed to SARS-CoV-2, as
defined by study authors.
Types of interventions
Intervention
Chloroquine (CQ) or hydroxychloroquine (HCQ) given by any route
of administration and dose used alone or in combination with other
treatments.
Control
No treatment, supportive treatment, or other experimental
antiviral treatment (i.e. any other treatment that does not contain
CQ or HCQ).
Types of outcome measures
Objective 1. For treatment of COVID-19 disease
Primary outcomes
• Death
• Time to negative PCR for SARS-CoV-2 on respiratory samples
Secondary outcomes
• Number of participants admitted to hospital (if receiving
ambulatory treatment)
• Number of participants requiring mechanical ventilation
• Length of hospital admission
• Time to clinical improvement, as defined by study authors
• Duration of mechanical ventilation postenrolment in survivors
of COVID-19
Objectives 2 and 3. For prevention of COVID-19 disease in people
at risk of exposure/who have been exposed to SARS-CoV-2
Primary outcomes
• Development of confirmed COVID-19, as defined by study
authors
• Production of antibodies to SARS-CoV-2
Secondary outcomes
• Development of COVID-19 in household contacts of the recipient
of the prophylaxis
• Disease severity of participants who develop COVID-19, as
defined by study authors
Adverse events (relating to objectives 1, 2, and 3)
• All adverse events
• All serious adverse events attributed to study drug (i.e. serious
adverse eJects)
• QT-interval prolongation
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress) up to 15 September 2020.
Electronic searches
We searched the following databases on 15 September 2020 using
the search terms and strategy described in Appendix 1:
the Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library, up to Issue 9 of 12, September
2020; MEDLINE (PubMed) (1966 to 15 September 2020); and
Embase  (1974 to 15 September 2020). We also searched Current
Controlled Trials (www.controlled-trials.com) and the World
Health Organization International Clinical Trials Registry Platform
(www.who.int/clinical-trials-registry-platform) using 'chloroquine',
'hydroxychloroquine', 'coronavirus', and 'COVID-19' as search terms
on 15 September 2020. We also searched COVID-specific resources
COVID-NMA (www.covid-nma.com) and the Cochrane COVID-19
Study Register (covid-19.cochrane.org/), which are updated daily
with lists of ongoing and published trials, using 'chloroquine' and
'hydroxychloroquine' on 15 September 2020.
Searching other resources
We contacted researchers in the field to identify any unpublished
or ongoing studies.
Data collection and analysis
Two review authors (BS and HR, MC, or TK)  independently
conducted each step of study selection and data extraction. Any
disagreements were resolved through discussion.
Selection of studies
Two review authors (BS and HR or MC) independently screened
the search results using Covidence (Covidence), and retrieved the
full-text articles of all potentially relevant trials. We examined each
trial report to ensure that we included multiple publications from
the same trial only once. We planned to contact  trial authors for
clarification if eligibility of a trial was unclear. Any disagreements
were resolved through discussion. We listed the excluded studies
and the reasons for their exclusion in the  'Characteristics of
excluded studies' table. The study selection process is illustrated in
a PRISMA diagram (Figure 1).
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Figure 1.   Study flow diagram.
 
Data extraction and management
Two review authors (BS and HR, MC, or TK)  used a piloted data
extraction form to extract data on participant characteristics,
diagnostic criteria, disease severity, comorbidity, CQ or HCQ
dose and administration, other treatments given, and outcome
measures. Any disagreements were resolved through discussion.
We contacted the corresponding trial author in the case of unclear
or missing data.
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For dichotomous outcomes, we recorded the number of
participants that experienced the event and the number of
participants randomized to each treatment group. We recorded
the number of participants analysed in each treatment/
prophylaxis arm, and used the discrepancy between the figures to
calculate the number of participants lost to follow-up, which would
allow us to perform sensitivity analyses to investigate the eJect of
missing data if necessary. For continuous outcomes, we planned
to extract means for the outcome in each group; we also recorded
medians for narrative comparisons where means were unavailable.
Assessment of risk of bias in included studies
Two review authors (BS and HR, MC, or TK) assessed the
methodological quality of studies using the Cochrane 'Risk of bias'
tool, and reported the results in a 'Risk of bias' figure (Higgins 2011).
We classified each 'Risk of bias' domain as either at high, low, or
unclear risk  of bias (Higgins 2011). We assessed the risk of bias
associated with blinding for each outcome separately and used
these judgements in the GRADE assessment, but made an overall
judgement  in the 'Risk of bias' assessment for each study based
on the primary outcome as stated by the study authors. For other
domains we assessed the risk of bias for the trial as a whole. We
planned to attempt to contact the trial authors if information was
not specified or was unclear. Any disagreements were resolved by
discussion between the review authors.
Measures of treatment eBect
We  presented dichotomous outcomes as risk ratios (RR) with
95% confidence intervals (CIs). We reported continuous outcomes
as mean diJerences (MD) with 95% CIs if the outcomes were
measured in the same way across all included trials. If included
trials measured continuous outcomes in diJerent ways, we would
use the standardized mean diJerence (SMD) and 95% CI as the
eJect measure. If using the SMD, we would re-express the SMD in
the units of one or more of the specific measurement instruments
used in the original studies, to aid interpretation. We presented
time-to-event outcomes as hazard ratios (HRs) and 95% CIs.
Unit of analysis issues
We did  not anticipate that any cluster-randomized studies
would meet our inclusion criteria. In the case that  cluster-
randomized studies did meet our inclusion criteria, we
would ensure appropriate analysis adjusting for the eJect of cluster
randomization was carried out before including eJects estimates
in a meta-analysis. If available, we planned to extract adjusted
measures of eJect from the trial reports. If only unadjusted data
were available, we would adjust these data ourselves using the
intracluster correlation coeJicient (ICC). If the ICC was not reported,
we would contact the study authors to obtain it, or borrow an
ICC value from a similar study, or estimate the ICC. If the ICC was
estimated, we would perform sensitivity analyses to investigate the
robustness of our analyses.
If we identified  multi-arm trials, we would either select relevant
arms for inclusion in our analyses, or if more than two arms were
relevant to this review, we would either combine intervention
arms so that there was one comparison, or split the control group
between multiple comparisons so that participants are not double-
counted in meta-analysis.
We did not anticipate that any cross-over trials for treatment of
COVID-19 would meet our inclusion criteria, as cross-over trials are
used to evaluate interventions that have a temporary eJect in the
treatment of stable, chronic conditions.
We also thought it unlikely that cross-over trials would have been
conducted for the prevention of COVID-19, due to the long half-
life of CQ/HCQ, meaning that a long wash-out period would be
required. It is also unknown whether the eJects of receiving CQ or
HCQ in the first period of the trial may have an irreversible eJect
that would subsequently impact outcomes in the second period
of the trial. If we identified cross-over trials for the prevention of
COVID-19, we would include data from the first period of the trial
only. We would carefully consider whether studies that reported
data only for the first period of a cross-over trial were at risk of bias,
and whether the omission of studies that did not report data from
the first period of the trial (i.e. only a paired analysis was reported)
would lead to bias at the meta-analysis level.
Dealing with missing data
The primary analysis for eJicacy outcomes was an available-
case analysis where the denominator is the number of patients
completing follow-up to the point of outcome assessment, where
possible. Where this was not possible, we performed an intention-
to-treat analysis, with investigation of the eJects of missing
data. For safety outcomes, we planned to include all participants
receiving at least one dose of the intervention drug or placebo.
We planned to carry out sensitivity analyses to explore the impact
of missing data on the primary outcomes. For dichotomous
outcomes, we planned to vary the event rate within the missing
patients from intervention and control groups within plausible
limits. For continuous data, we planned to also perform sensitivity
analyses using the methods described by Ebrahim 2013 and
Ebrahim 2014.
Assessment of heterogeneity
We assessed heterogeneity by visually inspecting the forest plots
to determine closeness of point estimates with each other and
overlap of CIs. We used the Chi2 test with a P value of 0.10 to
indicate statistical significance, and the I2 statistic to measure
heterogeneity. We used the following ranges outlined in the
Cochrane Handbook for Systematic Reviews of Interventions to
interpret the I2 statistic (Higgins 2019):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We also considered the magnitude and direction of eJects, and the
strength of evidence for heterogeneity (e.g. P value from the Chi2
test), when determining the importance of the observed I2 value.
Assessment of reporting biases
We planned to construct a funnel plot to investigate any potential
reporting bias if  10 or more studies were included for a given
outcome.
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Data synthesis
We analysed the data using Review Manager Web (RevMan Web
2019). We performed all meta-analyses using  random-eJects
models. Where a meta-analysis was not appropriate due to
important clinical or methodological heterogeneity, or if study
results diJered to the extent that combining them in a pooled
analysis would not make sense, we summarized data in tables.
Subgroup analysis and investigation of heterogeneity
We planned to investigate heterogeneity by performing the
following subgroup analyses for people with COVID-19.
• Disease severity at presentation
• Time in the illness when treatment started (< 7 days, and ≥ 7
days aQer symptoms started)




• Admitted to hospital  versus  receiving ambulatory/outpatient
treatment
• CQ or HCQ dosing regimen
We planned to investigate heterogeneity by performing the
following subgroup analyses for people exposed to SARS-CoV-2 or





• Comorbidity, such as cardiovascular disease, diabetes, and
immunosuppression
Sensitivity analysis
To explore the possible eJect of losses to follow-up on the eJect
estimates for the primary outcomes, we planned to perform
sensitivity analyses. For dichotomous outcomes, we planned to
vary the event rate within the missing patients from intervention
and control groups within plausible limits. For continuous data,
we planned to perform sensitivity analyses using the methods
described by Ebrahim 2013 and Ebrahim 2014.
Summary of findings and assessment of the certainty of the
evidence
We summarized the results of the analysis in 'Summary of findings'
tables, and presented the summary eJects estimates  for the
primary outcomes and other important outcomes with illustrative
comparative risks. We  used the GRADE framework to evaluate
the certainty of evidence for each outcome, as developed by
the GRADE Working Group and described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2019).
R E S U L T S
Description of studies
Results of the search
Our searches identified 953 records, 93 of which were excluded as
duplicate records. Of the remaining 860 records, we excluded 603
based on the assessment of titles and abstracts. We retrieved 257
full-text publications to assess for inclusion. The screening process
is illustrated in a flow diagram in Figure 1.
Ongoing studies
From our search on 15 September 2020 and reviewing the COVID-
NMA website, we identified 122 ongoing trials registered for
treatment or prevention of COVID-19. Due to the pressures of the
pandemic and fluctuating interest in CQ and HCQ, many trials
have been suspended or terminated, or had significant changes
in protocol. We have therefore presented a summary of those
ongoing  trials that are reported to be recruiting actively, or that
have completed recruitment but are yet to publish, and have a
target recruitment of 500 or more participants, in tables (Table
1 for 22 ongoing treatment trials; Table 2 for 15 ongoing prevention
trials). Up-to-date lists of ongoing trials can be found at www.covid-
nma.com, updated daily.
Included studies
We included  14 RCTs with a total of 11,915 participants. Further
details of the trials  are provided in subsections  for each  of the
review's objectives. A summary description is provided in Table 3,
with more details in the Characteristics of included studies section.
Objective 1. For treatment of COVID-19 disease
We included  12 RCTs (8569 participants) assessing treatment of
patients diagnosed with COVID-19.
Trial size
Trial size varied widely, from 22 participants in Huang 2020 to 4716
participants in Horby 2020. Five trials recruited fewer than 100
participants each (Chen 2020a; Chen 2020b; Chen 2020c; Davoodi
2020; Huang 2020).
Geographical location and time period
Four trials were conducted in China, early  in the pandemic; all
completed recruitment in February 2020 (Chen 2020a; Chen 2020b;
Huang 2020; Tang 2020). The other trials recruited from March
until May or June 2020:  in Brazil (Cavalcanti 2020);  Egypt (Abd-
Elsalam 2020); Iran (Davoodi 2020);  Spain (Mitjà 2020a);  Taiwan
(Chen 2020c); the UK (Horby 2020); the USA and Canada (Skipper
2020; around 90% of participants were in the USA); and one trial
recruited participants in 30 countries globally (Pan 2020).
Participants
None of the trials recruited children. The protocol of one trial was
modified on 9 May 2020 to allow recruitment of children, but none
of the participants in the study arms included in this review (i.e. HCQ
and standard care) were children (Horby 2020). The average age in
most trials was between 40 and 50 years old, except for Horby 2020,
in which the mean age of participants was around 65 years in both
arms, and Pan 2020, with a median somewhere between 50 and 69
years old.
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Nine trials recruited  hospitalized patients (Abd-Elsalam 2020;
Cavalcanti 2020; Chen 2020a; Chen 2020b; Chen 2020c; Horby
2020; Huang 2020; Pan 2020; Tang 2020), whilst the other
three  trials were focused on  ambulatory care and only included
outpatients (Davoodi 2020; Mitjà 2020a; Skipper 2020).
Overall, 7347/8569 (85.7%) participants had COVID-19 confirmed
by SARS-CoV-2 PCR on clinical samples. Six  trials  recruited
   participants only if they had a positive PCR (Chen 2020a; Chen
2020b; Chen 2020c; Huang 2020; Mitjà 2020a; Tang 2020). In three of
the remaining six trials, the majority of participants had a positive
PCR: 504/665 (75.8%; Cavalcanti 2020), 4234/4716  (89.8%; Horby
2020), and 1850/1853 (> 99%; Pan 2020).  Skipper 2020  reported
169/491 (34.4%) to have positive PCR testing, though the test result
was pending for 48/491 (9.8%), and not available or not done for
204/491 (41.5%) (Skipper 2020).  Abd-Elsalam 2020  and  Davoodi
2020 did not report number of participants with positive PCR test
results.
Where severity of COVID-19 disease  at enrolment  was not
reported using author label or defined criteria equivalent to
asymptomatic, mild, moderate, severe or critical, this was inferred
using classification as described by WHO guidance  (WHO 2020c).
Of  the 1800 participants (9 trials) amenable to classification, 100
(6%) were asymptomatic, 1183 (66%) had mild disease, 506 (28%)
moderate disease, and  11 (0.6%) severe disease. Participants in
Horby 2020 were classified according to receipt of oxygen or other
respiratory support: 1112/4716 (24%) were not receiving oxygen or
ventilation at enrolment (who would be labelled as asymptomatic
or mild);  2811/4716 (60%) received oxygen (who could have
moderate, severe or critical disease, depending on oxygen needs);
and  793/4716 (17%)  received  invasive  ventilation (who would
be classified as having critical disease). Participant disease
severity was reported similarly by  Pan 2020: 686/1853 (37%)
were not receiving oxygen at enrolment; 1000/1853 (54%) were
receiving oxygen or other respiratory support but not  invasive
ventilation; 167/1853 (9%) were receiving invasive ventilation.
Where reported, hypertension was usually the most common
comorbidity, though its prevalence varied widely:  from 6% of
participants in  Tang 2020  and 11% in  Skipper 2020, to 27%
in Chen 2020a and 39% in Cavalcanti 2020. The next most common
comorbidity was usually diabetes mellitus, though its prevalence
varied from  < 10% (Chen 2020a; Huang 2020; Skipper 2020), to
19% in  Cavalcanti 2020, 21% in  Pan 2020,  and 27% in  Davoodi
2020 and Horby 2020. In three of the five trials reporting chronic
heart and lung  disease (including asthma), prevalence for each
was < 15% of participants (Cavalcanti 2020; Mitjà 2020a; Skipper
2020);  Horby 2020  reported 26%  of participants to have heart
disease and 22% chronic lung disease; Pan 2020 reported 21% of
participants to have cardiac disease and 12% chronic lung disease
or asthma. Other reported comorbidities were present in < 5% of
participants, such as cancer and chronic renal or liver disease. Two
of the three  outpatient-treatment trials reported proportions of
participants with no known comorbidities: 47% for Mitjà 2020a
and 31% for  Skipper 2020. The third outpatient-treatment trial
reported 28%  of participants to have diabetes mellitus, and 1
of 54 participants had underlying lung disease (Davoodi 2020).
Two trials did not report comorbid conditions for their participants
(Chen 2020b; Chen 2020c).
Special patient populations were not commonly recruited.
Most  trials excluded pregnant women (Abd-Elsalam 2020;
Cavalcanti 2020; Chen 2020a; Chen 2020b; Chen 2020c; Huang
2020; Mitjà 2020a; Tang 2020).  Whilst not excluding pregnant
women from their trials,  Horby 2020 and Pan 2020 did not
report how many pregnant women were included, and  Skipper
2020  recruited none. Only  Skipper 2020  reported recruitment
of people with immunosuppression other than due to HIV (3
of 491  total participants); across  all trials, 26 participants were
reported to have HIV.
Two trials provided a breakdown of contact history: 238/293 (81%)
had healthcare exposure history and 2% were household
contacts in Mitjà 2020a; 51% of participants in Skipper 2020 were
healthcare workers, whilst  29% had household exposure to
someone with COVID-19.
Time from onset of symptoms to enrolment varied widely between
trials. The outpatient trials reporting this information enrolled very
soon aQer symptom onset, with medians of between one and
two days in  Skipper 2020 and three days in Mitjà 2020a.  Three
of the hospital-based trials recruited on average between  six
and nine days from onset (Cavalcanti 2020; Chen 2020a; Horby
2020).  Tang 2020  enrolled at a mean of 16 to 17 days from
onset, which contributed to the change in timing of their primary
outcome, from negative SARS-CoV-2 PCR at 28 days to 10 days from
enrolment. Huang 2020 recruited relatively early from onset, but
this appeared to be earlier for the CQ arm (median 2.5 days) than
for the lopinavir/ritonavir arm (6.5 days). Abd-Elsalam 2020, Chen
2020b, Chen 2020c, Davoodi 2020, and Pan 2020 did not report time
from symptom onset to enrolment.
Interventions and comparators
Four comparisons are reported for Objective 1  (see  EJects of
interventions), as follows.
1. HCQ versus standard care without HCQ, or placebo
Ten trials were included in this comparison  (Abd-Elsalam 2020;
Cavalcanti 2020; Chen 2020a; Chen 2020b; Chen 2020c; Horby
2020; Mitjà 2020a; Pan 2020; Skipper 2020; Tang 2020). Nine trials
compared HCQ to standard of care, and one trial, Skipper 2020,
compared HCQ to placebo (folic acid).  Two trials were multi-
arm trials:  Horby 2020 allocated to five arms in a 2:1:1:1:1 ratio
(the control arm (standard care)  was twice the size of each
intervention arm), and Pan 2020 randomized to one of five arms in
a 1:1:1:1:1 ratio, of which HCQ was one arm. Horby 2020 and Pan
2020 are ongoing adaptive trials that have each dropped the HCQ
arm.
2. CQ versus lopinavir/ritonavir 
One trial was included in this comparison (Huang 2020).
3. HCQ + azithromycin versus standard care
One trial was included in this comparison,  in which participants
were randomized 1:1:1 to receive HCQ, HCQ and azithromycin, or
standard of care without HCQ or azithromycin (Cavalcanti 2020).
4. HCQ versus febuxostat 
One trial was included in this comparison (Davoodi 2020). In this
trial, febuxostat was the experimental drug of interest, and HCQ was
the comparator.
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Dosing regimens for HCQ varied widely, and are summarized
in Table 4. To highlight the heterogeneity of regimens between the
trials, the loading daily dose on day 1 for participants in  Horby
2020 and Pan 2020 (2000 mg) was equivalent to the total cumulative
dose given to participants in Chen 2020a, Chen 2020b, and Davoodi
2020.
Huang 2020 administered 500 mg of CQ twice daily for 10 days to
participants in the CQ arm, without a loading dose on day one, for
a cumulative total dose of 10,000 mg.
Co-interventions
The pharmacological co-interventions reported per arm in the
treatment trials for comparison 1 (HCQ versus standard care
without HCQ or placebo) are shown in Table 5. Considerable
variability in reporting was observed. The following are of particular
note regarding co-interventions.
• Cavalcanti 2020 reported that fewer than 10% of participants did
not receive concurrent treatment with an antiviral, antibiotic, or
corticosteroid. However, corticosteroids were rarely given (13 of
448 participants).
• All participants in  Chen 2020a  received nebulized interferon-
alpha, and the majority (22/30) received umifenovir (Arbidol).
Both are postulated anti-SARS-CoV-2 drugs.
• Horby 2020  reported that a minority of participants received
concurrent corticosteroids (dexamethasone) (< 10%) and
azithromycin (< 20%).
• Participants initially enrolled into the HCQ arm of  Mitjà
2020a  received cobicistat-boosted darunavir with HCQ as a
planned combination, which was stopped when its activity
against SARS-CoV-2 was called into question.
• Skipper 2020 reported subgroup analyses for self-reported use
of zinc and vitamin C; this was common, with ~25% and ~50% of
participants reporting their use, respectively.
There did not appear to be a diJerence in receipt of
pharmacological co-interventions between trial arms, where this
information was reported. No trials reported concurrent use of
remdesivir.
Follow-up
One trial measured all outcomes up to six days (Chen 2020b); six
trials followed participants up until 14 to 15 days (Cavalcanti 2020;
Chen 2020a; Chen 2020c; Davoodi 2020; Huang 2020; Skipper 2020);
and four trials completed data collection at 28 days from enrolment
(Abd-Elsalam 2020;  Horby 2020; Mitjà 2020a; Tang 2020).  Pan
2020  followed participants up to discharge from hospital. Two
trials used telephone follow-up in place of or in addition to in-
person outcome assessment (Cavalcanti 2020; Mitjà 2020a);  one
trial employed  online surveys for enrolment and all follow-up
(Skipper 2020).
Outcome measures
Our predefined primary outcomes were death and time to negative
PCR for SARS-CoV-2 on respiratory samples. Ten  trials reported
death  (Abd-Elsalam 2020; Cavalcanti 2020; Chen 2020a; Chen
2020c; Davoodi 2020; Horby 2020; Mitjà 2020a; Pan 2020; Skipper
2020; Tang 2020).
PCR-based outcomes varied amongst the included trials. Three
trials reported time to negative PCR (Abd-Elsalam 2020;  Chen
2020a; Huang 2020); four trials reported negative PCR at specified
time points: 7 days (Chen 2020a; Tang 2020); 10 days (Huang 2020;
Tang 2020); and 14 days from enrolment (Chen 2020c; Huang 2020;
Tang 2020); and the primary outcome in one trial was reduction in
'viral load' (amount of virus per swab sample) at day 3 and day 7
aQer enrolment (Mitjà 2020a).
Regarding our secondary outcomes, the following information was
reported.
• Number of participants admitted to hospital (if receiving
ambulatory treatment): this was reported by the three
outpatient-based trials  (Davoodi 2020;  Mitjà 2020a; Skipper
2020).
• Number of participants requiring mechanical ventilation: three
trials reported this outcome (Cavalcanti 2020; Horby 2020; Tang
2020).
• Length of hospital admission: this was reported as a mean
by Abd-Elsalam 2020 and Cavalcanti 2020; the authors of Tang
2020  provided this upon  request.  Horby 2020  reported a
median, but without interquartile range, and no mean. Huang
2020  provided a Kaplan-Meier chart, but no mean; however,
proportion discharged by day 14 from enrolment was reported.
• Time to clinical improvement was reported as survival data
only by  Tang 2020. For the remaining trials, either a mean
(Abd-Elsalam 2020)  or median (Chen 2020a; Mitjà 2020a)  was
reported, and/or the definitions of time to clinical improvement
were not comparable (Chen 2020a; Chen 2020b).
• Duration of mechanical ventilation postenrolment in survivors
of COVID-19 was not reported by any trials.
Five of the 12 included trials did not report the number of
participants experiencing any adverse events  (Abd-Elsalam 2020;
Chen 2020c; Davoodi 2020; Horby 2020; Pan 2020). Five, with
some overlap (Abd-Elsalam 2020; Davoodi 2020; Horby 2020; Pan
2020;  Skipper 2020), did not report the number of participants
experiencing serious adverse events, with Skipper 2020 stating: “No
serious adverse events attributable to the study drug occurred”. The
remaining trials reported events without attribution to a particular
drug.
Additionally,  Skipper 2020  used the change in symptoms over
14 days from enrolment as their primary outcome. This diJered
significantly from our predefined outcomes, and  was not
comparable with the outcomes of other trials.
Objective 2. For prevention of COVID-19 disease in people at risk
of exposure to SARS-CoV-2
No eligible trials were identified for this objective.
Objective 3. For prevention of COVID-19 disease in people who
have been exposed to SARS-CoV-2
We included two trials for this objective: one with double-
blind  individual  randomization to  HCQ or placebo that enrolled
821 participants (Boulware 2020), and one open-label cluster-RCT
comparing HCQ with standard care that enrolled 2525 participants
(Mitjà 2020b).
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Geographical location and time period
Boulware 2020 was based in the USA and Canada, and recruited
from  17 March to  6 May 2020.  Mitjà 2020b  recruited in Spain
between 17 March and 28 April 2020.
Participants
Both trials only recruited asymptomatic people with a history of
exposure to people with laboratory-confirmed COVID-19 (Boulware
2020; Mitjà 2020b).
In Boulware 2020, exposure history was most commonly in
a healthcare setting (545/821, 66%), followed by household
contact (245/821, 30%). The corresponding figures for  Mitjà
2020b  were 12% for healthcare workers and 28% household
exposure; additionally,  49% worked and 13% lived in a nursing
home. Exposure was deemed to be high risk (neither eye protection
nor a surgical mask/respirator was worn) in 88% of participants,
with 60% in  Boulware 2020 wearing no personal protective
equipment. Participants were enrolled at a median of three days
aQer exposure in Boulware 2020 and four days aQer exposure in
Mitjà 2020b.
Children were excluded. Median age was 41 years in the HCQ arm
and 40 years in the placebo arm in Boulware 2020; mean age was
49 years in both the HCQ and standard care arms in Mitjà 2020b.
Most participants did not have comorbidities associated with
increased  risk of severe acute COVID-19. In Boulware 2020, 12%
had hypertension, 8% chronic respiratory disease (mostly asthma),
3% diabetes, and < 1% reported each of heart disease, kidney
disease, and cancer; 73% reported no pre-existing conditions. Mitjà
2020b  reported underlying cardiovascular  disease  in 13% of
participants, respiratory disease in 4%, metabolic disease in
8%, and some nervous system disease in 15%. HIV and non-
HIV immunosuppression were reported in 1/821 and 4/821
participants, respectively (Boulware 2020). Whilst pregnant women
were not excluded, their representation in the participants was
not reported (Boulware 2020).  Mitjà 2020b  did not report on
participants with HIV or other immunosuppression, nor whether
pregnant women were included.
Interventions and comparators
The HCQ dosing regimen in Boulware 2020 was the same as in
Skipper 2020:  1400 mg (800 mg, then 600 mg 6 to 8 hours later)
on day 1, followed by 600 mg once daily for  a further four days,
translating to a cumulative total of 3800 mg over five days. Mitjà
2020b  used the same HCQ dosing as in the paired treatment
trial Mitjà 2020a: 800 mg on day 1, followed by 400 mg once daily
for a further six days, for a total of 3200 mg over seven days.
The comparator in Boulware 2020  was placebo in the form
of  unmarked folic acid  tablets, which closely resembled HCQ
tablets, to be taken on the same schedule as HCQ. Mitjà 2020b used
neither placebo nor an active comparator.
Follow-up
In Boulware 2020, follow-up was conducted using online surveys
exclusively, with the final survey to be completed four to six weeks
aQer enrolment.  Mitjà 2020b  used a combined approach of  in-
person visits to the participant's home on days 1 and 14, and
telephone interviews on days 3, 7, and 28.
Outcome measures
Our primary outcome of development of COVID-19 was assessed at
14 days in both trials. In Boulware 2020, the definition of COVID-19
was expanded beyond confirmed (i.e. by PCR for SARS-CoV-2) to
include probable COVID-19 due to diJiculty accessing PCR testing,
whereas in Mitjà 2020b  development of COVID-19 required both
symptoms and a positive PCR test. Our second primary outcome,
production of antibodies to  SARS-CoV-2, was assessed by Mitjà
2020b at 14 days.
A variety of secondary outcomes were measured, including
hospitalization due to COVID-19, which partly addressed our
outcome of disease severity in participants developing COVID-19
(Boulware 2020; Mitjà 2020b). Onward transmission to household
contacts from index participants was not assessed.
Adverse events were assessed through self-reporting by
participants using an online survey in Boulware 2020, and through
telephone and in-person visits in Mitjà 2020b. QT prolongation was
not assessed due to lack of in-person assessment (which would be
necessary for electrocardiography to be performed) in Boulware
2020; there was one in-person assessment in Mitjà 2020b, but at the
participant's home, where electrocardiography may not have been
practical.
Excluded studies
We excluded 791 articles (see Figure 1), 88  of which were at the
full-text stage (see the Characteristics of excluded studies section),
for the following reasons:  35  were not RCTs; 16  lacked a control
group without CQ or HCQ; one did not include mention of CQ or
HCQ; 32 duplicates were found, which had not been apparent at
first screening; and four were excluded for other reasons.
Risk of bias in included studies
See Characteristics of included studies, which includes a 'Risk of
bias' table for each included trial. The results of the 'Risk of bias'
assessments across all included trials are summarized in Figure 2.
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Abd-Elsalam 2020 + - + + ? -
Boulware 2020 + + + + + ?
Cavalcanti 2020 + + ? + + -
Chen 2020a - ? + + + -
Chen 2020b + ? - - + -
Chen 2020c + ? + + - -
Davoodi 2020 ? + - + - -
Horby 2020 + + + + + +
Huang 2020 - ? + + + -
Mitjà 2020a + ? + + - - -
Mitjà 2020b ? ? - - + - -
Pan 2020 + ? + + + ?
Skipper 2020 + + + + ? - -
Tang 2020 + + + + ? ? -
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Allocation
We judged that 10 out of the 14  included trials were at
low risk of bias (Abd-Elsalam 2020; Boulware 2020; Cavalcanti
2020; Chen 2020b; Chen 2020c; Horby 2020; Mitjà 2020a; Pan
2020; Skipper 2020; Tang 2020), two were at unclear risk of
bias (Davoodi 2020; Mitjà 2020b), and two were at high risk
of bias for random sequence generation (Chen 2020a;  Huang
2020).   The description of the method of randomisation was
inadequate in Davoodi 2020 and Mitjà 2020b. Chen 2020a had 15
participants in each arm, and Huang 2020 had a notable imbalance
between treatment arms  raising concerns about the integrity of
the randomisation process; neither trial explicitly described the
method of randomisation.
We assessed six  trials as at low risk of bias for allocation
concealment (Boulware 2020; Cavalcanti 2020; Davoodi 2020;
Horby 2020; Skipper 2020; Tang 2020), and seven trials as at unclear
risk of bias due to lack of clear reporting of the method of allocation
concealment (Chen 2020a; Chen 2020b; Chen 2020c; Huang 2020;
Mitjà 2020a; Mitjà 2020b; Pan 2020). We judged Abd-Elsalam 2020 to
be at high risk of bias for allocation concealment, as the method
used was not reported, and there were more participants with
comorbidity (obesity and smoking history) in the intervention arm,
although there was not a statistically significant diJerence in these
characteristics between the treatment arms.
Blinding
We assessed the risk of bias associated with blinding for each
outcome separately (details are provided in the 'Risk of bias' table
for each trial), but made our overall judgement for each trial based
on the primary outcome as stated by the trial authors.
We assessed 10 trials as at low risk of performance bias (blinding
of participants and personnel) (Abd-Elsalam 2020; Boulware 2020;
Chen 2020a; Chen 2020c; Horby 2020; Huang 2020; Mitjà 2020a;
Pan 2020; Skipper 2020; Tang 2020). We judged Cavalcanti 2020 to
be at unclear risk of bias, as it was not blinded, and the primary
outcome consisted of an ordinal scale ranking clinical improvement
or deterioration.  We judged Chen 2020b  to be at high risk of
bias because although the authors stated that the researchers
and patients were unaware of treatment assignments, no placebo
was used and the methods of blinding were not described,
and the primary outcome was based on patient-reported clinical
recovery. We judged Davoodi 2020 to be at high risk of bias as it
was an open-label trial, and the primary outcome of hospitalization
could have been influenced by clinicians knowing the treatment
allocation. Similarly, we judged Mitjà 2020b to be at high risk of bias
as it was an open-label trial, and the primary outcome involved a
subjective assessment of symptoms.
We assessed 11 trials as at low risk of detection bias (blinding
of outcome assessment) (Abd-Elsalam 2020; Boulware 2020;
Cavalcanti 2020; Chen 2020a; Chen 2020c; Davoodi 2020; Horby
2020; Huang 2020; Mitjà 2020a; Pan 2020; Skipper 2020; Tang
2020). We judged Chen 2020b and Mitjà 2020b  to be at high risk
of detection bias, as the outcome assessors were not blinded to
treatment allocation, and the primary outcomes of time to clinical
improvement and development of symptoms are likely to have
been subjectively assessed.
Incomplete outcome data
We assessed eight trials as at low risk of bias for incomplete
outcome data (Boulware 2020; Cavalcanti 2020; Chen 2020a;
Chen 2020b; Horby 2020; Huang 2020; Mitjà 2020b; Pan 2020).
Three trials were at unclear risk of bias for this domain:  Abd-
Elsalam 2020  did not report on losses to follow-up or missing
data;  Skipper 2020  had significant losses to follow-up that were
balanced between each group, but no explanations for losses were
provided; and Tang 2020 had significant loss to follow-up beyond
21 days of  follow-up.  We assessed Mitjà 2020a  as at high risk of
bias for incomplete outcome data: 60 participants were excluded
from the intention-to-treat (ITT) analysis due to negative baseline
SARS-CoV-2 swab, missing reverse transcription polymerase chain
reaction (RT-PCR) at all follow-up visits, or consent withdrawal,
and a further 23 participants had protocol deviations including
eight participants lost to follow-up. We judged Chen 2020c as at
high risk of attrition bias, as the authors  reported loss to follow-
up of ~10% (3/33), and missing participants were imputed as having
negative results, which could have impacted on the results as the
sample size was small. We judged Davoodi 2020 as at high risk of
bias as there were no outcome data for 10% (6/60), which could
have impacted the results due to the small sample size.
Selective reporting
We assessed Horby 2020 as at low risk of bias for selective reporting.
Three trials were at unclear risk of bias for this domain: Boulware
2020 changed the primary outcome from confirmed COVID-19 cases
to probable due to a problem with access to testing; Pan 2020 was
accessed as a preprint at the time of writing of this review, which
did not include  all outcome data, and referencing one change
between protocol and trial report that was not explained;  Tang
2020  changed their primary outcome and gave justification for
this, but did not report the secondary outcomes. Ten trials were
at high risk of bias for selective reporting (Abd-Elsalam 2020;
Cavalcanti 2020; Chen 2020a; Chen 2020b; Chen 2020c; Davoodi
2020; Huang 2020; Mitjà 2020a; Mitjà 2020b; Skipper 2020), all of
which reported outcomes that deviated from those stated in the
protocol (described in Characteristics of included studies). 
Other potential sources of bias
We identified other potential sources of bias in four trials. Skipper
2020  and Tang 2020  were at high risk of bias as they were
terminated early, which could have introduced bias as both trials
had a time-updating variable  as the primary outcome.  Mitjà
2020a  was also at high risk of other bias: a  small number of
participants were randomized who were in fact not eligible for the
trial, but these participants were kept as part of the ITT population.
Mitjà 2020b was a cluster-randomized trial, and so was assessed
for risk of bias against five further domains specific to cluster-
randomized trials. We judged the trial to be at low risk for four out of
five domains (see Characteristics of included studies), and at high
risk of bias for comparability with individually randomized trials:
contamination was possible due to the open-label design,  and
the intervention would be expected  to work best when given
to all contacts of a case rather than some being randomized to
the intervention and some randomized to no intervention, which
would preclude comparability with an individually randomized
trial.
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EBects of interventions
See: Summary of findings 1 Hydroxychloroquine (HCQ) compared
to standard care or placebo for the treatment of people with
COVID-19; Summary of findings 2 Hydroxychloroquine (HCQ)
compared to placebo for the prevention of COVID-19 in people who
have been exposed to SARS-CoV-2
See Summary of findings 1 for Objective 1, Comparison 1,
and Summary of findings 2 for Objective 3.
Due to inability to  extract data disaggregated for  subgroups on
outcomes predefined in the review protocol, we did not perform
subgroup analyses. Furthermore, heterogeneity in most analyses
was minimal.
Objective 1. For treatment of COVID-19 disease
Comparison 1: HCQ versus standard care without HCQ or placebo
Ten trials  of treatment of people with COVID-19  compared
HCQ to standard care or placebo (8270  participants;  Abd-
Elsalam 2020;  Cavalcanti 2020; Chen 2020a; Chen 2020b;  Chen
2020c;  Horby 2020; Mitjà 2020a;  Pan 2020;  Skipper 2020; Tang
2020). The arm randomizing participants to a combination of HCQ
with azithromycin  in Cavalcanti 2020  was not included in this
comparison, but is included in Comparison 3 below.
Nine of the 10 trials reported death due to any cause (Abd-
Elsalam 2020; Cavalcanti 2020; Chen 2020a; Chen 2020c; Horby
2020; Mitjà 2020a; Pan 2020; Skipper 2020; Tang 2020). Meta-
analysis using ITT results for each trial found little or no diJerence
between HCQ and standard care without HCQ or placebo in all-
cause death (risk ratio (RR) 1.09, 95% confidence interval (CI) 0.99 to
1.19; 8208  participants; 9  RCTs;  Analysis 1.1). Sensitivity analysis
performed  using modified ITT results as reported by three trials
revealed no diJerence in the pooled eJect estimate (RR 1.09, 95%
CI 0.99 to 1.19; 8043 participants; 9 RCTs; Analysis 1.2) (Cavalcanti
2020; Mitjà 2020a; Skipper 2020).
Our predefined outcome involving tests  for SARS-CoV-2, time to
negative PCR for SARS-CoV-2 on respiratory samples, was reported
as a median by Chen 2020a and Chen 2020c, and as a mean by Abd-
Elsalam 2020  and  Tang 2020; all trials reported no significant
diJerence between the arm that received HCQ and the arm that did
not.  Two of the trials  reported the related outcome  of negative
PCR  for SARS-CoV-2 at day  7 aQer enrolment  as dichotomous
outcomes (Chen 2020a; Tang 2020), and three trials reported
negative PCR at day 14 (Chen 2020a; Chen 2020c; Tang 2020).
We deemed the latter (i.e. negative PCR at day 14) to be more
important based on the current understanding of COVID-19, so this
is displayed in Summary of findings 1 . No significant diJerence
between HCQ and standard care without HCQ was revealed in
meta-analysis of either negative PCR at day 14 (RR 1.00, 95% CI
0.91  to  1.10; 213 participants; 3 RCTs;  Analysis 1.3) or  negative
PCR at day 7  (RR  0.86, 95% CI 0.68  to  1.09;  180 participants; 2
RCTs; Analysis 1.4) aQer enrolment.
Of the two trials assessing ambulatory treatment of people with
COVID-19, only Skipper 2020 was included in the analysis of risk
of admission to hospital; Mitjà 2020a did not report denominators
disaggregated for allocation to HCQ versus standard care without
HCQ.  In  Skipper 2020, though the risk ratio may suggest  an
important benefit from HCQ, the confidence intervals were wide,
and included potential important harm (RR 0.41, 95% CI 0.13 to
1.27; 465 participants; 1 RCT; Analysis 1.5).
Three trials reported results for people hospitalized with COVID-19
going on to require  mechanical ventilation  (Cavalcanti 2020;
Horby 2020; Tang 2020). No significant diJerence was found
in participants progressing to mechanical ventilation when
comparing HCQ to no HCQ   (RR  1.11, 95% CI 0.91 to  1.37;  4521
participants; 3 RCTs; Analysis 1.6).
Three  trials reported mean length of hospital admission (Abd-
Elsalam 2020; Cavalcanti 2020; Tang 2020). We noted that early in
the pandemic suitability for discharge was oQen driven by infection
prevention and control considerations,  and therefore might not
have been a good reflection of the eJicacy of HCQ. Accordingly, we
decided not  to include results from  Tang 2020  in the analysis
for this outcome, as participants remained in hospital until they
were deemed no longer infectious. Pooled length of admission
in Abd-Elsalam 2020  and Cavalcanti 2020 did not diJer between
participants who received  HCQ and those who did not (mean
diJerence (MD) 0.15  days shorter with HCQ, 95% CI 0.75 shorter
to 0.45 longer; 642 participants; 2 RCTs; Analysis 1.7).
Time to clinical improvement (for symptomatic patients)  and
time to negative PCR for SARS-CoV-2 on respiratory samples
were  reported as hazard ratios (HRs) and corresponding 95%
CIs by Tang 2020. No significant diJerence was found for time to
clinical improvement (HR 1.01, 95% CI 0.59 to 1.74; 119 participants;
1 RCT; Analysis 1.8) or time to negative PCR for SARS-CoV-2 on
respiratory samples (HR 0.85, 95% CI 0.58 to 1.23; 150 participants;
1 RCT; Analysis 1.9).
Duration of mechanical ventilation postenrolment in survivors of
COVID-19 was not reported by any trials.
Six trials reported number of participants with any adverse
events (Cavalcanti 2020; Chen 2020a; Chen 2020b; Mitjà 2020a;
Skipper 2020; Tang 2020). Meta-analysis revealed a higher risk of
adverse events in participants receiving HCQ versus those receiving
standard care or placebo (RR 2.90, 95% CI 1.49 to 5.64;  1394
participants; 6 RCTs; Analysis 1.10). Adverse events reported in the
six trials are summarized in Table 6.  
Meta-analysis of six trials that reported the number of participants
experiencing serious adverse  events showed no significant
diJerence between participants receiving HCQ and those receiving
standard care (RR 0.82, 95% CI 0.37  to 1.79;  1004 participants;
6 RCTs; Analysis 1.11) (Cavalcanti 2020; Chen 2020a; Chen 2020b;
Chen 2020c; Mitjà 2020a; Tang 2020).   It was not possible to
disaggregate data for specific serious adverse events for each trial,
nor was it possible to disaggregate data for serious adverse events
attributed to the intervention drug for each trial.
Our  predefined  specific adverse event, prolongation of the QT-
interval on electrocardiogram (ECG), was reported by one trial
(Cavalcanti 2020).  Risk of QT-interval prolongation  increased in
participants receiving HCQ (without azithromycin)  versus those
receiving standard care or azithromycin  (RR 8.47, 95% CI 1.14 to
63.03; 147 participants; 1 RCT;  Analysis 1.12). Fewer than half of
participants had an ECG performed within seven days of enrolment;
this  appeared to be higher in those receiving HCQ  (89/199,
44.7%) than in those receiving standard care (58/177, 32.8%).
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Comparison 2: CQ versus lopinavir/ritonavir (LPV/r)
One trial (22 participants) reported this comparison (Huang 2020).
Due to the comparison not having been predefined, and this being
a single small trial with high risk of selection and reporting bias,
reporting few of our predefined outcomes, a separate 'Summary of
findings' table is not provided.
Death was not reported as an outcome (Huang 2020).
Time to negative PCR for SARS-CoV-2 on respiratory samples was
not reported, but the proportion with negative PCR ranged from
appreciable benefit to appreciable harm  between arms at day  7
from enrolment  (RR 1.20, 95% CI 0.64 to 2.25; 22 participants; 1
RCT; Analysis 2.1) and day 14 from enrolment (RR 1.08, 95% CI 0.85
to 1.36; 22 participants; 1 RCT; Analysis 2.2).
Number of participants admitted to hospital (if receiving
ambulatory treatment) was not relevant for this hospital inpatient-
based trial.
Number of participants requiring mechanical ventilation aQer
enrolment was not reported (Huang 2020).
We were unable to extract length of hospital admission as a mean,
but visual inspection of the Kaplan-Meier chart appeared to show
a median time to discharge of around 11 days for the CQ arm, and
around 14 days for the  LPV/r arm  (Huang 2020). The number of
participants discharged by day 14 from enrolment was reported to
be 10/10 in the CQ arm versus 6/12 in the LPV/r arm (RR 1.91, 95%
CI 1.09 to 3.34; 22 participants; 1 RCT; Analysis 2.3).
Time to clinical improvement  was not reported as a mean or
median  (Huang 2020). However, clinical recovery at day 10 was
reported as showing no significant diJerence between study arms
(RR 1.37, 95% CI 0.78 to 2.42; 22 participants; 1 RCT; Analysis 2.4).
There was no diJerence in the number of  participants
experiencing  adverse events between study arms  (RR  1.08, 95%
CI 0.78 to  1.50; 22 participants; 1 RCT; Analysis 2.5); QT-interval
prolongation was not specifically reported. No serious adverse
events were reported in either arm (Huang 2020).
Comparison 3: HCQ + azithromycin versus standard care
One trial (444 participants) reported this comparison (Cavalcanti
2020).  Due to the comparison not having been predefined,
and this trial having a high risk of reporting bias and unclear risk of
performance and detection bias, a separate 'Summary of findings'
table is not provided.
Death was reported as showing no diJerence between study arms
(RR 0.52, 95% CI 0.13 to 2.07; 444 participants; 1 RCT; Analysis 3.1).
Time to negative PCR for SARS-CoV-2 was not reported, and as
this was a trial of hospitalized patients, neither was number of
participants admitted to hospital (Cavalcanti 2020).
The number of participants requiring mechanical ventilation did
not diJer between study arms (RR  1.61, 95% CI 0.82 to  3.15;
444 participants; 1 RCT;  Analysis 3.2). Duration of mechanical
ventilation was not reported (Cavalcanti 2020).
Length of hospital admission was similar between groups (MD 0.50
days longer with HCQ + azithromycin, 95% CI 0.81 days shorter to
1.81 days longer; 444 participants; 1 RCT; Analysis 3.3).
Time to clinical improvement was not reported.
Adverse events were experienced by  a higher proportion of
participants who received at least one dose of HCQ + azithromycin
versus participants receiving neither HCQ nor azithromycin
(RR 1.74, 95% CI 1.27 to 2.38; 416 participants; 1 RCT; Analysis 3.4).
Serious adverse events did not diJer significantly between study
arms (RR 1.85, 95% CI 0.36 to 9.43; 416 participants; 1 RCT; Analysis
3.5).
When assessed, QT-interval prolongation on ECG was
more common  amongst  participants receiving HCQ +
azithromycin  (17/116) versus those receiving neither drug  (1/58)
(RR 8.50, 95% CI 1.16 to 62.31; 174 participants; 1 RCT; Analysis 3.6).
Performance of ECG within seven days of enrolment appeared to be
more frequent in the HCQ + azithromycin arm (116/239, 48.5%) than
in the standard care arm (58/177, 32.8%).
Comparison 4: HCQ versus febuxostat
One trial (60 participants) reported this comparison (Davoodi 2020).
A separate 'Summary of findings' table is not provided.
No deaths were reported in either study arm (Davoodi 2020).
Three participants in each arm (of 25 in the HCQ arm and 29 in
the febuxostat arm) required hospitalization during the 14 days
of follow-up  (RR 1.16, 95% CI 0.26 to  5.24; 54  participants; 1
RCT; Analysis 4.2).
Number of participants requiring mechanical ventilation was not
reported explicitly, but the authors reported: “All
hospitalised patients … did not require ICU care" (Davoodi 2020).
Length of hospital admission was not reported precisely, but
authors reported: “All
hospitalised patients were released from hospitals between 1 and
7 days of hospitalization” (Davoodi 2020).
Time to clinical improvement was not reported in a way that fit with
our planned data extraction or analysis.
Duration of mechanical ventilation was not reported.
Reduction in involvement of the lungs on CT scan between days
1 and 14  was reported to be no diJerent between the HCQ and
febuxostat arms.
Adverse events were not reported.
Objective 2. Preventing COVID-19 disease in people at risk of
exposure to SARS-CoV-2
No eligible trials provided outcome results for this objective.
Objective 3. Preventing COVID-19 disease in people who have
been exposed to SARS-CoV-2
We deemed the eJect of HCQ on the prevention of COVID-19 to be
susceptible to diJerences in administration to an individual, versus
a cluster of individuals all in contact with one  index person. We
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therefore did not pool results from  the individually-randomized
RCT, Boulware 2020, with those from the cluster-RCT (Mitjà 2020b).
Comparison 5: HCQ versus placebo by individual randomization
One trial (821 participants) reported this comparison (Boulware
2020). See Summary of findings 2.
Development of confirmed COVID-19 at 14 days from enrolment
was not found to diJer significantly between the two arms (RR 1.20,
95% CI 0.50 to 2.87; 821 participants; 1 RCT; Analysis 5.1).
Production of antibodies to SARS-CoV-2 and  development of
COVID-19 in household contacts of the recipient of the prophylaxis
were not reported (Boulware 2020).
For our predefined outcome of disease severity of participants
who develop COVID-19, we extracted data for participants
hospitalized  due to COVID-19; this did not diJer significantly
between those receiving HCQ and those receiving placebo (RR 0.98,
95% CI 0.06 to 15.66; 821 participants; 1 RCT; Analysis 5.2).
Participants receiving at least one dose of HCQ had an increased
risk of adverse events compared to those not receiving HCQ
(RR  2.39, 95% CI 1.83 to  3.11; 700 participants; 1 RCT;  Analysis
5.3). No serious adverse events were reported in either arm. QT-
interval prolongation on ECG was not reported, but follow-up
was performed remotely using an online survey, so ECG was not
performed as part of the trial (Boulware 2020).
Comparison 6: HCQ versus standard care by
cluster randomization
One trial (2525 participants) reported this comparison (Mitjà
2020b). Due to the cluster-RCT design and appropriate analysis by
the trial authors, adjusted risk ratios have been taken from the
report.
Development of symptomatic confirmed COVID-19 at 14 days
from enrolment was not found to diJer significantly between
participants randomized to HCQ (64/1116; 5.7%) and those
allocated to standard care (74/1198; 6.2%) (adjusted RR 0.89, 95%
CI 0.54 to 1.46; 2314 participants; 1 RCT; Mitjà 2020b).
Production of antibodies to SARS-CoV-2 at 14 days was reported
in 137/958 (14.3%) of the participants in HCQ clusters and 91/1042
(8.7%) in clusters not receiving HCQ (adjusted RR 1.6, 95% CI 0.96 to
2.69; 2000 participants; 1 RCT; Mitjà 2020b).
Development of COVID-19 in household contacts of the recipient of
the prophylaxis was not reported by either trial.
Disease severity of participants who developed COVID-19 was not
reported. Five participants in the HCQ clusters (with a denominator
of 1197, which is unexplained in its deviation from the randomized
total of 1225) and 8/1300 in the standard care clusters died (Mitjà
2020b). Causes of death were not reported.
Adverse events were reported in 671/1197 (56%) participants in the
HCQ clusters versus 77/1300 (6%) participants in the clusters not
receiving HCQ; a relative eJect estimate was not reported  (Mitjà
2020b). Serious adverse events were reported, but it was not clear
whether they were reported as number of events or number of
participants, and did not match the intensity grading reported by
the pharmacovigilance consultants employed by the trial  (Mitjà
2020b). QT-interval prolongation was not measured in this trial.
D I S C U S S I O N
Summary of main results
Treating COVID-19 disease
Ten trials compared HCQ versus standard care without HCQ, or
placebo (see Summary of findings 1).  HCQ makes little or no
diJerence to death due to any cause, compared with no HCQ (high-
certainty evidence).  HCQ may make little or no diJerence to the
likelihood of a negative PCR for SARS-CoV-2 on respiratory samples
at day 14 from enrolment (low-certainty evidence). HCQ probably
results in little to no diJerence in progression to mechanical
ventilation (moderate-certainty evidence). We are very uncertain
about the eJect of HCQ on  time to clinical improvement when
compared to standard care without HCQ or placebo (very low-
certainty evidence). HCQ probably results in  an increased  risk of
developing adverse events (moderate-certainty evidence), but may
make little or no diJerence  to the risk of serious adverse events
(low-certainty evidence). We are very uncertain about the eJect
of HCQ on prolongation of QT-interval on ECG when compared
with standard care without HCQ, or placebo (very low-certainty
evidence).
We have drawn no conclusions from small single-trial comparisons
of CQ versus lopinavir/ritonavir;  HCQ and azithromycin versus
standard care; and HCQ versus febuxostat.
Objective 2. For prevention of COVID-19 disease in people at
risk of exposure to SARS-CoV-2
No eligible studies were identified for this objective.
Objective 3. For prevention of COVID-19 disease in people who
have been exposed to SARS-CoV-2
One individually randomized trial compared HCQ with placebo
(see Summary of findings 2). We are very uncertain about the
eJect of HCQ on  the development of confirmed COVID-19 at
14 days from enrolment and the risk of hospitalization  due to
COVID-19, compared with placebo (very low-certainty evidence).
HCQ probably increases the risk of adverse events, compared with
placebo (moderate-certainty evidence). HCQ may result in little or
no diJerence in serious adverse events, compared with placebo,
though no participants in the trial  experienced any events (low-
certainty evidence).
A cluster-randomized trial compared HCQ with no intervention
for postexposure prevention of COVID-19. The results of this trial
could not be combined with those of the individually randomized
RCT. There was no diJerence in the risk of symptomatic confirmed
COVID-19 or production of antibodies to SARS-CoV-2 between study
arms.
Overall completeness and applicability of evidence
Objective 1. For treatment of COVID-19 disease
The 12 included trials were conducted in Brazil, Canada, China,
Egypt, Iran, Spain, Taiwan, the UK, and the USA.  The largest
trial, contributing the majority of participants  (4716/8569, 55%),
was based in the UK. It is as yet uncertain whether geographical
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diJerences may impact on the eJicacy or safety of interventions for
the treatment of COVID-19.
None of the trials included children or pregnant women,  so  the
evidence cannot be applied to these populations. Most participants
(86%)  had COVID-19 confirmed by  positive RT-PCR for SARS-
CoV-2.  Nine  of the 12 trials recruited hospitalized patients,
with the three  ambulatory treatment trials  contributing only
844/8569 (10%) of participants in the review, potentially
aJecting applicability of the findings to outpatient settings.
Severity of disease varied between trials. Whilst not all participants
could be classified according to WHO severity grading, 3139/8569
(37%) of participants did not require oxygen or other respiratory
support at enrolment; 5230/8569 (63%) were receiving oxygen or
higher respiratory support. The two largest trials (Horby 2020; Pan
2020), which mostly included  participants requiring oxygen or
higher respiratory support, contributed the majority of participants
to the meta-analysis of the outcome death due to any cause for
the comparison of HCQ versus standard care or placebo. Data
for participants with any or serious adverse events could  not
be extracted from these trials. This means that evidence for
the outcome of death was based on a population with more
severe disease. For adverse events outcomes,  the meta-analysed
population was less severely unwell, and so this eJects estimate
should be interpreted with this in mind as the baseline risk of
adverse events in more severely unwell patients is likely to be
higher. These trials were designed to assess the eJicacy of HCQ, and
may not be of suJicient power to detect any but the most common
adverse events.
HCQ and CQ have similar pharmacological actions, but only one
study used CQ, to which 10 participants were allocated, and so we
could not draw conclusions about the eJicacy and safety of CQ
for the treatment of COVID-19. This is likely due to the increased
rate of adverse eJects seen with CQ compared with HCQ in other
conditions.
Only one trial included an arm with a combination of HCQ and
azithromycin (217 participants), and so few conclusions can be
drawn about the eJicacy or safety of this combination treatment.
Dosing of HCQ varied considerably between trials (see Table 4). The
two largest trials used relatively high total cumulative doses, and so
it is unlikely that a lack of eJicacy for the primary outcome of death
is due to underdosing. As the data for adverse events were drawn
from the trials using lower doses, it is possible that this meta-
analysis underestimates dose-dependent adverse events.
Pharmacological co-interventions also varied considerably
between studies (see Table 5), and reporting was at times
incomplete. Co-interventions were mostly balanced between
intervention arms across the studies, and are unlikely to have
impacted on the summary eJects estimates for the primary
outcome.
Objective 2. For preventing COVID-19 disease in people at risk
of exposure to SARS-CoV-2
No eligible studies were identified for this objective.
Objective 3. For preventing COVID-19 disease in people who
have been exposed to SARS-CoV-2
One of the two trials included in this objective was conducted in
the USA and Canada; the other in Spain. Most participants were
healthcare or nursing home workers and  had  no comorbidities;
average age was  between 40 and 50 years.  Consequently, the
findings may have limited  applicability of the evidence to older
people with multi-morbidity, household contacts, and possibly
to lower-income settings. Additionally, as the assessment for the
development of COVID-19 was based on the presence of symptoms,
and no outcomes assessed  infection or disease  in household
or other contacts of the person with exposure to SARS-CoV-2,
no evidence was available for the eJect of HCQ on the risk of
asymptomatic infection or onward transmission.
Certainty of the evidence
We used the GRADE approach to assess the certainty of the
evidence, employing GRADEpro GDT soQware (GRADEpro GDT). The
GRADE assessment with explanatory footnotes is outlined in
Summary of findings 1 and Summary of findings 2.
For Objective 1 - treatment of COVID-19, we included nine RCTs and
assessed seven outcomes. We graded the eJect estimate for death
as high certainty, implying that treatment with HCQ results in no
diJerence to death from any cause in people with COVID-19. We
graded the eJect estimate for negative SARS-CoV-2 PCR at 14
days as low certainty, that is HCQ may make no diJerence to the
proportion of people who have a negative SARS-CoV-2 swab at 14
days; the certainty of the evidence was downgraded by one level for
serious risk of bias, as both trials in this analysis were at high risk of
bias across several domains; and one level for serious indirectness,
as almost all participants had mild or moderate COVID-19, all were
hospitalized, and all were from one country  (Chen 2020a; Tang
2020). We graded the eJect estimate for progression to mechanical
ventilation as moderate certainty, implying that HCQ probably has
no eJect on progression to mechanical ventilation in people with
COVID-19; the certainty of the evidence was downgraded by one
level for serious imprecision, as the lower bound of the confidence
interval around the estimate represents no benefit nor harm from
HCQ, whereas the upper bound suggests appreciable harm.  For
time to clinical improvement, we graded the estimate of eJect
as very low certainty, that is we do not know what eJect HCQ
has on this outcome.  Data for this outcome came from a single
trial (Tang 2020); we downgraded the certainty of the evidence for
serious risk of bias, serious indirectness (all hospitalized patients
with mild-moderate COVID-19 in one centre in China), and serious
imprecision (confidence interval extends from appreciable benefit
to appreciable harm).
For adverse eJects in people with COVID-19 treated with HCQ, we
graded the eJects estimate for participants with any adverse events
as moderate certainty, meaning that HCQ probably increases the
risk of developing adverse events. We downgraded the certainty
of the evidence by one level for serious risk of bias, as all trials
contributing to this analysis had high or unclear risk of bias
across various domains, and all but one trial were open-label. We
graded the eJects estimate for participants with serious adverse
events as low certainty, downgrading by two levels for very serious
imprecision, as the confidence intervals ranged from appreciable
benefit to appreciable harm; overall the rate of serious adverse
events was low.  We graded the eJects estimate for participants
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who developed prolonged QT interval on ECG as very low certainty;
data for this outcome came from one trial, and the certainty of the
evidence was downgraded for risk of bias, as the trial was open-
label;  indirectness, as severe COVID patients were excluded; and
imprecision, as the low event rate and small sample size led to a
broad confidence interval.
We found no studies addressing Objective 2 -  prevention of
COVID-19 disease in people at risk of exposure to SARS-CoV-2.
For Objective 3 - prevention of COVID-19 in people who have been
exposed to SARS-CoV-2, we included one RCT and graded four
outcomes (Boulware 2020). We graded the eJects estimate for
development of COVID-19 at 14 days from enrolment as very low
certainty, implying that we do not know whether HCQ prevents
COVID-19 in people exposed to SARS-CoV-2. We downgraded the
certainty of the evidence by one level for serious indirectness, as
data for this outcome came from a single trial  in  North America
with few older or comorbid participants; and by two levels for
very serious imprecision, as the confidence interval around the
eJects estimate included appreciable benefit and appreciable
harm. We graded the eJect estimate for participants hospitalized
due to COVID-19 as very low certainty, again downgrading by one
level for serious indirectness and by two levels for very serious
imprecision. We graded the eJects estimate for participants with
any adverse events as moderate certainty, implying that HCQ
probably increases the risk of adverse events when compared with
placebo; the certainty of the evidence was downgraded by one
level for serious indirectness, as described above. We graded the
eJects estimate for participants with serious adverse events as low
certainty, meaning that HCQ may result in no diJerence to the risk
of developing serious adverse events compared with placebo; the
certainty of the evidence was downgraded by one level for serious
indirectness and one level for serious imprecision.
Potential biases in the review process
We took measures to limit bias in the review process by following
the procedures outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019). The Cochrane Infectious
Diseases Group (CIDG) Information Specialist conducted the
literature search using a variety of general and COVID-19 specific
resources, and included preprints. In addition, we also checked
the COVID-NMA website at www.covid-nma.com/ for further studies
at regular intervals. We did not make a funnel plot, as fewer than
10 studies were included per comparison. Two review authors
independently examined the search results, assessed studies for
eligibility, and extracted data, in order to minimize bias in study
selection and data extraction.
Agreements and disagreements with other studies or
reviews
Several systematic reviews have been published examining
the treatment of COVID-19 with HCQ/CQ, all of which have
included RCTs and non-randomized studies.  For the most part
their conclusions match ours regarding the finding of HCQ
showing no benefit for mortality  from COVID-19, but with less
precision. Fiolet 2020, published in August 2020, describes results
from 29 studies including 3 RCTs, but studies with no mortality
were excluded. In participants treated with HCQ versus comparator
group for the outcome of death, the RR was 0.83 (95% CI 0.65 to
1.06); excluding non-randomized studies, the RR was 1.09 (95%
CI 0.97 to 1.24). The authors concluded that HCQ is not eJective
for COVID-19, and that further research is not needed. Elavarasi
2020, published in September 2020, is a systematic review of
RCTs, case series, and cohort studies with a comparator arm
including 12 non-randomized studies and 3 RCTs.  Meta-analysis
of the included studies revealed no diJerence in  mortality with
HCQ use (RR 0.98 95% CI 0.66 to 1.46), leading the authors to
conclude that the available evidence does not support the use of
HCQ and that further RCTs are required. Hernandez 2020, published
in August 2020, is a living systematic review which includes 3
RCTs, 8 cohort studies, and 3 case series. No meta-analysis was
conducted due to high heterogeneity between studies; the authors
concluded that the evidence on the benefits and harms of HCQ
for COVID-19 is weak and conflicting. Zang 2020, published in
September 2020, includes 3 RCTs, 2 prospective observational
studies, and 2 retrospective observational studies. In participants
treated with HCQ compared with standard therapy, meta-analysis
suggested increased mortality with HCQ (RR 1.92, 95% CI 1.26
to 2.93), although the authors identified significant unexplained
heterogeneity and problems with study quality, and concluded that
better RCTs are urgently needed. All these systematic reviews cite
the three Chinese RCTs included in this review (Chen 2020a; Chen
2020b; Tang 2020). Few systematic reviews have used GRADE to
assess the certainty of the evidence.
There are fewer studies and fewer reviews examining CQ and HCQ
as prophylaxis for COVID-19 (Objectives 2 and 3). Shah 2020  is a
systematic review of the evidence for HCQ in preventing COVID-19,
which was published in March 2020. Due to the lack of studies at
that time, the authors included only two pre-clinical studies and
three commentaries, concluding that although evidence from pre-
clinical studies is promising, there was no evidence to support the
eJicacy of CQ or HCQ in preventing COVID-19.
National and international guideline recommendations for the use
of CQ and HCQ have changed over the course of the pandemic. The
US National Institutes of Health published updated guidance on 27
August 2020 recommending against the use of CQ or HCQ for the
treatment of COVID-19 in hospitalized patients, and against the use
of CQ or HCQ in non-hospitalized patients except in the context of
a clinical trial (NIH 2020). In May 2020, WHO recommended that CQ
and HCQ not be administered to COVID-19 patients outside of the
context of a clinical trial (WHO 2020c).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Hydroxychloroquine for treatment
Hydroxychloroquine (HCQ) has no clinical benefit in treating
COVID-19 in hospitalized patients, with moderate- to high-certainty
evidence from several randomized trials, and a probable increase
in adverse events associated with its use.
Evidence for prevention of hospital admission in outpatients with
COVID-19 is very uncertain. However, given the lack of benefit in
hospitalized patients, and limited available evidence suggesting
little or no eJect on clearance of the virus from the respiratory tract,
benefit from treatment of outpatients appears unlikely.
Hydroxychloroquine for pre- or post-exposure prophylaxis
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The lack of any demonstrable clinical benefit in the treatment of
COVID-19 makes it less likely the drug will prevent the illness in
those who are exposed, but this eJect is not excluded.
No trials of the use of HCQ for prophylaxis of COVID-19 in those at
risk of exposure to SARS-CoV-2 were identified.
Evidence that HCQ is eJective as prophylaxis for COVID-19 in
people exposed to SARS-CoV-2 is limited. However, HCQ probably
increases adverse events, although there does not appear to be a
diJerence between comparison groups for serious adverse events.
Implications for research
No further trials in hospital inpatients are justified.
The evidence is less certain for ambulatory treatment of people
with mild COVID-19, and for prevention of COVID-19 in people with,
or at risk of, exposure to SARS-CoV-2.
If other reasons are identified that suggest the drugs may
have benefit in prevention despite no eJect in treatment, then
researchers should ensure that trials are adequately powered,
prioritize inclusion of people at risk for severe COVID-19, and
include risk of asymptomatic infection and onward transmission as
outcome measures.
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Methods Open-label trial comparing HCQ with standard care without HCQ for the treatment of COVID-19. No
placebo was used. Follow up for 4 weeks from enrolment.
Participants Setting: 3 tertiary hospitals in Egypt.
Number of participants: 194 total, 97 allocated to HCQ; 97 allocated to standard care
Inclusion criteria: "all patients admitted with SARS-CoV-2 infection". Note that no criteria for diagnosis
were reported.
Exclusion criteria: "allergy or contraindication to HCQ, pregnant and lactating females, and patients
with cardiac problem (chronic heart failure or prolonged QT interval on ECG)".
Age: HCQ arm: Mean 40.35 ± SD 18.65 years; standard care arm: Mean 41.09 ± SD 20.07 years.
Sex: HCQ arm: female:male 41:56; standard care arm: female:male 39:58.
Method of diagnosis: not reported.
Clinical presentation: not reported. 
COVID-19 disease severity at diagnosis: “The patients were randomized equally between the two
groups regarding the disease severity”.
Time from symptom onset to enrolment: not reported. 
Comorbidities: 
1. Obesity: HCQ 40/97 (41%); standard care 35/97 (36%)
2. Morbid obesity: HCQ 21/97 (22%); standard care 24/97 (25%)
3. Smoking: HCQ 35/97 (36%); standard care 25/97 (26%)
4. Liver disease: HCQ 0/97; standard care 2/97 (2%)
5. Renal impairment: HCQ 2/97 (2%); standard care 4/97 (4%)
6. "Comorbidities": HCQ 15/97 (15%); standard care 12/97 (12%)
Place of care: inpatients in hospital. 
Interventions HCQ group received 400 mg twice daily on day 1, then 200 mg twice daily up to 15 days.
Control group received standard care, without HCQ.
Outcomes Primary endpoint in the report was “percentage of recovery”. This was used for a retrospective power
calculation.
On ClinicalTrials.gov (clinicaltrials.gov/ct2/show/NCT04353336), primary outcomes were:
• number of patients with cure or death;
• number of patients with virological cure.
Note that the only primary outcome on the original registry entry (17 April 2020) was number of pa-
tients with virological cure. No secondary outcomes in registry entry.
Notes Dates of recruitment: March 2020 to June 2020.
Funding and sponsorship: not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Abd-Elsalam 2020  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk “Computerized random number generator using simple randomization with
an equal allocation ratio. During randomization, the proportional allocation of
each clinical stratum was equalized in both groups.” Appropriate method.
Allocation concealment
(selection bias)
High risk Not reported. Noted more comorbidity, obesity, smoking in HCQ group (al-
though not statistically significant) – this group may have had more risk for





Low risk Low for death.
High for length of admission and time to clinical improvement.
No blinding: open-label. Unlikely to influence mortality, but could affect length
of admission (clinician’s decision on this, if a clinical vs protocol/virological de-
cision) and time to clinical improvement.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for death.
High for length of admission and time to clinical improvement.
No blinding: open-label. Unlikely to influence mortality, but could affect length




Unclear risk No report of loss to follow-up, or missing data. No plan reported for imputa-
tion for missing data. No trial flow diagram.
Selective reporting (re-
porting bias)
High risk No detailed protocol provided with the report or found online. 1 outcome (vi-
rological response) in registry record not reported in trial report. Other out-






Methods Double-blind RCT comparing outcomes in people receiving HCQ as post-exposure prophylaxis vs those
receiving placebo.
Follow-up involved sending participants surveys by email – completed online on REDCap: at days 1, 5,
10, and 14; then at 4 to 6 weeks. “Participants who did not respond to follow-up surveys received text
messages, e-mails, telephone calls, or a combination of these to ascertain their outcomes. When these
methods were unsuccessful, the emergency contact provided by the enrollee was contacted to deter-
mine the participant’s illness and vital status. When all communication methods were exhausted, Inter-
net searches for obituaries were performed to ascertain vital status.”
Participants Setting: community; recruitment via social media.
Number of participants: 821 total: 414 allocated to HCQ; 407 allocated to placebo.
Inclusion criteria: "known exposure (by participant report) to a person with laboratory-confirmed COV-
ID-19, whether as a household contact, a health care worker, or a person with other occupational expo-
sures”. Recruited < 3 days after presumptive-case exposure (17 March); then updated to < 4 days after
confirmed-case exposure (23 March). Exposure was defined as < 6-feet distance, for > 10 minutes, with-
out full personal protection. This was subdivided into high risk (no mask and no eye protection) and
moderate risk (wearing a mask but no eye protection).
Boulware 2020 
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Exclusion criteria: < 18 years old; hospitalized; symptoms of COVID-19; PCR positive for SARS-CoV-2;
others listed in appendix, such as certain medical conditions and co-medications.
Age: HCQ arm: median 41 years (interquartile range: 33 to 51); placebo arm: median 40 years (interquar-
tile range: 32 to 50).
Sex: HCQ arm female:male 218:196; placebo arm female:male 206:201.
Types of participant: HCQ arm: 275 healthcare workers, 125 household contacts, 14 exposure not re-
ported; placebo arm: 270 healthcare workers, 120 household contacts, 17 exposure not reported.
Definition of development of COVID-19: confirmed: by PCR; probable: “presence of cough, shortness of
breath, or difficulty breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia,
headache, sore throat, and new olfactory and taste disorders”; possible: “presence of one or more com-
patible symptoms, which could include diarrhoea”. Probable and possible were defined by 4 blinded
physicians.
Comorbidities: HCQ arm (total 414) vs placebo arm (total 407): 4 vs 2 cardiac disease; 51 vs 48 hyper-
tension; 12 vs 16 diabetes mellitus; 1 vs 0 HIV; 2 vs 2 other immunosuppression; 31 vs 31 asthma; 3 vs 0
other chronic lung disease; 1 vs 2 cancer/malignancy; 0 vs 3 chronic kidney disease.
Interventions HCQ “800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for
4 more days for a total course of 5 days (19 tablets total).” Oral; could split doses if developed gastroin-
testinal upset.
Placebo = folate tablets; taken as per the HCQ schedule.
Outcomes Primary – at day 14 from enrolment: development of confirmed or probable COVID-19 (see Participants
for definitions).
Secondary: hospitalization for COVID-19 or death; PCR-confirmed SARS-CoV-2 infection; COVID-19
symptoms; discontinuation of the trial intervention - from any cause; “severity of symptoms (if any) at
days 5 and 14 according to a visual analogue scale (scores ranged from 0 [no symptoms] to 10 [severe
symptoms]).”
Adverse events: directed questioning for common side effects along with open-ended free text.
The authors stated regarding losses to follow-up:
Of the 821 participants who underwent randomization, 96 did not complete the day 14 follow-up sur-
vey, of whom 8 formally withdrew from the trial (4 in each group). Investigators confirmed the vital sta-
tus and lack of infection in 19 participants (10 in the hydroxychloroquine group and 9 in the control
group); 17 completed some follow-up surveys without symptoms before being lost to follow-up (13 in
the hydroxychloroquine group and 4 in the control group). A total of 52 participants never completed
any surveys after enrolment and did not respond to investigators e-mails, text messages, or telephone
calls (23 in the hydroxychloroquine group and 29 in the control group).
Notes Dates of recruitment: 17 March to 6 May 2020
Sponsors/funders: “Supported by David Baszucki and Jan Ellison Baszucki, the Alliance of Minnesota
Chinese Organizations, the Minnesota Chinese Chamber of Commerce, and the University of Minneso-
ta.”
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted-block sequence – variably sized blocks, stratified by country
Allocation concealment
(selection bias)
Low risk “Randomization will be recorded on an electronic log by the pharmacy. Study
investigators and subjects will be blinded.”
Boulware 2020  (Continued)
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Low risk Blinded participants and investigators – pharmacies that packaged drug were
separate and drug was sent by FedEx. A minority of participants knew what
their allocation was for HCQ and placebo.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Outcome assessors not in pharmacies, and blinded from allocation sequence.
Outcomes assessed by online survey, then analysed by outcome assessors – so




Low risk Reasonably low attrition (10% to 11%); similar between groups; similar char-
acteristics of those lost to follow-up in each group; sensitivity analysis includ-
ing these as having events found no difference in primary outcome.
Selective reporting (re-
porting bias)
Unclear risk There was a change in the primary outcome, from confirmed COVID-19, to in-
clude probable/possible cases. Confirmed also reported separately. Justified





Methods 3-arm RCT comparing HCQ with HCQ plus azithromycin and a control group receiving standard care for
treatment of COVID-19. Participants, clinicians, and outcome assessors in hospital were not blinded,
but researchers continuing post-discharge follow-up were. No placebo was used. Follow up to 15 days
post-randomization. 
Participants Setting: 55 hospitals in Brazil, mostly Southeast Brazil.
Number of participants: HCQ+AZ 217 (172 in modified ITT); HCQ alone 221 (159 in modified ITT); no
HCQ/AZ 227 (173 in modified ITT).
Inclusion criteria: Hospitalized patients aged 18 or older with suspected or confirmed COVID-19 with
symptom onset fewer that 14 days.
Confirmed COVID-19 was defined as RT-PCR positive from nose and throat swabs.  Suspected COVID-19
was defined according to the Brazilian Ministry of Health criteria: patients with fever and at least 1 res-
piratory sign or symptom (cough, shortness of breath, nasal congestion, sore throat, peripheral oxygen
saturation < 95%, cyanosis, dyspnoea); those from an endemic region or travelling from an endemic re-
gion in the last 14 days; or those in contact in the last 14 days with someone with a suspected or con-
firmed COVID-19 diagnosis.
Exclusion criteria:
1. Need for oxygen supplementation > 4 L/min via nasal cannula or ≥ 40% via Venturi mask.
2. Need for oxygen supplementation via high-flow nasal cannula.
3. Need for non-invasive ventilation.
4. Need for invasive mechanical ventilation.
5. Previous use of chloroquine, hydroxychloroquine, azithromycin, or any other macrolide for more than
24 hours before enrolment.
6. History of severe ventricular cardiac arrhythmia or electrocardiogram with QTc ≥ 480 ms.
7. History of liver cirrhosis.
8. Chronic renal failure (eGFR < 30 mL/min/1.73 m2).
9. Known retinopathy or macular degeneration.
10.History of pancreatitis.
11.Less than 18 years of age.
12.Known allergy to chloroquine or hydroxychloroquine.
Cavalcanti 2020 
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)










Cochrane Database of Systematic Reviews
13.Known allergy to azithromycin.
14.Pregnancy or breastfeeding.
Age (years): HCQ+AZ: Mean 49.5 ± 13.4 SD; HCQ alone: Mean 50.1 ± 13.5 SD; no HCQ/AZ: Mean 50.5 ± 14.7
SD.
Sex: HCQ+AZ: female:male 94:123; HCQ alone: female:male 79:142; no HCQ/AZ: female:male 106:123. 
Clinical presentation: not reported.
COVID-19 disease severity at presentation: Asymptomatic and severe patients excluded; HCQ+AZ: mild:
125/217 (58%); moderate 92/217 (42%); HCQ alone: mild 132/221 (60%); moderate 89/221 (40%); no
HCQ/AZ: mild 130/227 (57%); moderate 97/227 (43%).
Time from symptom onset to randomization: HCQ+AZ: median 7 [IQR 5-9] days; HCQ alone: median 7
[IQR 5-8] days; no HCQ/AZ: median 7 [IQR 4-9] days.
Comorbidities: 
1. Heart failure: HCQ+AZ 4/217; HCQ alone 3/221; No HCQ/AZ 3/227
2. Hypertension: HCQ+AZ 81/217; HCQ alone 94/221; No HCQ 83/227
3. Diabetes mellitus: HCQ+AZ 40/217; HCQ alone 47/221; No HCQ/AZ 40/227
4. HIV/AIDS: HCQ+AZ 1/217; HCQ alone 0/221; No HCQ/AZ 3/227
5. Chronic airways disease (asthma or COPD): HCQ+AZ 20/217; HCQ alone 13/221; No HCQ/AZ 19/227
6. Smoking history: HCQ+AZ 17/217; HCQ alone 12/221; No HCQ/AZ 15/227
7. Obesity: HCQ+AZ 29/217; HCQ alone 37/221; No HCQ/AZ 37/227
8. Cancer: HCQ+AZ 7/217; HCQ alone 4/221; No HCQ/AZ 8/227
9. Chronic renal disease: HCQ+AZ 2/217; HCQ alone 1/221; No HCQ/AZ 2/227
Place of care: inpatients in hospital. 
Interventions HCQ group received hydroxychloroquine 400 mg orally twice daily for 7 days.
HCQ plus azithromycin group received hydroxychloroquine 400 mg orally twice daily and azithromycin
500 mg orally once daily for 7 days.
Control group received standard care. 
Outcomes Primary outcome: clinical status on a 7-point ordinal scale at day 15.
1 - indicated not hospitalized with no limitations on activities;
2 - not hospitalized but with limitations on activities;
3 - hospitalized and not receiving supplemental oxygen;
4 - hospitalized and receiving supplemental oxygen;
5 - hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or
non-invasive ventilation;
6 - hospitalized and receiving mechanical ventilation; 
7 - death.
Secondary outcomes:
• Clinical status at 7 days on 6-point ordinal scale (points 1 and 2 above combined).
• Receipt of oxygen via high-flow nasal cannula or non-invasive ventilation.
• Indication for intubation within 15 days.
• Duration of hospital stay.
• In-hospital death.
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• Thromboembolic complications.
• Acute kidney injury.
• Number of days alive and free from respiratory support up to 15 days.
Notes Dates of recruitment: first patient randomized 29 March 2020; the last patient underwent randomiza-
tion on 17 May 2020; follow-up was completed on 2 June 2020.
Funding and sponsorship: the trial was funded by the hospitals and research institutes participating
in Coalition Covid-19 Brazil. EMS Pharma provided additional funding and logistic support for the trial
and also donated and supplied the trial drugs. EMS Pharma had no role in the conduct of the trial, the
analysis, or the decision to submit the manuscript for publication.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “Randomization was performed in blocks of six and was stratified according
to the use or nonuse of supplemental oxygen at the time of randomization.
Randomization was performed centrally by means of an electronic case-report
form system (RedCap) as described in the Supplementary Appendix.”




Low risk “The trial statistician, not involved with patient enrolment or care, generated
the randomization table in R software (R Core Team, 2019) and implemented
in the RedCap. The study treatment was revealed to investigators only after






Unclear risk Unclear for primary outcome
Low for mortality
Unclear for safety outcomes
No blinding of participants and personnel. Some participants in the control
group were given study drugs (12%), and decisions to discharge and institute
respiratory support may have been influenced. The effect of this is unclear for
all outcomes except mortality.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for primary outcome
Low for mortality
Unclear for safety outcomes
Assessors of the primary outcome were blinded, and the ordinal scale mea-
surement was sufficiently objective. Secondary outcomes were also measured








High risk Changes in outcome and analysis approach described, but they occurred after
start of participant recruitment, and without adequate explanation provided.
However, sensitivity analysis, ITT approach, and mITT approach do not show a
difference in results.
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Methods RCT investigating treatment with HCQ vs standard care without HCQ. No blinding or placebo used.
Follow-up: “On the 0th, 3rd, 5th and 7th day of enrolment, the subjects' vital signs, clinical symptoms,
laboratory test results, and adverse events recorded. The study was followed up for 2 weeks.” It was im-
plied that all of this occurred in hospital.
Participants Setting: Shanghai Public Health Clinical Center, Shanghai, China.
Number of participants: 30 randomized: 15 assigned to receive HCQ ("HCQ arm"); 15 assigned to stan-
dard care without HCQ ("standard care arm").
Inclusion criteria:
1. Age ≥ 18 years old
2. Confirmed COVID-19 according to Chinese national guidelines




3. "Combined heart, lung, kidney, brain, blood, etc. - patients with serious diseases of important organs
and dysfunction"
4. "Retinal diseases, hearing loss or hearing loss"
5. "Serious patients with neurological or psychiatric disorders"
6. "Researchers believe that they cannot complete the study as required or are not suitable to participate
in the research"
Age: HCQ arm: mean 50.5 ± 3.8; standard care arm: mean 46.7 ± 3.6.
Sex: HCQ arm: female:male 6:9; standard care arm: female:male 3:12.
Method of diagnosis: not reported; inferred that all had positive RT-PCR on “pharyngeal swabs, spu-
tum, or lower respiratory tract secretions”, as clearance of SARS-CoV-2 from these was the primary out-
come.
Clinical presentation: all 30 participants assumed to have lower respiratory tract disease, due to abnor-
mality on CT chest scan being present for all at baseline.
COVID-19 disease severity at presentation: all 30 participants assumed to have moderate severity, due
to abnormality on CT chest scan prompting classification as moderate severity in the Chinese diagnosis
and treatment guidelines, and exclusion of individuals with severe disease.
Time from symptom onset to enrolment (mean ± standard deviation): HCQ arm: 6.6 ± 3.9 days; stan-
dard care arm: 5.9 ± 4.1 days.
Comorbidities: hypertension in 5/15 HCQ arm participants vs 3/15 standard care; diabetes mellitus in
1/15 HCQ arm participants vs 1/15 standard care.
Place of care: all participants were cared for in hospital.
Interventions HCQ arm: HCQ 400 mg once daily for 5 days. Additionally, all had nebulized interferon alpha; 12/15 had
umifenovir (Arbidol).
Standard care arm: no HCQ; all had nebulized interferon alpha; 10/15 had umifenovir (Arbidol).
2 participants received lopinavir/ritonavir, but it is not reported which group they were in.
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Outcomes Primary: "virological clearance of pharyngeal swabs, sputum, or lower respiratory tract secretions on
day 7 or death"
Secondary: "occurrence of serious adverse drug events within 2 weeks or the subject’s condition
turned severe and critical"
Notes Dates of recruitment: 6 February to 25 February 2020
Sponsors/funders: “Shanghai Science and Technology Commission (20431900103); First-class univer-
sity and first-class discipline construction project of Fudan University (IDF162005) Zhejiang Universi-
ty New Coronavirus Pneumonia Emergency Scientific Research Project (2020XGZX030); Shanghai Pub-
lic Health Clinical Center New Coronavirus '2019-nCoV' scientific research project special project in the
hospital (2020YJKY01); Shanghai key specialty infectious disease project (shslczdzk01102); Haishi 'Med-
ical Garden New Star' Medical Talent Project (2019-72)”
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk No details reported, but an identical group size with such a small number of
participants is suspicious for poorly performing randomization process.
Allocation concealment
(selection bias)





Low risk No blinding, but performance bias unlikely.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Data are complete on the primary outcome.
Selective reporting (re-
porting bias)
High risk The publicly available protocol (clinicaltrials.gov/ct2/show/NCT04261517) re-






Methods RCT comparing outcomes in participants receiving HCQ vs those not receiving HCQ. Reported to be
double-blind, but no placebo given, and no details reported of methods used to blind participants and
investigators from knowledge of treatment allocation.
Follow-up: clinical assessment of body temperature and cough 3 times a day, until 6 days from enrol-
ment, “or severe adverse reactions appeared”.
Participants Setting: Renmin Hospital of Wuhan University, Wuhan, Hubei province, China (tertiary referral hospi-
tal).
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Number of participants: 62 total: 31 received HCQ ("HCQ arm"); 31 did not receive HCQ ("standard care
arm").
Inclusion criteria: “1. Age ≥ 18 years; 2. Laboratory (RT-PCR) positive of SARS-CoV-2; 3. Chest CT with
pneumonia; 4. SaO2/SPO2 ratio > 93% or PaO2/FiO2 ratio > 300 mmHg under the condition in the hos-
pital room (mild illness); 5. Willing to receive a random assignment to any designated treatment group
and not participating in another study at the same time.”
Exclusion criteria: “1. Severe and critical illness patients or participating in the trial does not meet the
patient's maximum benefit or does not meet any criteria for safe follow-up in the protocol after a doc-
tor’s evaluation; 2. Retinopathy and other retinal diseases; 3. Conduction block and other arrhythmias;
4. Severe liver disease (e.g., Child-Pugh score ≥ C or AST> twice the upper limit); 5. Pregnant or breast-
feeding; 6. Severe renal failure [eGFR ≤ 30 mL/min/1.73m2] or receiving renal replacement therapy; 7.
Possibility of being transferred to another hospital within 72 hours; 8. Received any trial treatment for
COVID-19 within 30 days before this research.”
Age: HCQ arm: mean 44.1 (SD 16.1) years; standard care arm: mean 45.2 (SD 14.7) years.
Sex: HCQ arm: female:male 17:14; standard care arm: female:male 16:15.
Method of diagnosis: positive PCR for SARS-CoV-2; specimen type not reported.
Clinical presentation: all had lower respiratory tract disease, as evidenced by pneumonia on chest CT
scan.
COVID-19 disease severity at presentation: all mild.
Time from symptom onset to enrolment: not reported.
Comorbidities: not reported.
Place of care: inpatients in hospital.
Interventions HCQ arm: HCQ 200 mg orally twice daily for 5 days.
Standard care arm: no HCQ.
“All received the standard treatment (oxygen therapy, antiviral agents, antibacterial agents, and im-
munoglobulin, with or without corticosteroids)”; no further details reported.
Outcomes Time to clinical recovery: “defined as the return of body temperature and cough relief, maintained for
more than 72 h. Normalization and mitigation criteria included the following: a. Body temperature
≤36.6 °C on the surface, ≤ 37.2 °C under the armpit and mouth or ≤ 37.8 °C in the rectum and tympanic
membrane; b. Cough from patients’ reports, slight or no cough was in the asymptomatic range.” Mea-
sured in 39 patients with fever at enrolment and 37 patients with cough at enrolment.
“For radiological changes, the chest CT results in one day before (Day 0) and one day after (Day 6) the
study for evaluation. Pulmonary recovery is defined as three levels: exacerbated, unchanged, and im-
proved, moderately improved when less than 50 % of pneumonia were absorbed, and more than 50 %
means significantly improved.”
Adverse events (all patients).
Notes Dates of recruitment: 4 February to 28 February 2020
Sponsors/funders: “Funding: This study was supported by the Epidemiological Study of COVID-19
Pneumonia to Science and Technology Department of Hubei Province (2020FCA005).”
This study was available as a preprint ahead of publication at the time of completion of this review. 
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Low risk “Randomization was performed through a computer-generated list stratified
by site.” Note only 1 hospital site is reported.
Allocation concealment
(selection bias)





High risk Reported as double-blinded: “Neither the research performers nor the pa-
tients were aware of the treatment assignments.”
However, oral tablets given, and no placebo given, and no methods describing
blinding of the prescribing clinician, nor what the patients were told about the
tablets they were given.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Due to the nature of the primary outcome (time to clinical improvement), out-
come assessment could have been influenced by lack of blinding, therefore





Low risk Data reported for all participants.
Selective reporting (re-
porting bias)
High risk Outcomes listed on the trial registry record differ from the reported outcomes,





Methods Open-label RCT comparing HCQ with standard care without HCQ. No placebo used. Followed up to 14
days.
Participants Setting: 11 public hospitals in northern, central, and southern Taiwan.
Inclusion criteria: “Enrolled patients were aged 20–79 y and confirmed positive for SARS-CoV-2 infec-
tion by real-time reverse transcription polymerase chain reaction (rRT-PCR).”
Exclusion criteria: "Participants presenting with severe illness were excluded from this study. The fol-
lowing patients were excluded from the trial: (a) documented history of hypersensitivity to quinine de-
rivatives; (b) retinal disease; (c) hearing loss; (d) severe neurological or mental illness; (e) pancreati-
tis; (f) lung disease; (g) liver disease (ALT/AST > 3× the normal upper limit); (h) kidney disease (eGFR <
30 mL/min/1.73 m2 according to MDRD or CKD-EPI); (i) haematological disease; (j) ECG screening with
long QT syndrome or QTcF interval > 450 msec for males and > 470 msec for females at screening; (k)
known HIV infection; (l) active hepatitis B or C without concurrent treatment (positive for hepatitis B
[HBsAg and HBeAg] or hepatitis C ribonucleic acid [RNA] titer > 800,000 IU/mL); (m) G6PD; (n) psychi-
atric disorders and alcohol/substance dependence/abuse that may jeopardize patient safety; and (o)
pregnant or breast-feeding women... Patients who had undetected virus within 2-days of hospitaliza-
tion were excluded.”
Age: HCQ arm: mean 33 (SD 12) years; standard care arm: mean 32.8 (SD 8.3) years.
Sex: HCQ arm female:male 10:11; standard care arm female:male 4:8.
Method of diagnosis: positive PCR for  SARS-CoV-2; specimen type not reported.
Clinical presentation: not reported specifically, but at least 2/21 in the HCQ arm and 2/12 in the stan-
dard care arm had some infiltration of the lungs on imaging of the chest.
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COVID-19 disease severity at presentation: HCQ arm: 19/21 mild, 2/21 moderate; standard care
arm: 10/12 mild, 2/12 moderate.
Time from symptom onset to enrolment: not reported.
Comorbidities: not reported.
Place of care: all hospitalized.
Interventions HCQ: 400 mg orally twice daily on day 1, then 200 mg twice daily on days 2 to 7.
Standard care: all participants with moderate disease had “(1) ceftriaxone 2 g daily for 7 days +/-
azithromycin 500 mg on day 1 and 250 mg on days 2–5; or (2) levofloxacin 750 mg daily for 5 d; or (3)
levofloxacin 500 mg daily; or (4) moxifloxacin 400 mg daily for 7–14 days for subjects allergic to ceftriax-
one or azithromycin or according to physician discretion.”
Outcomes Primary: “time to negative rRT-PCR assessments from randomization up to 14 days.”
Secondary:
• negative PCR for SARS-CoV-2 on hospital day 14
• “resolution of clinical symptoms (time to clinical recovery)”
• discharge by day 14
• mortality
“HCQ safety and tolerability were also evaluated.”
Notes Dates of recruitment: 1 April to 31 May 2020.
Sponsors/funders: “The authors thank the Hospital and Social Welfare Organizations Administration
Commission, Ministry of Health and Welfare for their research grant. This funding source played no role
in study design or conduction, data collection, analysis or interpretation, writing of the manuscript, or
decision to submit it for publication. The authors also thank Taiwan Biotech Co. Ltd. for their donation
of investigational products, the National Health Research Institutes, Taiwan Centers for Disease Con-
trol, Taiwan Food and Drug Administration, Center for Drug Evaluation, Taiwan for their technical assis-
tance”
A retrospective study was also conducted, reviewing records of patients preceding the trial. Its results
are not extracted here.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “randomly assigned by an interactive web response system in a 2:1 ratio to re-
ceive either HCQ plus standard of care (SOC) or SOC alone. They were stratified
by mild or moderate illnesses within 4 days of diagnosis.”
Allocation concealment
(selection bias)





Low risk Low for time to negative PCR, negative PCR on day 14, and mortality.
High for discharge by day 14 and adverse events.
Unclear for time to clinical recovery.
No blinding. Unlikely effect on time to negative PCR, negative PCR on day 14,
or mortality. High risk of bias for discharge and adverse events. Unclear risk of
bias for time to clinical recovery – no methods reported for how this was deter-
mined.
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for time to negative PCR, negative PCR on day 14, and mortality.
High for discharge by day 14, time to clinical recovery and adverse events.
No blinding. Unlikely effect on time to negative PCR, negative PCR on day 14,





High risk Attrition of ~10% (3/33) before first dose of HCQ (1/21 HCQ arm; 2/12 standard
of care arm), with no reason or characteristics reported.  Imputation of PCR re-
sults not available as negative results, with no sensitivity analysis, nor report-
ing of how much missing data there were for each outcome. With such a small
sample size, effect may be influenced by this degree of missing data.
Selective reporting (re-
porting bias)
High risk No trial protocol is available. Clinical efficacy outcomes were not reported in
the trial registry entry (clinicaltrials.gov/ct2/show/record/NCT04384380); only






Methods Open-label RCT comparing HCQ with febuxostat. No placebo.
Followed up to 14 days.
Participants Setting: outpatients at Mostafavian Fever Clinic in Sari, Iran.
Number of participants: 54 total: 25 received HCQ; 29 received febuxostat.
Inclusion criteria: “1; chest CT finding compatible with COVID-19 infection along with other symptoms
of coronavirus infection. Bilateral and peripheral ground-glass and consolidative pulmonary opacities
were the hallmarks of CT findings. 2; any symptoms of respiratory tract involvement including cough,
dyspnoea or tachypnoea along with a history of contact with a known case of COVID-19. 3; creatinine
clearance greater than 60 mL/min.”
Exclusion criteria: “1; Suspicious patients for COVID-19 pneumonia who had severe underlying diseases
such as cardiovascular, lung and kidney diseases, 2; patients with severe pneumonia needing hospital-
isation, 3; patient who were unable to take oral medications and 4; concurrent use of azathioprine, di-
danosine, mercaptopurine or pegloticase (due to drug interaction with febuxostat).”
Age: HCQ arm: mean 57.3 (standard error 2.2) years; febuxostat arm: mean 58 (standard error 1.47)
years.
Sex: HCQ arm female:male 9:16; febuxostat arm female:male 13:16.
Method of diagnosis: based on CT scan and symptoms, as in inclusion criteria above.
Clinical presentation: not specifically reported, but all had some lung abnormalities on CT chest scan.
COVID-19 disease severity at presentation: presumed to all have moderate disease based on WHO clas-
sification: all had pneumonia on CT.
Time from symptom onset to enrolment: not reported.
Comorbidities: 7/25 in the HCQ arm and 8/29 in the febuxostat arm had diabetes mellitus; 1/25 in the
HCQ arm and 0/29  in the febuxostat arm had underlying lung disease.
Place of care: ambulatory care.
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Interventions HCQ: 200 mg orally twice daily for 5 days.
Febuxostat: 80 mg orally once daily for 5 days.
“All patients were taken acetaminophen [paracetamol] 325 mg, as needed, for controlling the fever.”
No other co-interventions reported.
Outcomes Primary: need for hospitalization.
Secondary:
• “clinical improvements (eg, resolution of fever, cough and dyspnoea)”; and
• “improvement of CT findings”
at day 14 after initiation of the treatment.
Notes Dates of recruitment: 16 March to 10 April 2020.
Sponsors/funders: “This study was supported by a grant from Mazandaran University of Medical
Science, Sari, Iran (ID#7294).”
Febuxostat was the intervention drug of interest for this trial; HCQ was an active comparator.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description beyond “randomised using the balance block method”.
Allocation concealment
(selection bias)
Low risk "The patient receives the medication (intervention or comparison) in sealed
envelopes that are coded. The coding is done by a project colleague and the





High risk High for hospitalization (primary) and clinical improvement
Low for improvement of CT scan
Reported as open-label, but also states: “Both patients and physician did not
know the contents of tables [tablets].”
No measures for blinding described, and the interventions had different fre-
quencies of administration.
If assumed to be open-label, hospitalization and clinical improvement would
be at high risk of performance bias. Improvement of CT scan findings would be
at low risk of performance bias.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for hospitalization (primary) and improvement of CT scan
High for clinical improvement
Reported as open-label, but also states: “Both patients and physician did not
know the contents of tables [tablets].”
No measures for blinding described, and the interventions had different fre-
quencies of administration.
If assumed to be open-label, clinical improvement would be at high risk of de-
tection bias. Hospitalization and improvement of CT scan findings would be at
low risk of detection bias.
Davoodi 2020  (Continued)
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)














High risk No outcome data used for 5/30 participants randomized to HCQ arm and 1/30
to febuxostat arm. Reasons provided, but neither baseline characteristics nor
outcomes reported, and no imputation performed for these participants. With
small total trial numbers, and possibility of some participants not having re-
mained in trial due to poor outcomes, we judged this domain as high risk.
Selective reporting (re-
porting bias)
High risk In registry record, outcomes: CT scan findings (primary), fever, lymphocyte
count, CRP.
In report: hospitalization (primary), “clinical improvements (eg, resolution of
fever, cough and dyspnoea)”, “improvement of CT findings”.





Methods Adaptive factorial design RCT (RECOVERY) comparing a HCQ with standard of care (SOC) in patients
hospitalized with COVID-19. The RECOVERY trial evaluated several treatments, of which only HCQ was
relevant for this review. Centralized web-based randomization was done. There was no blinding of par-
ticipants or personnel.
Follow-up: Data were collected at time of death, discharge, or 28 days after randomization. Data were
available for 98% of participants for the 28-day follow-up.
Participants Setting: UK National Health Service (NHS) hospitals - secondary and tertiary facilities (176 in total)
Number of participants: 4674 total: 1542 received HCQ; 3132 received SOC
Inclusion criteria: hospitalized AND SARS-CoV-2 infection (clinically suspected or laboratory confirmed)
AND without a medical history that might, in the opinion of the attending clinician, put the patient at
significant risk if he/she were to participate in the trial. 
Exclusion criteria: only those 18 years and above were eligible, until 9 May after which children were in-
cluded. Exclusions included those with known prolonged electrocardiograph QTc interval. Co-adminis-
tration with medications that prolong the QT interval was not an absolute contraindication, but attend-
ing clinicians were advised to check the QT interval by performing an electrocardiogram.
Age: HCQ arm: mean 65.2 (SD 15.2) years; standard care arm: mean 65.4 (SD 15.4) years.
Sex: HCQ arm: female:male 600:961; standard care arm: female:male 1181:1974.
Method of diagnosis: clinically suspected or laboratory confirmed were included. Clinical suspicion
was suspected when a patient presented with (i) typical symptoms (e.g. influenza-like illness with fever
and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-
ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been consid-
ered unlikely or excluded (e.g. heart failure, influenza). Method of laboratory testing not specifically de-
scribed, but antibody testing not used in most UK hospitals.
HCQ: positive "SARS-COV-2 test": 1393 (89%); negative 153 (10%); unknown 15 (1%). SOC: positive
"SARS-COV-2 test": 2841 (90%); negative 291 (9%); unknown 23 (1%).
A small number of children (age < 18 years old) presented with atypical features, including a hyperin-
flammatory state and evidence of single or multi-organ dysfunction. Some did not have significant lung
involvement.
Clinical presentation: not specifically reported, but 77% (HCQ) vs 76% (SOC) were receiving oxygen or
invasive ventilation at enrolment.
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COVID-19 disease severity at presentation: 
HCQ: no oxygen received 362 (23%); received oxygen: 938 (60%); invasive ventilation 261 (17%).
SOC: no oxygen received 750 (24%); received oxygen: 1873 (59%); invasive ventilation 532 (17%).
Time from symptom onset to enrolment: HCQ: median 9 days (IQR 5 to 14); SOC: median 9 days (IQR 5
to 13); this is presumed to be time from symptom onset to randomization, not to hospital presentation.
Comorbidities: 
1. cardiac disease (such as coronary artery disease or heart failure): HCQ: 422 (27%) and SOC: 789 (25%);
2. diabetes mellitus: HCQ: 427 (27%) and SOC: 856 (27%);
3. HIV: HCQ: 8 and SOC: 13;
4. chronic airways disease (asthma, COPD): HCQ: 334 (21%) and SOC: 712 (23%);
5. severe liver disease:  HCQ: 18 (1%) and SOC: 46 (1%);
6. severe kidney impairment: HCQ: 111 (7%) and SOC: 261 (8%);
7. tuberculosis: HCQ: 4 and SOC: 9.
Place of care: inpatients in hospital.
Interventions Oral formulation of HCQ given at dosage of 800 mg at 0 and 6 hours, then 400 mg at 12 hours from first
dose and every 12 hourly for 10 days.
Outcomes Primary outcome: all-cause mortality at 28 days after randomization.
Secondary outcomes:
• duration of hospital stay
• need for (and duration of) ventilation
• composite endpoint of death or need for mechanical ventilation/ECMO
• need for renal replacement therapy
• new major cardiac arrhythmias
Regarding major new cardiac arrhythmia, data were collected for 698 (44.7%) patients in the HCQ arm
and 1357 (43.0%) in the SOC arm; supraventricular tachycardia was observed in 6.9% HCQ participants
vs 5.9% SOC; ventricular tachycardia or fibrillation in 0.9% HCQ vs 0.7% SOC; and atrioventricular block
requiring intervention in 0.1% HCQ vs 0.1% SOC. No other data regarding adverse events provided. 
Notes Dates of recruitment: 25 March to 5 June 2020
Sponsors/funders: NuJield Department of Population Health at University of Oxford. The RECOVERY
trial is supported by a grant to the University of Oxford from UK Research and Innovation/National In-
stitute for Health Research (NIHR) (Grant reference: MC_PC_19056) and by core funding provided by
NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the De-
partment for International Development, Health Data Research UK, the Medical Research Council Pop-
ulation Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections,
and NIHR Clinical Trials Unit Support Funding.
This study was available as a preprint ahead of publication at the time of completion of this review. 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Handled centrally, so unlikely.
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Low risk No blinding used.
Clinicians could decide eligibility for each arm of the trial on an individual ba-
sis, which could lead to systematic bias in comparability of the 2 groups; how-
ever, due to the comparison for each intervention being with controls who
were eligible for that intervention, and this is pre-randomization, it is unlikely
to lead to a high risk of bias.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for death and invasive ventilation
Unclear for discharge
Unlikely to influence mortality or need for invasive ventilation, but unclear ef-




Low risk Follow-up data available for 98% of participants.
Selective reporting (re-
porting bias)
Low risk Low for all outcomes, except unclear for time to discharge and adverse events.
Reported outcomes decided a priori. Insufficient detail of time to discharge






Methods RCT comparing outcomes in participants receiving CQ with those receiving lopinavir/ritonavir (LPV/r).
Blinding not reported.
Participants had daily clinical data collection and nasopharyngeal swab PCR for SARS-CoV-2. They had
follow-up CT chest scans (unclear frequency). Outcomes were reported to be measured up to 14 days.
Participants Setting: FiQh Affiliated Hospital of Sun Yat-sen University in Zhuhai, China.
Number of participants: 22 total: 10 received CQ; 12 received LPV/r.
Inclusion criteria: age ≥ 18 years old; hospitalized; positive PCR for SARS-CoV-2.
Exclusion criteria: “1. Pregnant woman patients; 2. Documented allergic history to Chloroquine; 3. Doc-
umented history of hematological system diseases; 4. Documented history of chronic liver and kidney
diseases; 5. Documented history of cardiac arrhythmia or chronic heart diseases; 6. Documented histo-
ry of retina or hearing dysfunction; 7. Documented history of mental illnesses; 8. Use of digitalis due to
the previous disease.”
Age: CQ arm: median 41.5 (IQR 33.8 to 50.0) years; LPV/r arm: median 53.0 (IQR 41.8 to 63.5) years.
Sex: CQ arm female:male 3:7; LPV/r arm female:male 6:6.
Method of diagnosis: positive PCR for SARS-CoV-2; specimen type not reported.
Clinical presentation: not reported specifically, but at least 8/10 in the CQ arm and 11/12 in the LPV/r
arm had some abnormalities on CT chest scan.
COVID-19 disease severity at presentation: CQ arm: 7/10 moderate, 3/10 severe; LPV/r arm: 7/12 moder-
ate, 5/12 severe.
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Time from symptom onset to enrolment: CQ arm: median 2.5 (IQR 2 to 3.75) days; LPV/r arm: medi-
an 6.5 (4.75 to 8.5) days.
Comorbidities: 1/10 in the CQ arm and 3/12 in the LPV/r arm had hypertension; 0 in the CQ arm and
1/12 in the LPV/r arm had history of stroke/cerebrovascular disease; 1/10 in the CQ arm and 1/12 in the
LPV/r arm had diabetes mellitus; 2/10 in the CQ arm and 0 in the LPV/r had a history of smoking.
Place of care: all inpatients in hospital.
Interventions CQ: 500 mg orally twice daily for 10 days.
LPV/r: 400/100 mg orally twice daily for 10 days.
No other co-interventions reported.
Outcomes Primary outcome: time to conversion of SARS-CoV-2 PCR on nasal and pharyngeal swab samples from
positive to negative, and proportion (reported as "rate") negative at day 10 and day 14.
Secondary outcomes: “rate of hospital discharge at Day 14, clinical recovery at day 10, CT scan im-
provement at Day 10 and 14, and the frequency of adverse events. The criteria of clinical recovery
were: no fever, axilla temperature ≤36.6°C or oral temperature ≤37.2°C or rectal/tympanic temperature
≤37.8°C; respiratory rate ≤24/minute on room air; oxygen saturation >94% on room air; mild or absent
of cough (the scale of cough is classified as severe, moderate, mild, absent). The criteria of hospital dis-
charge were: the temperature returned to normal for more than 3 days; the respiratory symptoms im-
proved significantly; the pulmonary imaging showed that the inflammation was obviously absorbed;
and the detection of respiratory pathogenic nucleic acid was negative twice in a row (the sampling time
is at least 1 day apart). The criteria of CT scan improvement were: exudation or consolidation of the le-
sion absorbed; the lesion area was gradually narrowed; and there might be residual linear fibrosis.”
Notes Dates of recruitment: 27 January to 15 February 2020.
Sponsors/funders: not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk No information about method of randomization in trial report, however base-
line differences seem significant for duration of symptoms prior to hospital ad-
mission, age, baseline severity, and baseline radiographic characteristics. The
trial registry protocol states that the study is non-randomized.
Allocation concealment
(selection bias)





Low risk No blinding, but low risk of performance bias.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk No blinding, and little detail on assessment of outcome, so although possi-
ble, it is unlikely that interpretation of the result may have been influenced by




Low risk Complete data for all participants.
Selective reporting (re-
porting bias)
High risk Protocol on the trials registry (ChiCTR2000029542) lists different outcomes
from protocol in the article supplement.
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Methods RCT evaluating early treatment of mild COVID-19 with HCQ compared to standard of care (SOC) 
Follow up: on day 1, patients were visited at home for baseline assessment and participant enrolment.
Outbreak field teams verified the selection criteria for eligibility, obtained patients’ signed informed
consent, assessed specific symptoms associated with COVID-19, and collected relevant epidemiologi-
cal information from a structured interview. Disease progression, safety, and self-reported treatment
compliance were monitored by the Clinical Trials Unit of Hospital Germans Trias Pujol at days 3 and 7
(home visits), 14 and 28 (telephone reviews).
Participants Setting: participants identified via an electronic registry of the Epidemiological Surveillance Emergency
Service of Catalonia (SUVEC) of the National Department of Health, from 3 health administrative re-
gions in Catalonia, Spain. They were managed at home, not hospitalized.
Number of participants: 293 total: 136 allocated to HCQ; 157 allocated to standard of care.
Inclusion criteria: adult patients aged 18 years or more were eligible if they had mild symptoms of COV-
ID-19 (i.e. fever, acute cough, shortness of breath, sudden olfactory or gustatory loss, or influenza-like
illness) for less than 5 days before enrolment, were non-hospitalized, and had a positive PCR test for
SARS-CoV-2 in the baseline nasopharyngeal swab.
Exclusion criteria: moderate-to-severe COVID-19 disease (e.g. required hospitalization), any condition
that might preclude following the study procedures safely (e.g. mental disability), known allergy or
hypersensitivity to study drugs, known retinal and severe liver or renal diseases, history of cardiac ar-
rhythmia, known QT prolongation or other diseases that could be exacerbated by study drugs (e.g. pso-
riasis), active treatment with medications that are contraindicated with study drugs, or known HIV in-
fection. Females who were pregnant (verbally declared or positive pregnancy test) or breastfeeding
were also excluded.
Age: HCQ arm: mean 41.6 years (SD 12.4); control arm: mean 41.7 years (SD 12.6).
Sex: HCQ arm female:male 98:38; standard of care arm female:male 103:54.
Types of participant: HCQ arm: 106 healthcare workers, 4 household contacts, 8 nursing home workers,
18 exposure not reported; control arm: 132 healthcare workers, 1 household contacts, 8 nursing home
workers, 16 exposure not reported.
Severity on presentation: not reported.
Time from symptom onset to presentation: all < 5 days by definition; however, note that 4 reported > 5
days symptoms, but duration not reported.
Definition of development of COVID-19: positive PCR on nasopharyngeal swab
Comorbidities: 
1. cardiac disease (such as coronary artery disease or heart failure): HCQ: 20 (14.7%) and SOC: 15 (9.6%);
2. chronic airways disease (asthma, COPD): HCQ: 7 (5%) and SOC: 10 (6%);
3. metabolic disease: HCQ: 9 (6.6%) and SOC: 11 (9%);
4. nervous system disease: HCQ: 19 (14%) and SOC: 21 (13.4%);
5. any co-existing disease: HCQ: 71 (52.2%) and SOC: 85 (54.1%).
Care setting: home-based care
Interventions Intervention group received oral dose of HCQ 800 mg on day 1, followed by 400 mg daily for a further
6 days (total duration of treatment 7 days).
Comparator group received standard of care. 
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Outcomes Primary: reduction of viral RNA load in nasopharyngeal swabs at days 3 and 7 after start of treatment.
Secondary: clinical progression measured by a simplified version of the WHO progression scale (1, not
hospitalized with or without resumption of normal activities; 2, hospitalized, requiring supplemental
oxygen; 3, hospitalized, requiring invasive mechanical ventilation; and 4, death); time from randomiza-
tion to complete resolution of symptoms within the 28-day follow-up period.
Resolution of symptoms was assessed sequentially using a symptoms questionnaire designed to gath-
er information on the type of symptom and last day experienced; complete resolution was considered
when no COVID-19-related symptoms were reported.
Safety outcomes: adverse events occurring during treatment, serious adverse events, adverse events of
special interest (i.e. cardiac), and premature discontinuation of therapy.
Notes Recruitment: 17 March to 26 May 2020
Sponsor/ funding: mainly supported by the crowdfunding campaign JoEmCorono (www.yomecoro-
no.com/) with the contribution of over 72,000 citizens and corporations. The study also received finan-
cial support from Laboratorios Rubió, Laboratorios Gebro Pharma, Zurich Seguros, SYNLAB Barcelona,
and Generalitat de Catalunya. Laboratorios Rubió also contributed to the study with the required doses
of hydroxychloroquine (Dolquine).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Low for viral load reduction at 3 days and 7 days.
High for admission to hospital, time to clinical improvement, and adverse
events.
“Laboratory technicians were unaware of participants’ treatment allocation,
treatment response, and previous PCR results at all time points.”
None for participants or investigators (i.e. open-label).
Outcomes not affected by lack of blinding: viral load reduction at 3 days and 7
days.
Outcomes prone to lack of blinding: admission to hospital and adverse events.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Low for viral load reduction at 3 days and 7 days.
High for admission to hospital, time to clinical improvement, and adverse
events.
“Laboratory technicians were unaware of participants’ treatment allocation,
treatment response, and previous PCR results at all time points.”
None for participants or investigators (i.e. open-label).
Outcomes not affected by lack of blinding: viral load reduction at 3 days and 7
days.
Outcomes prone to lack of blinding: admission to hospital and adverse events.
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High risk Low attrition numbers labelled as "lost to follow up", and 2 further participants




High risk Reported to be a secondary trial within this combined postexposure prophy-
laxis and treatment trial (clinicaltrials.gov/ct2/show/NCT04304053). Not re-
ported clearly in article how many participants were contacts vs index cases.
Virological clearance at 3 days reported in ClinicalTrials.gov registry record,
but not reported in trial report. Also ClinicalTrials.gov record does not report
the ordinal outcome scale used in the report (which is not standard e.g. WHO).
Other bias High risk A small number of participants were randomized who were in fact not eligi-
ble for the trial; however, these participants were kept in the ITT population,





Methods Open-label cluster-randomized trial comparing HCQ with standard care when given to individuals with
a history of exposure to SARS-CoV-2, for prevention of COVID-19.
Follow-up was up to day 28, using in-person visits to the participant's home on days 1 and 14, and tele-
phone interviews on days 3, 7, and 28.
Participants Setting: community; “screened using the electronic registry of the Epidemiological Surveillance Emer-
gency Service of Catalonia (SUVEC) of the Department of Health. During the COVID-19 outbreak in Cat-
alonia, a public health ordinance required all patients who tested positive for COVID-19 in any of the
designated diagnostic laboratories to be notified to the SUVEC.”
Number of participants: 2525 total: 1225 allocated to HCQ; 1300 allocated to standard care. (Note
that baseline characteristics and efficacy outcomes use a modified ITT population as their denomina-
tor: 1116 HCQ; 1198 standard care. Adverse events are reported for all randomized participants: 1225
HCQ; 1300 standard care.)
Inclusion criteria: “adult individuals ≥ 18 years of age with a recent history of close contact exposure
to a PCR confirmed COVID-19 case (i.e., > 15 minutes within two meters, up to seven days before en-
rolment) and absence of COVID-19-like symptoms on the two weeks preceding enrolment, as either a
healthcare worker, a household contact, a nursing home worker or a nursing home resident.”
Exclusion criteria: symptoms or signs of COVID-19 at baseline assessment; “all eligibility criteria are list-
ed in the Supplementary Appendix.” (No appendix was available with the preprint publication.)
Age: HCQ arm: mean 48.6 (SD 18.7) years; standard care arm: mean 48.7 (SD 19.3) years.
Gender: HCQ arm F:M 813:303; standard care arm F:M 875:323.
Types of participant: HCQ arm: 131 (12%) healthcare workers; 302 (27%) household contacts; 550 (49%)
nursing home workers; 133 (12%) nursing home residents. Standard care arm: 130 (11%) healthcare
workers; 338 (28%) household contacts; 584 (49%) nursing home workers; 160 (13%) nursing home res-
idents. (Note that the denominator for the standard care arm is 1212 rather than 1198.)
Definition of development of COVID-19: "confirmed COVID-19 episode, defined as symptomatic ill-
ness (at least one of the following symptoms: fever, cough, difficulty breathing, myalgia, headache,
sore throat, new olfactory and taste disorder(s), or diarrhoea) and a positive SARS-CoV-2 RT-PCR test";
“SARS-CoV-2 infection, defined as either the RT-PCR detection of SARS-CoV-2 in a nasopharyngeal spec-
imen or the presence of any of the aforementioned symptoms compatible with COVID-19”.
Comorbidities:
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1. cardiovascular disease: HCQ: 130 (11.6%) and standard care: 178 (14.9%);
2. respiratory disease: HCQ: 64 (5.7%) and standard care: 47 (3.9%);
3. metabolic disease: HCQ: 99 (8.9%) and standard care: 94 (7.8%);
4. nervous system disease: HCQ: 170 (15.2%) and standard care: 170 (14.2%).
Interventions HCQ: 800 mg orally on day 1, followed by 400 mg once daily for 6 days. Total 7 days.
Standard care: no treatment.
Co-interventions not reported.
Outcomes Primary outcome: “confirmed COVID-19 episode, defined as symptomatic illness (at least one of the
following symptoms: fever, cough, difficulty breathing, myalgia, headache, sore throat, new olfactory
and taste disorder(s), or diarrhoea) and a positive SARS-CoV-2 RT-PCR test. The primary outcome was
assessed in all asymptomatic individuals, irrespective of the PCR result; in a post hoc analysis, we ex-
plored the outcome in individuals with positive and negative PCR separately. Time-to-event was de-
fined as the number of days from the date of randomization/exposure to the confirmed date of the on-
set of symptomatic illness.”
Secondary efficacy outcomes:
• “incidence of SARS-CoV-2 infection, defined as either the RT-PCR detection of SARS-CoV-2 in a na-
sopharyngeal specimen or the presence of any of the aforementioned symptoms compatible with
COVID-19”
• “serological positivity (IgM/IgG) of contacts at day 14”
Safety outcomes: “frequency and severity of adverse events (AE), serious AE (SAE), and AE of special in-
terest (e.g., cardiac) up to 28 days from treatment start. Causality was assessed by an external panel of
pharmacovigilance consultants.” (Note that this included death and hospitalization.)
Notes Recruitment: 17 March to 28 April 2020.
Sponsor/funding: "mainly supported by the crowdfunding campaign JoEmCorono (https://www.y-
omecorono.com/) with the contribution of over 72,000 citizens and corporations. The study also re-
ceived financial support from Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB Barcelona,
and Generalitat de Catalunya. Laboratorios Rubió also contributed to the study with the required doses
of hydroxychloroquine (Dolquine®).”
Note that LR and GP are pharmaceutical companies. No mention of their involvement in the study, or
lack thereof.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk “Randomization was performed remotely by a member of the study team not
involved in participants’ enrollment.”
No description of sequence generation method.
Allocation concealment
(selection bias)
Unclear risk “Randomization was performed remotely by a member of the study team not
involved in participants’ enrollment… The allocation was revealed to partici-





High risk High for symptomatic confirmed COVID-19 (primary outcome) and adverse
events.
Low for antibody positivity.
Open-label study. Due to symptoms being required to define primary out-
come, this would be at high risk of bias due to lack of blinding, as would safe-
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ty outcomes. Antibody positivity at day 14 would not be influenced by knowl-
edge of group allocation.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk High for symptomatic confirmed COVID-19 (primary outcome); composite
symptoms without PCR positivity OR PCR-positive asymptomatic COVID-19;
and adverse events.
Low for antibody positivity and death.
No blinding. As above, due to symptoms being required to define primary out-
come, this would be at high risk of bias due to lack of blinding, as would safe-
ty outcomes. Antibody positivity at day 14/death would not be influenced by




Low risk Low for efficacy outcomes.
Unclear for adverse events.
Exclusions from "intention-to-treat (ITT)" (assessed as modified ITT; prima-
ry analysis) were < 10%; reasons were reported, and loss to follow-up was <
5%. Numbers seemed to be balanced between the 2 treatment arms. Compar-
ison of characteristics between those included vs excluded not presented in
preprint. This applies to all efficacy outcomes. There was no imputation for
missing data.
The safety sample included all randomized participants, so there was low risk
of bias for the outcomes of adverse events and death. < 3% of participants ei-
ther did not receive HCQ in the HCQ arm or started HCQ in the control arm.
However, denominators were unclear: 1197 vs 1225 in the intervention arm.
Selective reporting (re-
porting bias)
High risk Both of the outcomes currently specified in the trial registry entry (clinicaltrial-
s.gov/ct2/show/NCT04304053) were included in the report.
However, disease in contacts of contacts was also specified and is not report-
ed, with no reason provided.
Other bias High risk Additional domains for cluster-RCTs:
Recruitment bias: low risk. Appears unlikely, as the rings (clusters) were ran-
domized first, and then the contacts were told their allocation.
Baseline imbalance: low risk. No stratified or pair-matched randomization.
Baseline characteristics not disaggregated by cluster. But many clusters, so
unlikely to lead to baseline imbalance.
Loss of clusters: low risk. No clusters lost.
Incorrect analysis: low risk. The analysis accounted for clustering.
Comparability with individually randomized trials: high risk. Contamination-
 possible, as this was an open-label study, and people within clusters may en-
courage differential adherence to intervention. However, reported adherence
was > 95%. This intervention would be expected to work best when given to
all contacts of a case rather than some being randomized to the intervention
and some randomized to no intervention, which would preclude comparabili-
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Study characteristics
Methods Adaptive open-label RCT comparing multiple different experimental pharmaceutical interventions vs
standard care. Participants in treatment arms were compared only with those eligible for that treat-
ment but that were randomized to standard care. No placebo used.
Followed up to hospital discharge.
Participants Setting: hospitals in 30 countries in all 6 WHO regions; ~60% of participants recruited in Africa/Asia.
Number of participants: 1853 total: 947 received HCQ; 906 received standard care.
Inclusion criteria: hospitalized adults (> 18 years old) with confirmed COVID-19, receiving any treatment
other than the study drugs, with no contraindications to any study drug, and no transfer planned with-
in the subsequent 72 hours. 
Exclusion criteria: "1. Any of the available study drugs are contra-indicated (e.g. because of patient
characteristics, chronic liver or heart disease, or some concurrent medication).
2. Declined to participate in the study."
Note that an initial exclusion criterion was pregnancy, but this was removed early in the trial.
Age: HCQ arm: 335 participants (< 50 years), 410 (50 to 69 years), 202 (≥ 70 years); standard care arm:
317 participants (< 50 years), 396 (50 to 69 years), 193 (≥ 70 years).
Sex: HCQ arm: female:male 373:574; standard care arm: female:male 371:535.
Method of diagnosis: not reported, but presumed PCR positivity due to "confirmed" inclusion criterion
and WHO-sponsored study.
Clinical presentation: not reported.
COVID-19 disease severity at presentation: HCQ: 862/947 moderate or severe (of whom 517 were re-
ceiving oxygen at randomization), 85 critical; standard care: 824/906 moderate or severe (of whom 483
were receiving oxygen at randomization), 82 critical.
Time from symptom onset to enrolment: not reported.
Comorbidities: 
1. cardiac disease: HCQ: 193/947 and standard care: 194/906;
2. diabetes mellitus: HCQ: 199/947 and standard care: 194/906;
3. chronic lung disease: HCQ: 62/947 and standard care: 66/906;
4. chronic liver disease: HCQ: 15/947 and standard care: 14/947;
5. asthma: HCQ: 41/947 and standard care: 46/906.
Place of care: all inpatients in hospital.
Interventions HCQ: 800 mg orally at 0 and 6 hours, then 400 mg twice daily from 12 hours onwards, for a total of 10
days.
Standard care: any drugs that were not part of the study.
Co-interventions not reported.
Outcomes Primary: all-cause death in hospital.
Secondary:
• Initiation of ventilation (initial on protocol as on 16 October 2020: “Time to first receiving ventilation
(or intensive care)”).
• Time to discharge from hospital.
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Notes Dates of recruitment: 22 March to 4 October 2020 for whole report, from which data were extracted;
HCQ arm stopped on 18 June 2020.
Sponsors/funders: drugs donated by drug companies; WHO and national governments shared sponsor-
ship.
Details of the trial results were taken from a preprint publication.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralized computer generated.
Allocation concealment
(selection bias)





Low risk No blinding, but unlikely to lead to performance bias for death.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Near-complete data for death outcome.
Selective reporting (re-
porting bias)
Unclear risk Preprint with not all outcomes reported, and 1 changed between protocol and






Methods RCT comparing outcomes in people receiving HCQ for prophylaxis vs those receiving placebo for pre-
vention of COVID-19.
Follow-up: participants were sent surveys by email on days 1 (medication start date), 3, 5 (medication
stop date), 10, and 14 to assess medication adherence, adverse effects, presence and severity of COV-
ID-19 symptoms, COVID-19 test results, and hospitalization status. If participants were hospitalized, fol-
low-up continued to assess outcomes.
Participants Setting: community; recruitment via social media campaign.
Number of participants: 491 total: 244 allocated to HCQ; 247 allocated to placebo.
Inclusion criteria: non-hospitalized adults who were required to have 4 or fewer days of symptoms and
either PCR-confirmed SARS-CoV-2 infection or compatible symptoms after a high-risk exposure to a
person with PCR-confirmed COVID-19 within the past 14 days. High-risk exposure was defined as an im-
mediate household contact or a close occupational exposure to someone with COVID-19 (e.g. health-
care worker or first responder). Healthcare workers who had COVID-19-compatible symptoms and
high-risk exposure but whose contact had PCR results pending were enrolled after symptom review by
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an infectious diseases physician. All of these participants met the COVID-19 case definition of the US
Council of State and Territorial Epidemiologists.
Exclusion criteria: age < 18 years old, current hospitalization, HCQ allergy, retinal disease, known glu-
cose-6 phosphate dehydrogenase deficiency, known chronic kidney disease (stage 4 or 5 or receiving
dialysis), known porphyria, weight less than 40 kg, receiving chemotherapy, current use of HCQ, CQ,
current use of cardiac arrhythmia medicines of: flecainide; amiodarone; digoxin; procainamide; or so-
talol. In Canada, additional exclusions mandated by regulatory authorities were: pregnancy,  breast-
feeding; severe diarrhoea or vomiting; known cirrhosis with encephalopathy or ascites; known pro-
longed cardiac QT interval, ventricular arrhythmia, or history of sudden cardiac death; or QT-prolong-
ing medicines. On 20 April 2020, additional US exclusions were added for weight less than 50 kg, struc-
tural or ischaemic heart disease, personal or family history of cardiac QT prolongation, and QT-pro-
longing medications. Concomitant QT-prolonging medications included current use of: antimicro-
bials: azithromycin clarithromycin, erythromycin, ciprofloxacin, levofloxacin, moxifloxacin, ketocona-
zole, itraconazole, or mefloquine; antidepressants: amitriptyline, citalopram, desipramine, escitalo-
pram, imipramine, doxepin, fluoxetine, bupropion (Wellbutrin), or venlafaxine; antipsychotic or mood
stabilizers: haloperidol, droperidol, lithium, quetiapine, thioridazine, ziprasidone, methadone, suma-
triptan, zolmitriptan. The prohibition of azithromycin and other QT-prolonging medicines was at the re-
quest of the US Food and Drug Administration as potentially unsafe in an outpatient clinical trial.
Age: HCQ arm: median 41 years (IQR 33 to 49); placebo arm: median 39 years (IQR 31 to 50).
Sex: HCQ arm female:male 136:123; placebo arm female:male 130:115.
Types of participant: HCQ arm: 132 healthcare workers, 59 household contacts; placebo arm: 128
healthcare workers, 82 household contacts.
Disease severity: not specifically reported, but it appeared that most were mild at presentation. 47
were asymptomatic in the HCQ arm, and 52 were asymptomatic in the placebo arm. All were < 7 days
from onset of symptoms.
Definition of development of COVID-19: confirmed SARS-CoV-2 by PCR or meeting the case definition
of the US Council of State and Territorial Epidemiologists: in outpatient or telehealth settings at least
2 of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore
throat, new olfactory and taste disorder(s), OR at least 1 of the following symptoms: cough, shortness
of breath, or difficulty breathing OR severe respiratory illness with at least 1 of the following: clinical or
radiographic evidence of pneumonia, or acute respiratory distress syndrome (ARDS) AND no alterna-
tive more likely diagnosis.
Comorbidities: 
1. cardiac disease (such as coronary artery disease or heart failure): HCQ: 4 (1.6%) and placebo: 2 (0.8%);
2. hypertension: HCQ: 23 (10.8%) and placebo: 23 (10.9%);
3. diabetes mellitus: HCQ: 8 (3.8%) and placebo: 7 (3.3%);
4. HIV: HCQ: 1 and placebo: 0;
5. chronic airways disease (asthma, COPD): HCQ: 30 (12.3%) and placebo: 21 (8.5%);
6. chronic liver disease: HCQ: 1 and placebo: 1.
Interventions Intervention: oral dosing of HCQ: 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then
600 mg (3 tablets) once daily for 4 more days (5 days in total).
Placebo: folic acid in the USA and lactose in Canada - unlabelled placebo tablets.
Outcomes Primary outcomes: initial outcome was the ordinal outcome by day 14 of not hospitalized, hospitalized,
or intensive care unit stay or death; however, this was amended on 24 April when fewer patients were
hospitalized than anticipated. The primary outcome was therefore change in symptom severity over 14
days as longitudinally measured on a 10-point visual analogue scale.
Secondary outcomes: incidence of death and hospitalization, incidence of study medicine withdrawal.
Notes Dates of recruitment: 22 March to 6 May with follow-up for all outcomes until 15 June 2020.
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Sponsors/funders: Steve Kirsch, Jan and David Baszucki, the Minnesota Chinese Chamber of Com-
merce, the Alliance of Minnesota Chinese Organizations, and the University of Minnesota Founda-
tion. Canadian funding was received from various sources. In Quebec, funds were received from the
Clinical Practice Assessment Unit of the McGill University Health Centre and the McGill Interdiscipli-
nary Initiative in Infection and Immunity's Emergency COVID-19 Research Funding. In Manitoba, re-
search support was received from the Manitoba Medical Service Foundation and Research Manitoba.
Purolator Canada provided in-kind courier support for the participating Canadian sites. Apotex Canada
and Rising Pharmaceuticals in the USA provided a donation of some of the hydroxychloroquine tablets
used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “The trial statistician generated a permuted block randomization sequence
using differently sized blocks in a 1:1 allocation, stratified by country. A sepa-
rate randomization stratum also existed for persons who were initially asymp-
tomatic at the time of informed consent but became symptomatic before re-
ceiving the study medication on day 1.”
Appropriate method; adequate description.
Allocation concealment
(selection bias)
Low risk “The research pharmacies held this list, and statisticians verified that the ran-
domization sequence was followed.”





Low risk Appropriate method: the tablets were unmarked.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Outcomes were self-assessed by participants.
“We assessed the efficacy of study medicine masking on day 14. Of the 194
participants who completed day-14 surveys in the intervention group, 49% (n
= 94) correctly identified that they had received hydroxychloroquine, 7% (n =
14) believed that they had received placebo, and 44% (n = 86) were unsure. Of
the 182 who completed day-14 surveys in the placebo group, 30% (n = 54) cor-
rectly guessed placebo, 25% (n = 46) incorrectly guessed hydroxychloroquine,
42% (n = 76) were unsure of their randomization assignment, and 3% (n = 6)
did not respond. Thus, masking was generally effective, with adverse effects




Unclear risk Unclear for all outcomes.
The primary outcome was self-reported by participants, therefore it relied on
follow-up data responses. There was significant attrition from enrolment to
availability of follow-up data (14%), with similar percentages in each group,
but unknown reasons for loss to follow-up.
Imputation for missing data in participants who were asymptomatic at base-
line or who were hospitalized or died could have mitigated the effect of this,
but the number for whom this occurred is not reported.
Sensitivity analyses only included different denominators (or used a median
in place of mean), rather than imputing data for all missing participants, for
the primary outcome of change in severity – only for absolute severity: “An
additional sensitivity analysis was performed using overall symptom sever-
ity scores (rather than change in scores) and which included the 68 partici-
pants with no follow-up symptom data. We generated 1000 estimates from
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simple random samples of n=400, and derived a mean difference of -0.17 over-
all symptom severity with a corresponding 95%CI of -0.39 to 0.06.”
Adverse events were also conducted on the same subset of participants, with
no imputation for missing data.
For hospitalization and death, attrition was lower (< 10%) in each arm, though
no imputation was conducted.
Selective reporting (re-
porting bias)
High risk The change in primary outcome was justified due to low recruitment levels
and an inability to attain adequate numbers to reach primary outcome. This
was approved by the DSMB, and the final primary outcome was clinically rele-
vant, and a modification of initial secondary outcomes.
However, selective reporting of outcomes occurred separately from this, and
was not explained: the original ordinal primary outcome was not analysed
“because of the low event rate”. Despite the low event rate, such an analysis
should have been reported in the supplementary appendix.
Other bias High risk The trial was terminated early, and as the primary outcome was a longitudinal





Methods RCT comparing outcomes for participants receiving HCQ ("HCQ arm") vs those not receiving HCQ
("standard care arm"). No blinding or placebo.
Follow-up: planned PCR on respiratory tract samples on days 4, 7, 10, 14, 21, and 28 from enrolment.
“In addition to SARS-CoV-2 testing, patients were assessed on each scheduled visit for vital signs, C re-
active protein, erythrocyte sedimentation rate, tumour necrosis factor α, interleukin 6, complete blood
cell count with differential, blood chemistry, coagulation panel, pulse oximetry, and respiratory symp-
toms. Records of administration of hydroxychloroquine and adverse events were reviewed daily to en-
sure fidelity to the protocol and, more importantly, patient safety. Computed tomography of the chest
was assessed on screening and at the last visit of the treatment period (day 14 for patients with mild to
moderate disease and day 21 for severe disease).”
Participants Setting: “16 government designated covid-19 treatment centres in three provinces in China (Hubei,
Henan, and Anhui)”, China.
Number of participants: 150 total: 75 HCQ arm; 75 standard care arm.
Inclusion criteria: “age 18 years or older, ongoing SARS-CoV-2 infection confirmed in upper or lower res-
piratory tract specimens with RT-PCR, willingness to participate, and consent not to be enrolled in oth-
er clinical trials during the study period”
Exclusion criteria: “age below 18 years; severe conditions including malignancies, heart, liver, or kid-
ney disease or poorly controlled metabolic diseases; unsuitability for oral administration; pregnancy
or lactation; allergy to hydroxychloroquine; inability to cooperate with investigators due to cognitive
impairments or poor mental status; severe hepatic impairment (for example, Child-Pugh grade C, ALT
more than fivefold the upper limit); and severe renal impairment (eGFR ≤30 mL/min/1.73 m2) or receipt
of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis.” Initially excluded pa-
tients with severe disease; on 17 February this decision was overturned due to probable anti-inflamma-
tory effects of HCQ being seen as desirable for these patients.
Age: HCQ arm: mean 48.0 years (SD 14.1); standard care arm: mean 44.1 years (SD 15.0).
Sex: HCQ arm female:male 33:42; standard care arm female:male 35:40.
Tang 2020 
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Method of diagnosis: positive RT-PCR for SARS-CoV-2 on upper or lower respiratory tract sample.
Clinical presentation: HCQ arm: 15/75 upper respiratory tract illness; 60/75 lower respiratory tract ill-
ness. Standard care arm: 7/75 upper respiratory tract illness; 68/75 lower respiratory tract illness.
COVID-19 disease severity at presentation: HCQ arm: 15/75 mild; 59/75 moderate; 1/75 severe. Stan-
dard care arm: 7/75 mild; 67/75 moderate; 1/75 severe.
Time from symptom onset to enrolment: HCQ arm: mean 16.0 days (SD 9.9; 73 participants); standard
care arm: mean 17.1 days (SD 11.1; 74 participants).
Comorbidities: 6/75 in the HCQ arm and 3/75 in the standard care arm had hypertension; 12/75 in the
HCQ arm and 9/75 in the standard care arm had diabetes mellitus.
Place of care: all inpatients in hospital.
Interventions HCQ arm: HCQ 400 mg orally 3 times a day for 3 days, then twice daily from day 4, for a total of 14 days
for those with mild/moderate disease, and 21 days for severe disease. 37/75 had umifenovir (Arbidol);
13/75 ribavirin; 13/75 lopinavir/ritonavir; 8/75 oseltamivir; 1/75 entecavir; 6/75 corticosteroids; 32/75
antibacterials.
Standard care arm: 33/75 had umifenovir (Arbidol); 15/75 ribavirin; 12/75 lopinavir/ritonavir; 9/75 os-
eltamivir; 1/75 entecavir; 2/75 ganciclovir; 4/75 corticosteroids; 27/75 antibacterials.
Outcomes Primary: “negative conversion of SARS-CoV-2 by 28 days and whether patients with severe COVID-19
had clinical improvement by 28 days” (Negative conversion: “two consecutive reports of a negative re-
sult for SARS-CoV-2 at least 24 hours apart without a subsequent report of a positive result by the end
of the study. We considered the date of the first negative report as the date of negative conversion.”)
Changed primary outcome on 17 February (6 days into trial) from “Negative conversion rate by Day 10”.
Secondary outcomes: “Probability of negative conversion at day 4, 7, 10, 14, or 21”; adverse events; al-
leviation of clinical symptoms within 28 days: “resolving from fever to an axillary temperature of 36.6°C
or below, normalization of SpO2 (>94% on room air), and disappearance of respiratory symptoms in-
cluding nasal congestion, cough, sore throat, sputum production, and shortness of breath.”
Also planned, but not reported: “probabilities of alleviation of clinical symptoms; improvement of C re-
active protein, erythrocyte sedimentation rate, tumour necrosis factor α, interleukin 6, and absolute
blood lymphocyte count; improvement of lung lesions on chest radiology; all cause death; and disease
progression in patients with mild to moderate disease. The time frame for these secondary outcomes
was from randomisation to 28 days.”
Notes Dates of recruitment: 11 February to 29 February 2020.
Sponsors/funders: “Emergent Projects of National Science and Technology (2020YFC0844500), Nation-
al Natural Science Foundation of China (81970020, 81770025), National Key Research and Develop-
ment Program of China (2016YFC0901104), Shanghai Municipal Key Clinical Specialty (shslczdzk02202,
shslczdzk01103), National Innovative Research Team of High-level Local Universities in Shanghai,
Shanghai Key Discipline for Respiratory Diseases (2017ZZ02014), National Major Scientific and Tech-
nological Special Project for Significant New Drugs Development (2017ZX09304007), Key Projects
in the National Science and Technology Pillar Program during the Thirteenth Five-year Plan Period
(2018ZX09206005-004, 2017ZX10202202-005-004, 2017ZX10203201-008)."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated sequence. Stratified by disease severity (mild/moderate
vs severe) with 1:1 randomization within strata.
Tang 2020  (Continued)
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Allocation concealment
(selection bias)





Low risk No blinding, but performance bias unlikely.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Attrition appeared to be low, but is difficult to quantify, with varying denomi-
nators, and follow-up beyond 21 days appears low.
Selective reporting (re-
porting bias)
Unclear risk The primary outcome was changed during the trial, but a reasonable justifi-
cation was provided. However, only the primary outcome and adverse events
were reported in the final report.
Other bias High risk The trial was stopped early, and follow-up was incomplete. This may lead to
changes in survival analysis, which is what was employed for the primary out-
come of time to negative PCR for SARS-CoV-2.
Tang 2020  (Continued)
ALT - Alanine aminotransferase
AST - Aspartate aminotransferase
AZ - Azithromycin
CKD-EPI - Chronic Kidney Disease Epidemiology Collaboration
COPD - Chronic obstructive pulmonary disease
CQ - Chloroquine
CT - Computerized tomography
ECMO - Extracorporeal membrane oxygenation
eGFR - Estimated glomerular filtration rate
FiO2 - Fraction of inspired oxygen
HCQ - Hydroxychloroquine
HIV - Human Immunodeficiency Virus
IgG - Immunoglobulin G
IgM - Immunoglobulin M
ITT - Intention to treat
IQR - Interquartile range
L/min - Litres per minute
LPV/r - Lopinavir/ritonavir
MDRD - Modification of Diet in Renal Disease Study equation
msec - Milliseconds
PaO2 - Partial pressure of oxygen in arterial blood
PCR - Polymerase chain reaction
QTc - Corrected QT interval
QTcF - Corrected QT interval, calculated according to Fridericia's formula
RCT - Randomized controlled trial
RNA - Ribonucleic acid
RT-PCR - Reverse transcription polymerase chain reaction
SaO2 - Saturation of oxygen, ascertained by direct measurement of oxygen bound to haem protein of haemoglobin in the blood
SD - Standard deviation
SOC - Standard of care
SpO2 - Saturation of oxygen, ascertained by indirect measurement of oxygen bound to haem protein of haemoglobin in the blood using
pulse oximetry
WHO - World Health Organization
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Agrawal 2020 Not an RCT
Alia 2020 Not an RCT
Brown 2020 Not an RCT
ChiCTR2000029542 Not an RCT
ChiCTR2000029609 Not an RCT
ChiCTR2000029898 No control group without CQ/HCQ
ChiCTR2000029899 No control group without CQ/HCQ
Colson 2020a Not an RCT
Colson 2020b Not an RCT
EUCTR2020-000890-25-FR Not an RCT
EUCTR2020-001421-31-ES No control group without CQ/HCQ
Ferner 2020 Not an RCT
Gao 2020 Not an RCT
Gendrot 2020 Not an RCT
Heldwein 2020 Not an RCT
Lee 2020 Not an RCT
Lofgren 2020 Not an RCT
Nau 2020 Not an RCT
NCT04304053 Duplicate
NCT04321278 No control group without CQ/HCQ
NCT04321993 Not an RCT
NCT04323527 No control group without CQ/HCQ
NCT04326725 Not an RCT
NCT04329572 Not an RCT
NCT04329611 Duplicate
NCT04332094 No control group without CQ/HCQ
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Study Reason for exclusion
NCT04333225 Not an RCT
NCT04334512 Not an RCT
NCT04335084 Not an RCT
NCT04341493 No control group without CQ/HCQ
NCT04341727 No control group without CQ/HCQ
NCT04343092 No control group without CQ/HCQ
NCT04343677 Trial removed from trial registry.
NCT04344457 Not an RCT
NCT04345419 No control group without CQ/HCQ
NCT04345653 Not an RCT
NCT04346147 No control group without CQ/HCQ
NCT04347798 Not an RCT
NCT04348474 Not an RCT
NCT04350281 No control group without CQ/HCQ
NCT04350450 Not an RCT
NCT04351620 Not an RCT
NCT04351919 Not an RCT
NCT04354870 Not an RCT
NCT04361461 No control group without CQ/HCQ
NCT04362189 No CQ/HCQ
NCT04370262 CQ was part of standard care at the start of the trial, but then abandoned.
NCT04395768 No control group without CQ/HCQ
Pagliano 2020 Not an RCT
Patri 2020 Not an RCT
Principi 2020 Not an RCT
Rathi 2020 Not an RCT
Sahraei 2020 Not an RCT
Yu 2020 Not an RCT
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CQ, chloroquine; HCQ, hydroxychloroquine; RCT, randomized controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   HCQ versus standard care without HCQ, or placebo, for treatment





Statistical method Effect size
1.1 Death due to any cause 9 8208 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.99, 1.19]
1.2 Death due to any cause (sensitivity analysis) 9 8043 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.99, 1.19]
1.3 Negative PCR for SARS-CoV-2 on respiratory
samples at day 14 from enrolment
3 213 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.91, 1.10]
1.4 Negative PCR for SARS-CoV-2 on respiratory
samples at day 7 from enrolment
2 180 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.68, 1.09]
1.5 Proportion admitted to hospital (if receiv-
ing ambulatory treatment)
1 465 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.13, 1.27]
1.6 Progression to mechanical ventilation 3 4521 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.91, 1.37]
1.7 Length of hospital admission (in days) 2 642 Mean Difference (IV, Random, 95%
CI)
-0.15 [-0.75, 0.45]
1.8 Time to clinical improvement 1   Hazard Ratio (IV, Random, 95% CI) 1.01 [0.59, 1.74]
1.9 Time to negative PCR for SARS-CoV-2 on
respiratory samples
1   Hazard Ratio (IV, Random, 95% CI) 0.85 [0.58, 1.23]
1.10 Participants with any adverse events 6 1394 Risk Ratio (M-H, Random, 95% CI) 2.90 [1.49, 5.64]
1.11 Participants with serious adverse events 6 1004 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.37, 1.79]
1.12 Participants with prolongation of QT-inter-
val on electrocardiogram
1 147 Risk Ratio (M-H, Random, 95% CI) 8.47 [1.14, 63.03]
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Analysis 1.1.   Comparison 1: HCQ versus standard care without













Heterogeneity: Tau² = 0.00; Chi² = 0.52, df = 4 (P = 0.97); I² = 0%
Test for overall effect: Z = 1.72 (P = 0.09)























































M-H, Random, 95% CI
1.20 [0.38 , 3.80]
1.20 [0.41 , 3.51]
Not estimable
Not estimable
1.07 [0.97 , 1.19]
Not estimable
1.18 [0.90 , 1.56]
1.01 [0.06 , 16.09]
Not estimable
1.09 [0.99 , 1.19]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10


































































Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Analysis 1.2.   Comparison 1: HCQ versus standard care without HCQ, or













Heterogeneity: Tau² = 0.00; Chi² = 0.48, df = 4 (P = 0.97); I² = 0%
Test for overall effect: Z = 1.71 (P = 0.09)























































M-H, Random, 95% CI
1.20 [0.38 , 3.80]
1.09 [0.32 , 3.69]
Not estimable
Not estimable
1.07 [0.97 , 1.19]
Not estimable
1.18 [0.90 , 1.56]
1.01 [0.06 , 16.10]
Not estimable
1.09 [0.99 , 1.19]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours HCQ Favours standard care or placebo
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Analysis 1.3.   Comparison 1: HCQ versus standard care without HCQ, or placebo, for treatment,







Heterogeneity: Tau² = 0.00; Chi² = 0.19, df = 2 (P = 0.91); I² = 0%
Test for overall effect: Z = 0.03 (P = 0.98)





























M-H, Random, 95% CI
1.00 [0.88 , 1.13]
1.08 [0.73 , 1.59]
0.98 [0.84 , 1.15]
1.00 [0.91 , 1.10]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100




























Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Analysis 1.4.   Comparison 1: HCQ versus standard care without HCQ, or placebo, for treatment,






Heterogeneity: Tau² = 0.01; Chi² = 1.40, df = 1 (P = 0.24); I² = 29%
Test for overall effect: Z = 1.26 (P = 0.21)
























M-H, Random, 95% CI
0.93 [0.73 , 1.18]
0.77 [0.56 , 1.06]
0.86 [0.68 , 1.09]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours standard care without HCQ Favours HCQ
 
 
Analysis 1.5.   Comparison 1: HCQ versus standard care without HCQ, or placebo, for






Test for overall effect: Z = 1.55 (P = 0.12)



















M-H, Random, 95% CI
0.41 [0.13 , 1.27]
0.41 [0.13 , 1.27]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ Favours standard care or placebo
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Analysis 1.6.   Comparison 1: HCQ versus standard care without HCQ, or







Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)





























M-H, Random, 95% CI
1.26 [0.62 , 2.57]
1.11 [0.89 , 1.37]
0.33 [0.01 , 8.05]
1.11 [0.91 , 1.37]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10




























Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Analysis 1.7.   Comparison 1: HCQ versus standard care without HCQ, or





Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 1 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.63)




























IV, Random, 95% CI
-0.23 [-0.92 , 0.46]
0.10 [-1.12 , 1.32]
-0.15 [-0.75 , 0.45]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours HCQ Favours standard care
 
 
Analysis 1.8.   Comparison 1: HCQ versus standard care without HCQ,





Test for overall effect: Z = 0.04 (P = 0.97)









IV, Random, 95% CI
1.01 [0.59 , 1.74]
1.01 [0.59 , 1.74]
Hazard Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours  usual care Favours HCQ
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Analysis 1.9.   Comparison 1: HCQ versus standard care without HCQ, or placebo, for





Test for overall effect: Z = 0.87 (P = 0.38)









IV, Random, 95% CI
0.85 [0.58 , 1.23]
0.85 [0.58 , 1.23]
Hazard Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours standard care Favours HCQ
 
 
Analysis 1.10.   Comparison 1: HCQ versus standard care without HCQ, or










Heterogeneity: Tau² = 0.48; Chi² = 38.18, df = 5 (P < 0.00001); I² = 87%
Test for overall effect: Z = 3.13 (P = 0.002)












































M-H, Random, 95% CI
1.49 [1.07 , 2.08]
2.00 [0.43 , 9.32]
5.00 [0.25 , 100.08]
8.23 [5.11 , 13.28]
1.99 [1.48 , 2.68]
3.43 [1.55 , 7.58]
2.90 [1.49 , 5.64]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100

















































(1) Cavalcanti 2020 - safety population included participants who received at least one dose of HCQ, and participants who received neither HCQ nor azithromycin.
(2) Chen 2020a and Chen 2020b - safety population assumed to be the same as ITT population. All participants assumed to have received treatment according to group they were randomised to. 
(3) Mitjà 2020 - safety population was based on participants randomised to each group, rather than participants who received the study drug.
(4) Skipper 2020 - Safety population excludes participants with no follow up data, and those with only vital status data, including deaths.
(5) Tang 2020 - Safety population based on all those who received at least one dose of HCQ versus all those who received no HCQ.
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
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Analysis 1.11.   Comparison 1: HCQ versus standard care without HCQ, or










Heterogeneity: Tau² = 0.05; Chi² = 4.18, df = 4 (P = 0.38); I² = 4%
Test for overall effect: Z = 0.50 (P = 0.61)











































M-H, Random, 95% CI
0.89 [0.13 , 6.25]
3.00 [0.13 , 68.26]
0.11 [0.01 , 1.98]
Not estimable
0.73 [0.30 , 1.73]
5.70 [0.28 , 116.84]
0.82 [0.37 , 1.79]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
















































(1) Cavalcanti 2020 - safety population included participants who received at least one dose of HCQ, and participants who received neither HCQ nor azithromycin.
(2) Chen 2020a and Chen 2020b - safety population assumed to be the same as ITT population. All participants assumed to have received treatment according to group they were randomised to. 
(3) Tang 2020 - Safety population based on all those who received at least one dose of HCQ versus all those who received no HCQ. 
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Analysis 1.12.   Comparison 1: HCQ versus standard care without HCQ, or placebo, for






Test for overall effect: Z = 2.09 (P = 0.04)



















M-H, Random, 95% CI
8.47 [1.14 , 63.03]
8.47 [1.14 , 63.03]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100















Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
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Comparison 2.   CQ versus lopinavir/ritonavir for treatment





Statistical method Effect size
2.1 Negative PCR for SARS-CoV-2 on respiratory
samples at day 7 from enrolment
1 22 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.64, 2.25]
2.2 Negative PCR for SARS-CoV-2 on respiratory
samples at day 14 from enrolment
1 22 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.85, 1.36]
2.3 Discharge from hospital at day 14 from en-
rolment
1 22 Risk Ratio (M-H, Random, 95% CI) 1.91 [1.09, 3.34]
2.4 Clinical improvement at day 10 from enrol-
ment
1 22 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.78, 2.42]
2.5 Total adverse events 1 22 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.78, 1.50]
2.6 Serious adverse events 1 22 Risk Ratio (M-H, Random, 95% CI) Not estimable
 
 
Analysis 2.1.   Comparison 2: CQ versus lopinavir/ritonavir for treatment, Outcome






Test for overall effect: Z = 0.57 (P = 0.57)



















M-H, Random, 95% CI
1.20 [0.64 , 2.25]
1.20 [0.64 , 2.25]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lopinavir/ritonavir Favours CQ
 
 
Analysis 2.2.   Comparison 2: CQ versus lopinavir/ritonavir for treatment, Outcome






Test for overall effect: Z = 0.63 (P = 0.53)



















M-H, Random, 95% CI
1.08 [0.85 , 1.36]
1.08 [0.85 , 1.36]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lopinavir/ritonavir Favours CQ
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Analysis 2.3.   Comparison 2: CQ versus lopinavir/ritonavir for treatment,






Test for overall effect: Z = 2.27 (P = 0.02)



















M-H, Random, 95% CI
1.91 [1.09 , 3.34]
1.91 [1.09 , 3.34]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lopinavir/ritonavir Favours CQ
 
 
Analysis 2.4.   Comparison 2: CQ versus lopinavir/ritonavir for






Test for overall effect: Z = 1.09 (P = 0.28)



















M-H, Random, 95% CI
1.37 [0.78 , 2.42]
1.37 [0.78 , 2.42]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lopinavir/ritonavir Favours CQ
 
 






Test for overall effect: Z = 0.46 (P = 0.64)



















M-H, Random, 95% CI
1.08 [0.78 , 1.50]
1.08 [0.78 , 1.50]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours CQ Favours Lopinavir/ritonavir
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Test for overall effect: Not applicable





















M-H, Random, 95% CI
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Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Comparison 3.   HCQ + azithromycin versus standard care for treatment





Statistical method Effect size
3.1 Death due to any cause 1 444 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.13, 2.07]
3.2 Progression to mechanical ventilation 1 444 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.82, 3.15]
3.3 Length of hospital stay in days 1 444 Mean Difference (IV, Random, 95% CI) 0.50 [-0.81, 1.81]
3.4 Participants with any adverse events 1 416 Risk Ratio (M-H, Random, 95% CI) 1.74 [1.27, 2.38]
3.5 Participants with serious adverse
events
1 416 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.36, 9.43]
3.6 Participants with prolongation of QT-in-
terval on electrocardiogram
1 174 Risk Ratio (M-H, Random, 95% CI) 8.50 [1.16, 62.31]
 
 
Analysis 3.1.   Comparison 3: HCQ + azithromycin versus






Test for overall effect: Z = 0.92 (P = 0.36)



















M-H, Random, 95% CI
0.52 [0.13 , 2.07]
0.52 [0.13 , 2.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ + azithromycin Favours standard care
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Analysis 3.2.   Comparison 3: HCQ + azithromycin versus standard care






Test for overall effect: Z = 1.39 (P = 0.17)



















M-H, Random, 95% CI
1.61 [0.82 , 3.15]
1.61 [0.82 , 3.15]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ + azithromycin Favours standard care
 
 
Analysis 3.3.   Comparison 3: HCQ + azithromycin versus standard care





Test for overall effect: Z = 0.75 (P = 0.46)





















IV, Random, 95% CI [Days]
0.50 [-0.81 , 1.81]
0.50 [-0.81 , 1.81]
Mean Difference
IV, Random, 95% CI [Days]
-100 -50 0 50 100
Favours HCQ + azithromycin Favours standard care
 
 
Analysis 3.4.   Comparison 3: HCQ + azithromycin versus standard care






Test for overall effect: Z = 3.45 (P = 0.0006)



















M-H, Random, 95% CI
1.74 [1.27 , 2.38]
1.74 [1.27 , 2.38]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ + azithromycin Favours standard care
Footnotes
(1) The safety population in this trial included participants who received at least one dose of HCQ and azithromycin, versus participants who received neither HCQ nor azithromycin.
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Analysis 3.5.   Comparison 3: HCQ + azithromycin versus standard care






Test for overall effect: Z = 0.74 (P = 0.46)



















M-H, Random, 95% CI
1.85 [0.36 , 9.43]
1.85 [0.36 , 9.43]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ + azithromycin Favours standard care
Footnotes
(1) The safety population in this trial included participants who received at least one dose of HCQ and azithromycin, versus participants who received neither HCQ nor azithromycin.
 
 
Analysis 3.6.   Comparison 3: HCQ + azithromycin versus standard care for treatment,






Test for overall effect: Z = 2.11 (P = 0.04)



















M-H, Random, 95% CI
8.50 [1.16 , 62.31]
8.50 [1.16 , 62.31]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ + azithromycin Favours standard care
Footnotes
(1) The safety population in this trial included participants who received at least one dose of HCQ and azithromycin, versus participants who received neither HCQ nor azithromycin. For this outcome, only patients who were tested for QT interval prolongation using ECG were included in the denominator.
 
 
Comparison 4.   HCQ versus febuxostat for treatment





Statistical method Effect size
4.1 Death due to any cause 1 54 Risk Ratio (M-H, Random, 95% CI) Not estimable
4.2 Admission to hospital 1 54 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.26, 5.24]
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Test for overall effect: Not applicable





















M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ Favours Febuxostat
 
 






Test for overall effect: Z = 0.19 (P = 0.85)



















M-H, Random, 95% CI
1.16 [0.26 , 5.24]
1.16 [0.26 , 5.24]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100















Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Comparison 5.   HCQ versus placebo for postexposure prophylaxis





Statistical method Effect size
5.1 Development of confirmed COVID-19 at 14
days from enrolment
1 821 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.50, 2.87]
5.2 Patients hospitalized due to COVID-19 1 821 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.06, 15.66]
5.3 Participants with any adverse events 1 700 Risk Ratio (M-H, Random, 95% CI) 2.39 [1.83, 3.11]
5.4 Participants with serious adverse events 1 700 Risk Ratio (M-H, Random, 95% CI) Not estimable
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Analysis 5.1.   Comparison 5: HCQ versus placebo for postexposure prophylaxis,






Test for overall effect: Z = 0.41 (P = 0.68)



















M-H, Random, 95% CI
1.20 [0.50 , 2.87]
1.20 [0.50 , 2.87]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100















Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)




Analysis 5.2.   Comparison 5: HCQ versus placebo for postexposure






Test for overall effect: Z = 0.01 (P = 0.99)



















M-H, Random, 95% CI
0.98 [0.06 , 15.66]
0.98 [0.06 , 15.66]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ Favours placebo
 
 
Analysis 5.3.   Comparison 5: HCQ versus placebo for postexposure






Test for overall effect: Z = 6.42 (P < 0.00001)



















M-H, Random, 95% CI
2.39 [1.83 , 3.11]
2.39 [1.83 , 3.11]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100















Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
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Analysis 5.4.   Comparison 5: HCQ versus placebo for postexposure






Test for overall effect: Not applicable





















M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HCQ Favours placebo
 
 
A D D I T I O N A L   T A B L E S
 






















Adaptive platform trial including HCQ, or HCQ +


















USA  Pragmatic adaptive HCQ vs lopinavir/ritonavir


















































Table 1.   Ongoing trials for treatment: actively recruiting or completed; not yet published 
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Cochrane Database of Systematic Reviews
ClinicalTrials.gov COVERAGE
PACTR202004801273802
Pan African Clinical Trials Reg-
istry














Canada Azithromycin plus hydroxychloroquine or
chloroquine (AZCT) vs AZCT plus interferon be-








Denmark Convalescent plasma vs sarilumab vs HCQ vs
baricitinib vs intravenous and subcutaneous

















































HCQ vs lopinavir/ritonavir vs HCQ plus











HCQ vs remdesivir vs lopinavir/ritonavir vs in-





























Table 1.   Ongoing trials for treatment: actively recruiting or completed; not yet published  (Continued)
CQ, chloroquine; HCQ, hydroxychloroquine
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Spain Emtricitabine/tenofovir (Truvada) vs HCQ vs






































USA Daily HCQ vs weekly HCQ vs placebo







Iranian Clinical Trials Registry











































Table 2.   Ongoing trials for prevention: actively recruiting or completed; not yet published 
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review)
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Table 2.   Ongoing trials for prevention: actively recruiting or completed; not yet published  (Continued)






















Types of participant at enrolment (type of con-



















HCQ: mean 40.4 y (SD
18.7 y)
Standard care: mean







“The patients were randomized equally between
the two groups regarding the disease severi-


























































49.6 y (SD 14.2 y)
HCQ: mean 51.3 y (SD
14.5 y)
Standard care:











HCQ + azithromycin: 125/217 mild; 92/217 moder-
ate disease
HCQ: 132/221 mild; 89/221 moderate disease
















HCQ: mean 50.5 y (SD
3.8 y)
Standard care: mean







All 30 participants had moderate disease.
Table 3.   Summary of characteristics of included studies 
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HCQ: mean 44.1 y
(SD 16.1 y)
Standard care: mean
























HCQ: mean 33 y (SD 12
y)
Standard care: mean


























HCQ: mean 57.3 y
(standard error 2.2 y)
Febuxostat: mean 58 y





All ambulatory patients, symptomatic, with ab-
normalities on CT scan of the chest, but no fea-


















HCQ: mean 65.2 y (SD
15.2 y)
Standard care:









Inferred from level of oxygen/respiratory support
need:




Standard care: 750/3155 asymptomatic/mild (no
oxygen received); 1873/3155 moderate/severe



















CQ: median 41.5 y (IQR
33.8 to 50 y)
LPV/r: median 53 y





CQ: 7/10 moderate; 3/10 severe disease

















HCQ: mean 41.6 y (SD
12.4 y)
Standard care: mean






All ambulatory patients with mild disease, except
for 1 patient with severe disease included in the
HCQ arm, despite this being an exclusion criterion














HCQ: mean 48.6 y (SD
18.7 y)
Standard care: mean





HCQ: 131 (12%) healthcare workers; 302 (27%)
household contacts; 550 (49%) nursing home
workers; 133 (12%) nursing home residents
Table 3.   Summary of characteristics of included studies  (Continued)
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Standard care: 130 (11%) healthcare workers;
338 (28%) household contacts; 584 (49%) nursing





















HCQ: 335 (< 50 years),
410 (50 to 69 years),
202 (≥ 70 years)
Standard care: 317 (<
50 years), 396 (50 to 69








HCQ: 862/947 moderate or severe (of whom 517
receiving oxygen), 85 critical
Standard care: 824/906 moderate or severe (of



















HCQ: median 41 y (IQR
33 to 49 y)
Placebo: median 39 y





All ambulatory patients, so presumed to have






















HCQ: mean 48 y (SD
14.1 y)
Standard care: mean







HCQ: 15/75 mild; 59/75 moderate; 1/75 severe dis-
ease
Standard care: 7/75 mild; 67/75 moderate; 1/75
severe disease
Table 3.   Summary of characteristics of included studies  (Continued)
CQ: chloroquine; CT: computed tomography; HCQ: hydroxychloroquine; IQR: interquartile range; ITT: intention-to-treat; NR: not reported;
RCT: randomized controlled trial; SD: standard deviation; WHO: World Health Organization; y: years.
 
 






800 mg on day 1, followed by 400 mg daily for further 14 days (total dura-
tion of treatment 15 days)
Standard care 6400 mg
Cavalcanti 2020
2
400 mg orally twice daily for 7 days Standard care 5600 mg
Chen 2020a 3 400 mg once daily for 5 days Standard care  2000 mg
Chen 2020b 200 mg orally twice daily for 5 days Standard care 2000 mg
Chen 2020c
 
800 mg on day 1, followed by 400 mg daily for further 6 days (total duration
of treatment 7 days)
Standard care 3200 mg
Table 4.   Dosing regimens in hydroxychloroquine treatment trials1 
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Davoodi 2020
 
200 mg orally twice daily for 5 days Standard care 2000 mg
Horby 2020 800 mg at 0 and 6 hours, then 400 mg at 12 hours from first dose and every
12 hourly for 10 days
Standard care 10,000 mg
Mitjà 2020a 800 mg on day 1, followed by 400 mg daily for further 6 days (total duration
of treatment 7 days)
Standard care 3200 mg
Pan 2020
 
2000 mg on day 1, followed by 800 mg daily for further 9 days (total dura-
tion of treatment 10 days)
Standard care 9200 mg
Skipper 2020 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600
mg (3 tablets) once daily for 4 more days (5 days in total)
Placebo: folic




Tang 2020 400 mg orally 3 times a day for 3 days, then twice daily from day 4, for a total
of 14 days for those with mild/moderate disease and 21 days for those with
severe disease





Table 4.   Dosing regimens in hydroxychloroquine treatment trials1  (Continued)
1See Table 5 for co-interventions given in each trial.
2 Cavalcanti 2020 - hydroxychloroquine plus azithromycin group received HCQ 400 mg orally twice daily and azithromycin 500 mg orally
once daily for seven days.
3 Chen 2020a - additionally, all participants in the HCQ arm had nebulized interferon alpha; 12/15 had umifenovir (Arbidol). Standard care
arm: no HCQ; all had nebulized interferon alpha; 10/15 had umifenovir (Arbidol).
 
 
Study Co-interventions in HCQ arm Co-interventions  in comparator arm
Abd-Elsalam 2020 Authors report: "The Egyptian Ministry of Health (MOH) adopted a standard of care treatment protocol for
COVID-19 patients. It included paracetamol, oxygen, fluids (according to assessment), empiric antibiotic
(cephalosporins), oseltamivir if needed (75 mg/12 hours for 5 days), and invasive mechanical ventilation with
hydrocortisone for severe cases if PaO2 < 60 mmHg, O2 saturation < 90% despite oxygen or noninvasive ven-
tilation, progressive hypercapnia, respiratory acidosis (pH < 7.3), and progressive or refractory septic shock".


















Table 5.   Pharmacological co-interventions given in treatment trials for comparison 1 (HCQ versus standard care or
placebo) 
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Carbapenem 6/221
Quinolone 22/221




No other antiviral, antibiotic, or corticosteroids
18/227
Chen 2020a 2 Nebulized interferon alpha 15/15
Umifenovir 12/15
Nebulized interferon alpha 15/15
Umifenovir 10/15
Chen 2020b Authors report “all received the standard treatment (oxygen therapy, antiviral agents, antibacterial agents,
and immunoglobulin, with or without corticosteroids)”.
Chen 2020c 3 Azithromycin 1/21 Azithromycin 2/12




Mitjà 2020a 5 Cobicistat-boosted darunavir 49/136 Cobicistat-boosted darunavir 0/157
Pan 2020 The authors report that co-medications will appear in supplementary tables, but these are not provided with
the currently available preprint publication.


















Table 5.   Pharmacological co-interventions given in treatment trials for comparison 1 (HCQ versus standard care or
placebo)  (Continued)
HCQ, hydroxychloroquine; PaO2, partial pressure of oxygen
1 Cavalcanti 2020 - this was a three-arm trial, of which the third arm received HCQ + azithromycin.
2 Chen 2020a - authors report that two participants received lopinavir/ritonavir, but it is unclear which study arms these participants were
in. Whether or not any participants received corticosteroids or antibiotics is not reported.
3 Chen 2020c - in addition to the above, authors report: "Both study group and comparison group received standard of care comprising
supportive treatment for subjects with mild clinical COVID-19 symptoms and antimicrobial therapy for subjects presenting with moderate
clinical COVID-19 symptoms. The treatment consisted of: (1) ceQriaxone 2 g daily for 7 days +/- azithromycin 500 mg on day 1 and 250 mg
on days 2–5; or (2) levofloxacin 750 mg daily for 5 d; or (3) levofloxacin 500 mg daily; or (4) moxifloxacin 400 mg daily for 7–14 days for
subjects allergic to ceQriaxone or azithromycin or according to physician discretion. Oseltamivir 75 mg b.i.d. will be administered for 5 days
to subjects presenting with concomitant influenza A or B infection".
4 Horby 2020 - authors presented the percentage of participants in each arm receiving dexamethasone or azithromycin. Data on antibiotics
and other antivirals not reported. This trial was a platform trial with other arms testing tocilizumab, azithromycin, and dexamethasone, as
well as convalescent plasma.
5 Mitjà 2020a - the trial was originally designed to test HCQ with cobicistat-boosted darunavir, but this was modified during the trial as
further information became available that cobicistat-boosted darunavir had no in vitro activity against SARS-CoV-2.
6 Skipper 2020 - whether or not participants received antimicrobials or corticosteroids is not reported.
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Study HCQ  No HCQ





































Mitjà 2020a Gastrointestinal disorders (148/169)
General disorders (30/169)
Infections and infestations (9/169)
Injury, poisoning, and procedural complications (1/169)
Metabolic and nutrition disorders (2/169)
Musculoskeletal and connective tissue disorders (1/169)
Nervous system disorders (63/169)
Psychiatric disorders (2/169) 
Renal and urinary disorders (1/169)
Reproductive system and breast disorders (1/169)
Respiratory, thoracic, and mediastinal disorders (2/169)




Infections and infestations (12/184)
Metabolic and nutrition disorders
(1/184)
Nervous system disorders (3/184)
Table 6.   Adverse events for HCQ versus standard care without HCQ, or placebo, for treatment 
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Skipper 2020 2 Upset stomach/nausea (66/212)
Diarrhoea, other GI symptoms, vomiting (50/212)
Neurologic (nervousness, irritability, dizziness, vertigo) (20/212)
Skin reaction, rash (6/212)
Ringing in ears (8/212)
Allergic reaction, self-reported (5/212)
Changes in vision (4/212)
Warmth, hot flashes, night sweats (2/212)
Headache (2/212)
Upset stomach/nausea (26/211)




Skin reaction, rash (2/211)
Ringing in ears (5/211)
Changes in vision (5/211)
Taste, dry mouth (1/211)
Heart racing, anxiety, panic attack
(1/211)
 
Tang 2020 Disease progression (1/70)

















Decreased white blood cell (1/70)
Increased ALT (1/70)
Increased serum amylase (1/70)






Increased serum amyloid A (1/80)
 
Table 6.   Adverse events for HCQ versus standard care without HCQ, or placebo, for treatment  (Continued)
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ALT: alanine aminotransferase; AST: aspartate transaminase; GI: gastrointestinal; HCQ: hydroxychloroquine
1Authors of Chen 2020a comment that “among the test group the occurrence of adverse events in subjects with moderate to severe disease
is not related to medication. All adverse reactions aQer drug withdrawal or symptomatic treatment disappeared”.
2 Skipper 2020 - authors describe these adverse events as side eJects reported at day 5.
 
 
A P P E N D I C E S
Appendix 1. Search strategies
Search strategy PubMed (MEDLINE)
 
#1 Search "Coronavirus"[Mesh]
#2 Search (coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan*
or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19"
or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCoV or "HCoV-19" or HCoV19 or CoV
or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-
CoV2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or
Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*) Field: Title/Abstract
#3 Search (((respiratory* AND (symptom* or disease* or illness* or condition*)) or "seafood market*"
or "food market*") AND (Wuhan* or Hubei* or China* or Chinese* or Huanan*)). Field: Title/Abstract
#4 Search "severe acute respiratory syndrome*" Field: Title/Abstract
#5 Search ((outbreak* or wildlife* or pandemic* or epidemic*) AND (China* or Chinese* or Huanan*))
Field: Title/Abstract
#6 Search (corona* or corono*) AND (virus* or viral* or virinae*) Field: Title/Abstract
#7 Search (((((#1) OR #2) OR #3) OR #4) OR #6)
#8 Search chloroquin* Field: Title/Abstract
#9 Search Hydroxychloroquin* OR Oxychloroquin* Field: Title/Abstract
#10 Search ("Hydroxychloroquine"[Mesh]) OR "Chloroquine"[Mesh]
#11 Search Aralen or Plaquenil Field: Title/Abstract
#12 Search antimalaria* or anti-malaria* Field: Title/Abstract
#13 Search (((#8) OR #9) OR #10) OR #11OR #12
#14 Search (#13) AND #7
Database: Embase 1947-Present, updated daily
--------------------------------------------------------------------------------
1 coronavirus.mp. or Coronavirinae/
2 exp Coronavirinae/
3 (coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-nCoV" or
2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCoV or "HCoV-19"
or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or SARSCov19
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or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChi-
na* or NcovChinese*).mp.
4 (respiratory* adj2 (symptom* or disease* or illness* or condition*)).mp.
5 ("seafood market*" or "food market*").mp.
6 4 or 5
7 (Wuhan* or Hubei* or China* or Chinese* or Huanan*).mp.
8 6 and 7
9 SARS coronavirus/ or severe acute respiratory syndrome/ or "severe acute respiratory syndrome*".mp.
10 ((outbreak* or wildlife* or pandemic* or epidemic*) adj2 (China* or Chinese* or Huanan*)).mp.
11 ((corona* or corono*) adj2 (virus* or viral* or virinae*)).mp.
12 1 or 2 or 3 or 8 or 9 or 10 or 11
13 hydroxychloroquine/ or chloroquine/ or chloroquin*.mp.
14 Oxychloroquin*.mp.
15 (Aralen or Plaquenil).mp.
16 (antimalaria* or anti-malaria*).mp.
17 antimalarial agent/ or antimalarial agent*.mp.
18 13 or 14 or 15 or 16 or 17
19 12 and 18
Search Name: Cochrane Central Register of Controlled Trials
Issue 9 of 12, September 2020
#1 MeSH descriptor: [Coronavirus] explode all trees
#2 (coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-
nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCoV or
"HCoV-19" or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or
SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei*
or NcovChina* or NcovChinese*)
#3 respiratory* AND (symptom* or disease* or illness* or condition*) AND (Wuhan* or Hubei* or China* or Chinese* or Huanan*)
#4 ("seafood market*" or "food market*") AND (Wuhan* or Hubei* or China* or Chinese* or Huanan*)
#5 "severe acute respiratory syndrome*"
#6 ((outbreak* or wildlife* or pandemic* or epidemic*) AND (China* or Chinese* or Huanan*))
#7 (corona* or corono*) AND (virus* or viral* or virinae*)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 chloroquin*
#10 Hydroxychloroquin* OR Oxychloroquin*
#11 MeSH descriptor: [Chloroquine] explode all trees
#12 MeSH descriptor: [Hydroxychloroquine] explode all trees
  (Continued)
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#13 Aralen or Plaquenil
#14 antimalaria* or anti-malaria*
#15 #9 or #10 or #11 or #12 or #13 or #14
#16 #8 and #15
  (Continued)
 
H I S T O R Y
Protocol first published: Issue 4, 2020
Review first published: Issue 2, 2021
 
Date Event Description
22 April 2020 Amended Amended protocol title and updated Hannah Ryan affiliation de-
tails
 
C O N T R I B U T I O N S   O F   A U T H O R S
BS and HR prepared initial draQs of Background and Methods; selected studies; assessed risk of bias; extracted data; synthesized data; and
prepared initial draQs of results, 'Summary of findings' tables, discussion, and conclusions.
MC helped complete the Background and Methods; selected studies; assessed risk of bias; extracted data; synthesized data; and helped
prepare and complete results, 'Summary of findings' tables, discussion, and conclusions.
TK helped complete  the  Background and Methods; assessed risk of bias; extracted data; and helped prepare and complete
results, 'Summary of findings' tables, discussion, and conclusions.
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All authors read and approved the final version of the review.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Regarding outcomes for  Objective 1 - treatment of COVID-19, the review uses a diJerent primary outcome measure for virological
clearance: negative polymerase chain reaction (PCR) test at 14 days is used in place of time to negative PCR for SARS-CoV-2; the latter
was not measured and reported consistently by trials. For serious adverse events, because most trials did not report attribution to
hydroxychloroquine, and as a comparative outcome it may also be more relevant, total participants with any serious adverse events was
used for analysis.
No subgroup analyses were conducted due to an inability to extract disaggregated data for the predefined subgroups.
Trials reported intention-to-treat as the primary analysis approach for the review's primary outcomes, so this was used for the primary
meta-analyses within the review, rather than the planned available-case analysis. We performed a sensitivity analysis using modified
intention-to-treat data, where trials reported this information.
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